[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 8360
1. Buljan M, Bulat V, Situm M, Mihić LL, Stanić-Duktaj S: Variations in clinical presentation of basal cell carcinoma. Acta Clin Croat; 2008 Mar;47(1):25-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Variations in clinical presentation of basal cell carcinoma.
  • Basal cell carcinoma (basalioma, BCC) is the most common skin cancer and the most common human malignancy in general, with a continuously increasing incidence.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18714644.001).
  • [ISSN] 0353-9466
  • [Journal-full-title] Acta clinica Croatica
  • [ISO-abbreviation] Acta Clin Croat
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Croatia
  • [Number-of-references] 13
  •  go-up   go-down


2. Davoodpour P, Landström M: 2-Methoxyestradiol-induced apoptosis in prostate cancer cells requires Smad7. J Biol Chem; 2005 Apr 15;280(15):14773-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 2-Methoxyestradiol (2-ME), an endogenous metabolite of estradiol-17beta, inhibits tumor angiogenesis while also exerting potent cytotoxic effects on various cancer cells.
  • Moreover, Smad7 was found to be important for the basal expression of Bim, a pro-apoptotic Bcl-2 family member, and for 2-ME-induced expression of Bim.
  • [MeSH-major] Apoptosis. DNA-Binding Proteins / metabolism. Estradiol / analogs & derivatives. Estradiol / pharmacology. Prostatic Neoplasms / pathology. Trans-Activators / metabolism
  • [MeSH-minor] Apoptosis Regulatory Proteins. Blotting, Western. Carrier Proteins / metabolism. Cell Line, Tumor. Cell Nucleus / metabolism. Cytoskeletal Proteins / metabolism. Humans. Male. Membrane Proteins / metabolism. Neovascularization, Pathologic. Proto-Oncogene Proteins / metabolism. RNA / metabolism. RNA, Small Interfering / metabolism. Signal Transduction. Smad7 Protein. Time. Time Factors. Transforming Growth Factor beta / metabolism. beta Catenin. p38 Mitogen-Activated Protein Kinases / metabolism

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Pharmacogenomics Knowledge Base. meta-databases - Pharmacogenomic Annotation 827850893 for PMID:15708859 [PharmGKB] .
  • Hazardous Substances Data Bank. ESTRADIOL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15708859.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / Bcl-2-like protein 11; 0 / CTNNB1 protein, human; 0 / Carrier Proteins; 0 / Cytoskeletal Proteins; 0 / DNA-Binding Proteins; 0 / Membrane Proteins; 0 / Proto-Oncogene Proteins; 0 / RNA, Small Interfering; 0 / SMAD7 protein, human; 0 / Smad7 Protein; 0 / Trans-Activators; 0 / Transforming Growth Factor beta; 0 / beta Catenin; 4TI98Z838E / Estradiol; 63231-63-0 / RNA; 6I2QW73SR5 / 2-methoxyestradiol; EC 2.7.11.24 / p38 Mitogen-Activated Protein Kinases
  •  go-up   go-down


3. Nan H, Qureshi AA, Hunter DJ, Han J: A functional SNP in the MDM2 promoter, pigmentary phenotypes, and risk of skin cancer. Cancer Causes Control; 2009 Mar;20(2):171-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The MDM2 oncoprotein is a key negative regulator of the tumor suppressor p53.
  • We evaluated the effect of MDM2 SNP309 and its interaction with the p53 Arg72Pro polymorphism on pigmentary phenotypes and skin cancer risk in a nested case-control study within the Nurses' Health Study (NHS) among 219 melanoma cases, 286 squamous cell carcinoma (SCC) cases, 300 basal cell carcinoma (BCC) cases, and 873 controls, and among controls from other studies.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Epidemiol. 2000 Jan 1;151(1):72-7 [10625176.001]
  • [Cites] Br J Cancer. 2000 May;82(9):1605-9 [10789732.001]
  • [Cites] Photodermatol Photoimmunol Photomed. 2000 Oct;16(5):195-201 [11068857.001]
  • [Cites] Nature. 2000 Nov 16;408(6810):307-10 [11099028.001]
  • [Cites] Arch Dermatol. 2000 Dec;136(12):1550-1 [11115171.001]
  • [Cites] J Natl Cancer Inst. 2001 Jun 6;93(11):824-42 [11390532.001]
  • [Cites] J Photochem Photobiol B. 2001 Oct;63(1-3):19-27 [11684448.001]
  • [Cites] Melanoma Res. 2002 Oct;12(5):513-9 [12394194.001]
  • [Cites] Nat Genet. 2003 Mar;33(3):357-65 [12567188.001]
  • [Cites] Oncogene. 2003 May 19;22(20):3042-52 [12789279.001]
  • [Cites] Cancer Detect Prev. 2003;27(4):311-5 [12893080.001]
  • [Cites] Nat Rev Cancer. 2003 Aug;3(8):559-70 [12894244.001]
  • [Cites] Int J Cancer. 2004 Jan 10;108(2):196-9 [14639602.001]
  • [Cites] J Invest Dermatol. 2004 Oct;123(4):760-2 [15373782.001]
  • [Cites] Am J Epidemiol. 1976 Dec;104(6):609-20 [998608.001]
  • [Cites] J Am Acad Dermatol. 1983 Nov;9(5):724-33 [6358278.001]
  • [Cites] Mol Cell Biol. 1987 Feb;7(2):961-3 [3547088.001]
  • [Cites] Cell. 1992 Jun 26;69(7):1237-45 [1535557.001]
  • [Cites] Nature. 1993 Apr 29;362(6423):857-60 [8479525.001]
  • [Cites] J Clin Invest. 1994 May;93(5):2258-62 [8182158.001]
  • [Cites] BMJ. 1995 Apr 8;310(6984):912-6 [7719184.001]
  • [Cites] Oncogene. 1995 Dec 7;11(11):2445-9 [8570197.001]
  • [Cites] Nat Med. 1996 Aug;2(8):912-7 [8705862.001]
  • [Cites] Int J Epidemiol. 1996 Apr;25(2):245-51 [9119548.001]
  • [Cites] Oncogene. 1997 Mar 6;14(9):1123-8 [9070662.001]
  • [Cites] Trends Genet. 1997 Oct;13(10):410-4 [9351343.001]
  • [Cites] Oncogene. 1998 Nov 12;17(19):2543-7 [9824166.001]
  • [Cites] Mol Cell Biol. 1999 Feb;19(2):1092-100 [9891044.001]
  • [Cites] Oncogene. 1999 Feb 18;18(7):1419-34 [10050879.001]
  • [Cites] Cell. 2004 Nov 24;119(5):591-602 [15550242.001]
  • [Cites] Curr Cancer Drug Targets. 2005 Feb;5(1):3-8 [15720184.001]
  • [Cites] Int J Biochem Cell Biol. 2005 Aug;37(8):1547-53 [15896663.001]
  • [Cites] J Invest Dermatol. 2005 Dec;125(6):1252-8 [16354196.001]
  • [Cites] Cancer Res. 2006 Mar 1;66(5):2608-15 [16510579.001]
  • [Cites] Cancer Lett. 2006 Aug 28;240(2):195-7 [16239061.001]
  • [Cites] Clin Cancer Res. 2006 Aug 15;12(16):4867-71 [16914573.001]
  • [Cites] Int J Cancer. 2006 Oct 15;119(8):1976-84 [16721784.001]
  • [Cites] Int J Epidemiol. 2006 Dec;35(6):1514-21 [16943234.001]
  • [Cites] Gynecol Oncol. 2007 Mar;104(3):660-4 [17123590.001]
  • [Cites] Nature. 2007 Feb 22;445(7130):843-50 [17314970.001]
  • [Cites] Cell. 2007 Mar 9;128(5):853-64 [17350573.001]
  • [Cites] Cancer Causes Control. 2007 Aug;18(6):621-5 [17387621.001]
  • [Cites] Br J Dermatol. 2007 Aug;157(2):375-7 [17553029.001]
  • [Cites] Carcinogenesis. 2007 Nov;28(11):2262-7 [17827408.001]
  • [Cites] Br J Dermatol. 2008 Aug;159(2):314-21 [18510673.001]
  • (PMID = 18814047.001).
  • [ISSN] 1573-7225
  • [Journal-full-title] Cancer causes & control : CCC
  • [ISO-abbreviation] Cancer Causes Control
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA122838-01A2; United States / NCI NIH HHS / CA / R01 CA122838; United States / NCI NIH HHS / CA / CA128080; United States / NCI NIH HHS / CA / R03 CA128080; United States / NCI NIH HHS / CA / CA122838
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53; EC 6.3.2.19 / MDM2 protein, human; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2
  • [Other-IDs] NLM/ NIHMS70183; NLM/ PMC2631619
  •  go-up   go-down


Advertisement
4. Hameed O, Humphrey PA: Stratified epithelium in prostatic adenocarcinoma: a mimic of high-grade prostatic intraepithelial neoplasia. Mod Pathol; 2006 Jul;19(7):899-906
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stratified epithelium in prostatic adenocarcinoma: a mimic of high-grade prostatic intraepithelial neoplasia.
  • Typically glands of prostatic adenocarcinoma have a single cell lining, although stratification can be seen in invasive carcinomas with a cribriform architecture, including ductal carcinoma.
  • The histomorphological features and immunohistochemical profile of cases of non-cribriform prostatic adenocarcinoma with stratified malignant glandular epithelium were analyzed.
  • The main attribute in all these foci was the presence of glandular profiles lined by several layers of epithelial cells with cytological and architectural features resembling flat or tufted high-grade prostatic intraepithelial neoplasia, but lacking basal cells as confirmed by negative 34betaE12 and/or p63 immunostains in all cases.
  • Prostatic adenocarcinoma with stratified malignant glandular epithelium can be identified in prostate needle biopsy samples harboring non-cribriform prostatic adenocarcinoma and resembles glands with high-grade prostatic intraepithelial neoplasia.
  • [MeSH-major] Adenocarcinoma / pathology. Epithelium / pathology. Prostatic Intraepithelial Neoplasia / pathology. Prostatic Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Biopsy, Needle. Diagnosis, Differential. Humans. Immunohistochemistry. Keratins / metabolism. Male. Membrane Proteins / metabolism. Middle Aged. Neoplasm Invasiveness. Prostate-Specific Antigen / blood. Racemases and Epimerases / metabolism. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16607376.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CKAP4 protein, human; 0 / Membrane Proteins; 68238-35-7 / Keratins; EC 3.4.21.77 / Prostate-Specific Antigen; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


5. Lanteri M, Ollier L, Giordanengo V, Lefebvre JC: Designing a HER2/neu promoter to drive alpha1,3galactosyltransferase expression for targeted anti-alphaGal antibody-mediated tumor cell killing. Breast Cancer Res; 2005;7(4):R487-94
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Designing a HER2/neu promoter to drive alpha1,3galactosyltransferase expression for targeted anti-alphaGal antibody-mediated tumor cell killing.
  • INTRODUCTION: Our goal was to specifically render tumor cells susceptible to natural cytolytic anti-alphaGal antibodies by using a murine alpha1,3galactosyltransferase (malphaGalT) transgene driven by a designed form of HER2/neu promoter (pNeu), the transcription of which is frequently observed to be above basal in breast tumors.
  • METHOD: Expression of the endogenous c-erbB-2 gene was investigated in various cell lines by northern blotting.
  • These constructs were transferred into HEK-293 control and breast tumor cell lines.
  • [MeSH-major] Breast Neoplasms / genetics. Breast Neoplasms / pathology. Galactosyltransferases / biosynthesis
  • [MeSH-minor] Antibodies. Epitopes. Female. Flow Cytometry. Genetic Therapy. Humans. Promoter Regions, Genetic. Receptor, ErbB-2. Transgenes. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Med. 2000 Feb;6(2):189-95 [10655108.001]
  • [Cites] Clin Cancer Res. 1996 Jul;2(7):1215-9 [9816290.001]
  • [Cites] Adv Exp Med Biol. 1998;451:359-63 [10026897.001]
  • [Cites] Front Biosci. 1999 Apr 15;4:D416-32 [10209058.001]
  • [Cites] Int J Biochem Cell Biol. 1999 Jan;31(1):201-13 [10216954.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Apr 27;96(9):4995-5000 [10220407.001]
  • [Cites] Xenotransplantation. 2000 Feb;7(1):42-7 [10809056.001]
  • [Cites] Cancer Res. 2000 Oct 15;60(20):5887-94 [11059787.001]
  • [Cites] Oncogene. 2000 Dec 11;19(53):6093-101 [11156522.001]
  • [Cites] Oncogene. 2000 Dec 11;19(53):6115-21 [11156524.001]
  • [Cites] Oncogene. 2000 Dec 18;19(55):6490-502 [11175365.001]
  • [Cites] Clin Chem. 2001 May;47(5):844-51 [11325887.001]
  • [Cites] Breast Cancer Res. 2001;3(6):395-8 [11737892.001]
  • [Cites] Semin Oncol. 2001 Dec;28(6 Suppl 18):30-5 [11774203.001]
  • [Cites] Int J Oncol. 2002 Mar;20(3):607-10 [11836576.001]
  • [Cites] Expert Opin Investig Drugs. 2002 Dec;11(12):1715-36 [12457433.001]
  • [Cites] Cancer Res. 2003 Mar 1;63(5):987-93 [12615713.001]
  • [Cites] Exp Cell Res. 2003 Mar 10;284(1):99-110 [12648469.001]
  • [Cites] Int J Cancer. 2003 Jul 1;105(4):444-53 [12712433.001]
  • [Cites] J Biol Chem. 2003 May 23;278(21):19396-405 [12626523.001]
  • [Cites] J Leukoc Biol. 2003 Oct;74(4):593-601 [12960261.001]
  • [Cites] Oncogene. 2003 Sep 29;22(42):6570-8 [14528282.001]
  • [Cites] Int J Cancer. 2003 Dec 20;107(6):910-8 [14601050.001]
  • [Cites] Glycobiology. 2003 Dec;13(12):909-18 [12925577.001]
  • [Cites] J Gen Virol. 1977 Jul;36(1):59-74 [886304.001]
  • [Cites] J Exp Med. 1984 Nov 1;160(5):1519-31 [6491603.001]
  • [Cites] Science. 1985 Dec 6;230(4730):1132-9 [2999974.001]
  • [Cites] Proc Natl Acad Sci U S A. 1986 May;83(10):3194-8 [3458176.001]
  • [Cites] Science. 1987 Jan 9;235(4785):177-82 [3798106.001]
  • [Cites] EMBO J. 1987 Mar;6(3):605-10 [3034598.001]
  • [Cites] J Biol Chem. 1988 Nov 25;263(33):17755-62 [2460463.001]
  • [Cites] Science. 1989 May 12;244(4905):707-12 [2470152.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Jun;87(12):4499-503 [1972274.001]
  • [Cites] Transplant Proc. 1992 Apr;24(2):559-62 [1566430.001]
  • [Cites] Oncogene. 1993 Feb;8(2):257-65 [8426736.001]
  • [Cites] Cancer. 1994 Jun 1;73(11):2771-8 [7514954.001]
  • [Cites] J Exp Med. 1994 Nov 1;180(5):1609-17 [7964449.001]
  • [Cites] J Biol Chem. 1995 Sep 15;270(37):21437-40 [7545161.001]
  • [Cites] Transplantation. 1996 Jan 15;61(1):13-9 [8560551.001]
  • [Cites] Transplant Proc. 1996 Apr;28(2):556-7 [8623267.001]
  • [Cites] Oncogene. 1997 Feb 6;14(5):561-8 [9053854.001]
  • [Cites] Gene Ther. 1997 Apr;4(4):317-22 [9176517.001]
  • [Cites] Eur J Biochem. 1997 Jul 15;247(2):558-66 [9266697.001]
  • [Cites] Int J Cancer. 1997 Dec 10;73(6):875-9 [9399669.001]
  • [Cites] Oncol Res. 1997;9(6-7):313-25 [9406237.001]
  • [Cites] Gene Ther. 1997 Oct;4(10):1045-52 [9415310.001]
  • [Cites] Anticancer Res. 1998 Jul-Aug;18(4A):2301-8 [9703870.001]
  • [Cites] Hum Gene Ther. 1998 Aug 10;9(12):1775-98 [9721088.001]
  • [Cites] J Clin Invest. 2000 May;105(9):1161-7 [10791987.001]
  • (PMID = 15987454.001).
  • [ISSN] 1465-542X
  • [Journal-full-title] Breast cancer research : BCR
  • [ISO-abbreviation] Breast Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies; 0 / Epitopes; EC 2.4.1.- / Galactosyltransferases; EC 2.4.1.87 / N-acetyllactosaminide alpha-1,3-galactosyltransferase; EC 2.7.10.1 / Receptor, ErbB-2
  • [Other-IDs] NLM/ PMC1175063
  •  go-up   go-down


6. Hu H, Li GX, Wang L, Watts J, Combs GF Jr, Lü J: Methylseleninic acid enhances taxane drug efficacy against human prostate cancer and down-regulates antiapoptotic proteins Bcl-XL and survivin. Clin Cancer Res; 2008 Feb 15;14(4):1150-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • EXPERIMENTAL DESIGN: DU145 and PC-3 HRPCa cell lines were used to evaluate the in vitro apoptosis effects of paclitaxel, docetaxel and their combination with MSeA, and the molecular mechanisms.
  • The tumor samples were used to examine Bcl-XL and survivin protein abundance.
  • MSeA decreased the basal and paclitaxel-induced expression of Bcl-XL and survivin in vitro and in vivo.
  • CONCLUSIONS: MSeA enhanced the efficacy of paclitaxel against HRPCa in vitro and in vivo, at least in part, by down-regulating the basal and paclitaxel-induced expression of both Bcl-XL and survivin to increase caspase-mediated apoptosis.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / pharmacology. Microtubule-Associated Proteins / drug effects. Neoplasm Proteins / drug effects. Prostatic Neoplasms / drug therapy. Prostatic Neoplasms / metabolism. bcl-X Protein / drug effects
  • [MeSH-minor] Animals. Apoptosis / drug effects. Cell Line, Tumor. Down-Regulation. Drug Synergism. Humans. Immunoblotting. Inhibitor of Apoptosis Proteins. Male. Mice. Organoselenium Compounds / administration & dosage. Organoselenium Compounds / pharmacokinetics. Paclitaxel / administration & dosage. Paclitaxel / pharmacokinetics. Reverse Transcriptase Polymerase Chain Reaction. Taxoids / administration & dosage. Taxoids / pharmacokinetics. Xenograft Model Antitumor Assays

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. TAXOL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18281549.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA92231; United States / NCI NIH HHS / CA / CA95642
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / Organoselenium Compounds; 0 / Taxoids; 0 / bcl-X Protein; 15H5577CQD / docetaxel; 28274-57-9 / methylselenic acid; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


7. Salvatico J, Kim JH, Chung IK, Muller MT: Differentiation linked regulation of telomerase activity by Makorin-1. Mol Cell Biochem; 2010 Sep;342(1-2):241-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study we examined expression and regulation of endogenous MKRN1 during the cell cycle and terminal differentiation.
  • When WI-38 cells transition from active growth into a resting G1 state, basal levels of MKRN1 were found to increase by sixfold.
  • The data are consistent with the idea that MKRN1 represents a telomerase elimination pathway to rapidly draw down the activity during differentiation or cell cycle arrest when telomerase action at chromosome ends is no longer necessary.
  • [MeSH-major] Cell Cycle. Cell Differentiation. Gene Expression Regulation, Neoplastic. Nerve Tissue Proteins / metabolism. Ribonucleoproteins / metabolism. Telomerase / genetics
  • [MeSH-minor] Blotting, Western. Cell Proliferation. Cells, Cultured. Colorectal Neoplasms / metabolism. Colorectal Neoplasms / pathology. Fibroblasts / cytology. Fibroblasts / metabolism. HL-60 Cells. HeLa Cells. Humans. Kidney / cytology. Kidney / metabolism. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochem Biophys Res Commun. 2007 Sep 28;361(3):615-20 [17673177.001]
  • [Cites] Genes Dev. 2005 Apr 1;19(7):776-81 [15805468.001]
  • [Cites] Leuk Res. 1998 Aug;22(8):711-7 [9680098.001]
  • [Cites] Nucleic Acids Res. 2005 Dec 02;33(21):6850-60 [16326864.001]
  • [Cites] FASEB J. 1999 Dec;13(15):2091-104 [10593857.001]
  • [Cites] Mol Cancer Ther. 2004 Aug;3(8):1003-9 [15299083.001]
  • [Cites] Exp Cell Res. 2003 Oct 1;289(2):326-34 [14499633.001]
  • [Cites] EMBO J. 2009 Jul 22;28(14):2100-13 [19536131.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Sep 26;92(20):9082-6 [7568077.001]
  • [Cites] J Biol Chem. 2004 Aug 13;279(33):34750-5 [15190070.001]
  • [Cites] J Gerontol A Biol Sci Med Sci. 2002 Jul;57(7):B257-69 [12084796.001]
  • [Cites] Ciba Found Symp. 1997;211:20-8; discussion 28-34 [9524749.001]
  • [Cites] Cell. 2003 Jul 25;114(2):241-53 [12887925.001]
  • [Cites] Blood. 1997 Feb 15;89(4):1299-307 [9028953.001]
  • [Cites] Genes Dev. 2005 Sep 15;19(18):2100-10 [16166375.001]
  • [Cites] Anticancer Res. 2000 Mar-Apr;20(2A):773-8 [10810353.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Jul 4;306(3):650-9 [12810068.001]
  • [Cites] Cancer. 1998 Oct 15;83(8):1471-82 [9781940.001]
  • [Cites] Pharmacol Ther. 2003 Dec;100(3):257-90 [14652113.001]
  • [Cites] J Leukoc Biol. 2008 May;83(5):1240-8 [18276798.001]
  • [Cites] Cell. 2009 Aug 7;138(3):463-75 [19665970.001]
  • [Cites] Mol Cell Biol. 1996 Jun;16(6):2932-9 [8649404.001]
  • [Cites] Int J Oncol. 2008 Mar;32(3):625-31 [18292940.001]
  • [Cites] Cell Cycle. 2007 Jun 15;6(12):1496-501 [17525530.001]
  • [Cites] Cancer Lett. 2010 Apr 1;290(1):76-86 [19751963.001]
  • [Cites] Genes Chromosomes Cancer. 2004 Sep;41(1):26-37 [15236314.001]
  • [Cites] Annu Rev Genet. 2008;42:301-34 [18680434.001]
  • [Cites] EMBO J. 1992 May;11(5):1921-9 [1582420.001]
  • [Cites] Cancer Res. 1999 Dec 1;59(23):5917-21 [10606235.001]
  • [Cites] Cell. 2008 Mar 21;132(6):945-57 [18358808.001]
  • [Cites] Eur J Cancer. 1997 Apr;33(5):787-91 [9282118.001]
  • [Cites] Differentiation. 2002 Jan;69(4-5):188-97 [11841477.001]
  • [Cites] Genes Dev. 1999 Apr 1;13(7):817-26 [10197982.001]
  • [Cites] J Biol Chem. 1997 Jul 4;272(27):16729-32 [9201974.001]
  • [Cites] J Biol Chem. 1998 Dec 11;273(50):33436-42 [9837921.001]
  • [Cites] Cancer Res. 1998 Sep 15;58(18):4168-72 [9751630.001]
  • [Cites] Mol Cancer Res. 2008 Oct;6(10):1582-93 [18922974.001]
  • [Cites] J Biol Chem. 2009 Mar 27;284(13):8557-66 [19164295.001]
  • [Cites] Nucleic Acids Res. 2007;35(4):1245-56 [17267411.001]
  • [Cites] Science. 1995 Sep 15;269(5230):1533-4 [7545310.001]
  • [Cites] Genomics. 2000 May 15;66(1):76-86 [10843807.001]
  • [Cites] Gene. 2004 Sep 29;340(1):1-10 [15556289.001]
  • [Cites] Blood. 1995 May 1;85(9):2315-20 [7727765.001]
  • [Cites] J Biol Chem. 2001 May 11;276(19):15571-4 [11274138.001]
  • [Cites] Science. 1998 Jan 16;279(5349):349-52 [9454332.001]
  • [Cites] Cell. 2001 Sep 21;106(6):661-73 [11572773.001]
  • [Cites] Cell. 2001 Nov 2;107(3):347-59 [11701125.001]
  • [Cites] Int J Cancer. 2001 Mar 1;91(5):644-9 [11267974.001]
  • [Cites] Exp Cell Res. 1999 Sep 15;251(2):492-9 [10471333.001]
  • [Cites] J Immunol. 2001 Apr 15;166(8):4826-30 [11290757.001]
  • [Cites] Cell. 1997 Oct 3;91(1):25-34 [9335332.001]
  • [Cites] J Biol Chem. 1999 May 7;274(19):13085-90 [10224060.001]
  • [Cites] Genes Dev. 1998 Jun 15;12(12):1769-74 [9637678.001]
  • (PMID = 20473778.001).
  • [ISSN] 1573-4919
  • [Journal-full-title] Molecular and cellular biochemistry
  • [ISO-abbreviation] Mol. Cell. Biochem.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA127416
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Makorin ring finger protein 1; 0 / Nerve Tissue Proteins; 0 / RNA, Messenger; 0 / Ribonucleoproteins; EC 2.7.7.49 / TERT protein, human; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


8. Chen GS, Yu HS, Lan CC, Chow KC, Lin TY, Kok LF, Lu MP, Liu CH, Wu MT: CXC chemokine receptor CXCR4 expression enhances tumorigenesis and angiogenesis of basal cell carcinoma. Br J Dermatol; 2006 May;154(5):910-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CXC chemokine receptor CXCR4 expression enhances tumorigenesis and angiogenesis of basal cell carcinoma.
  • BACKGROUND: Chemokines and their receptors, well known for their ability to attract leucocytes, also play important roles for tumour progression.
  • OBJECTIVES: To investigate the possible involvement of chemokine receptors in the pathogenesis of cutaneous basal cell carcinoma (BCC).
  • METHODS: We performed an expression analysis of chemokine receptors using a well-characterized human BCC cell line.
  • Upon the finding of CXCR4 expression by BCC, retroviral transduction of BCC cells with the CXCR4 gene was employed to address its functional significance for BCC in vitro and in vivo.
  • RESULTS: We found expression of the CXC chemokine receptor CXCR4 by a human cell line and a subset of tissue samples from BCC, especially in noduloulcerative and sclerosing types.
  • Moreover, xenograft tumour transplants produced by injection of CXCR4-BCC yielded significant tumour progression in nude mice, whereas additional serial injections of CXCR4-blocking peptides resulted in tumour regression.
  • CONCLUSIONS: CXCR4 expression may play a critical role in tumour progression and angiogenesis of certain subtypes of BCC with more aggressive nature, and functional blockade of CXCR4 could be a potential therapeutic strategy for these tumours.
  • [MeSH-major] Carcinoma, Basal Cell / metabolism. Cell Transformation, Neoplastic / metabolism. Neovascularization, Pathologic / metabolism. Receptors, CXCR4 / metabolism. Skin Neoplasms / metabolism
  • [MeSH-minor] Animals. Apoptosis / radiation effects. Cell Proliferation. Chemokine CXCL12. Chemokines, CXC / physiology. Disease Progression. Female. Humans. Mice. Mice, Nude. Neoplasm Proteins / metabolism. Neoplasm Transplantation. Reverse Transcriptase Polymerase Chain Reaction / methods. Signal Transduction. Transduction, Genetic. Transplantation, Heterologous. Tumor Cells, Cultured. Ultraviolet Rays

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16634895.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CXCL12 protein, human; 0 / Chemokine CXCL12; 0 / Chemokines, CXC; 0 / Cxcl12 protein, mouse; 0 / Neoplasm Proteins; 0 / Receptors, CXCR4
  •  go-up   go-down


9. Makrantonaki E, Zouboulis CC: Molecular mechanisms of skin aging: state of the art. Ann N Y Acad Sci; 2007 Nov;1119:40-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In sun-protected areas the most pronounced changes occur within the epidermis and affect mostly the basal cell layer.
  • Recent data obtained by expression-profiling studies and studies of progeroid syndromes (e.g., Hutchinson-Gilford progeria, Werner syndrome, Rothmund-Thomson syndrome, Cockayne syndrome, ataxia teleangiectasia, and Down syndrome) illustrate that among the most important biological processes involved in skin aging are alterations in DNA repair and stability, mitochondrial function, cell cycle and apoptosis, ubiquitin-induced proteolysis, and cellular metabolism.
  • However, hormones at age-specific levels may not only regulate age-associated mechanisms but also regulate tumor-suppressor pathways that influence carcinogenesis.
  • [MeSH-minor] Apoptosis / radiation effects. Cell Cycle / radiation effects. DNA Repair / radiation effects. Hormones / metabolism. Humans. Mitochondria / metabolism. Mitochondria / pathology. Models, Biological. Neoplasms, Radiation-Induced / metabolism. Neoplasms, Radiation-Induced / pathology. Skin Neoplasms / metabolism. Skin Neoplasms / pathology. Sunlight / adverse effects. Syndrome. Ultraviolet Rays / adverse effects

  • MedlinePlus Health Information. consumer health - Seniors' Health.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18056953.001).
  • [ISSN] 0077-8923
  • [Journal-full-title] Annals of the New York Academy of Sciences
  • [ISO-abbreviation] Ann. N. Y. Acad. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hormones
  • [Number-of-references] 57
  •  go-up   go-down


10. Fonseca RB, Grzeszczak EF: Case 128: Bilateral ovarian fibromas in nevoid basal cell carcinoma syndrome. Radiology; 2008 Jan;246(1):318-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case 128: Bilateral ovarian fibromas in nevoid basal cell carcinoma syndrome.
  • [MeSH-major] Basal Cell Nevus Syndrome / diagnosis. Fibroma / diagnosis. Neoplasms, Multiple Primary / diagnosis. Ovarian Neoplasms / diagnosis


11. Buijs JT, Henriquez NV, van Overveld PG, van der Horst G, Que I, Schwaninger R, Rentsch C, Ten Dijke P, Cleton-Jansen AM, Driouch K, Lidereau R, Bachelier R, Vukicevic S, Clézardin P, Papapoulos SE, Cecchini MG, Löwik CW, van der Pluijm G: Bone morphogenetic protein 7 in the development and treatment of bone metastases from breast cancer. Cancer Res; 2007 Sep 15;67(18):8742-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Because EMT is involved in cancer, we investigated whether BMP7 plays a role in breast cancer growth and metastasis.
  • In line with these clinical observations, BMP7 expression is inversely related to tumorigenicity and invasive behavior of human breast cancer cell lines.
  • Moreover, BMP7 decreased the expression of vimentin, a mesenchymal marker associated with invasiveness and poor prognosis, in human MDA-MB-231 (MDA-231)-B/Luc(+) breast cancer cells under basal and transforming growth factor-beta (TGF-beta)-stimulated conditions.
  • Furthermore, in a well-established bone metastasis model using whole-body bioluminescent reporter imaging, stable overexpression of BMP7 in MDA-231 cells inhibited de novo formation and progression of osteolytic bone metastases and, hence, their metastatic capability.
  • [MeSH-major] Bone Morphogenetic Proteins / biosynthesis. Bone Morphogenetic Proteins / pharmacology. Bone Neoplasms / drug therapy. Bone Neoplasms / secondary. Breast Neoplasms / drug therapy. Breast Neoplasms / pathology
  • [MeSH-minor] Animals. Bone Morphogenetic Protein 7. Cell Line, Tumor. Disease Progression. Epithelial Cells / pathology. Female. Humans. Mesoderm / pathology. Mice. Mice, Inbred BALB C. Mice, Nude. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Retrospective Studies. Signal Transduction. Transforming Growth Factor beta / metabolism. Xenograft Model Antitumor Assays


12. Brinckmann S, Kim JY, Greer JR: Fundamental differences in mechanical behavior between two types of crystals at the nanoscale. Phys Rev Lett; 2008 Apr 18;100(15):155502
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fundamental differences in mechanical behavior between two types of crystals at the nanoscale.
  • We present differences in the mechanical behavior of nanoscale gold and molybdenum single crystals.
  • A significant strength increase is observed as the size is reduced to 100 nm.
  • Both nanocrystals exhibit discrete strain bursts during plastic deformation.
  • We postulate that they arise from significant differences in the dislocation behavior.
  • Dislocation starvation is the predominant mechanism of plasticity in nanoscale fcc crystals, while junction formation and hardening characterize bcc plasticity.
  • A statistical analysis of strain bursts is performed as a function of size and compared with stochastic models.

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18518121.001).
  • [ISSN] 0031-9007
  • [Journal-full-title] Physical review letters
  • [ISO-abbreviation] Phys. Rev. Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


13. Sellheyer K, Krahl D: Basal cell (trichoblastic) carcinoma common expression pattern for epithelial cell adhesion molecule links basal cell carcinoma to early follicular embryogenesis, secondary hair germ, and outer root sheath of the vellus hair follicle: A clue to the adnexal nature of basal cell carcinoma? J Am Acad Dermatol; 2008 Jan;58(1):158-67
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell (trichoblastic) carcinoma common expression pattern for epithelial cell adhesion molecule links basal cell carcinoma to early follicular embryogenesis, secondary hair germ, and outer root sheath of the vellus hair follicle: A clue to the adnexal nature of basal cell carcinoma?
  • BACKGROUND: Basal cell carcinoma (BCC) is still viewed by many dermatologists as a tumor of the interfollicular epidermis, although references were made early in the dermatopathologic literature to the resemblance of BCC to the hair follicle.
  • OBJECTIVE: Our aim was to characterize the common expression pattern for the epithelial cell adhesion molecule (Ep-CAM) in BCCs, various stages of follicular embryogenesis, and adult hair follicles and, thereby, in analogy point to the similarity between BCC and the hair follicle.
  • CONCLUSION: BCC expresses the cell-cell adhesion molecule Ep-CAM similar to the embryonic hair germ, the secondary hair germ of the terminal hair follicle, and the outer root sheath of the vellus hair follicle.
  • We suggest that this may be a clue to the adnexal nature of BCC and propose that BCC is the most primitive follicular tumor.
  • [MeSH-major] Antigens, Neoplasm / metabolism. Carcinoma, Basal Cell / metabolism. Cell Adhesion Molecules / metabolism. Hair Follicle / embryology. Hair Follicle / metabolism. Skin Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18158927.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Cell Adhesion Molecules; 0 / tumor-associated antigen GA733
  •  go-up   go-down


14. Kamei Y, Kito K, Takeuchi T, Imai Y, Murase R, Ueda N, Kobayashi N, Abe Y: Human scribble accumulates in colorectal neoplasia in association with an altered distribution of beta-catenin. Hum Pathol; 2007 Aug;38(8):1273-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human scribble accumulates in colorectal neoplasia in association with an altered distribution of beta-catenin.
  • The loss of epithelial polarity and tissue architecture is a diagnostic feature of malignant tumors.
  • In Drosophila, genetic studies identified 3 neoplastic tumor suppressor genes (nTSGs), and a loss of nTSGs has been shown to result in a disruption of apical-basal polarity and neoplastic growth in epithelial cells.
  • We herein immunohistochemically examined the distributions of hScrib protein in human colorectal neoplasia using affinity-purified antibody.
  • In an immunofluorescence analysis on cultured cell lines, the loss of membranous staining of hScrib was observed according to the cytoplasmic translocation of beta-catenin.
  • [MeSH-major] Adenocarcinoma / pathology. Adenoma / pathology. Biomarkers, Tumor / metabolism. Colorectal Neoplasms / pathology. Membrane Proteins / metabolism. Tumor Suppressor Proteins / metabolism. beta Catenin / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Blotting, Western. Cell Line, Tumor. Female. Fluorescent Antibody Technique, Indirect. Humans. Immunoenzyme Techniques. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17509663.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CTNNB1 protein, human; 0 / Membrane Proteins; 0 / SCRIB protein, human; 0 / Tumor Suppressor Proteins; 0 / beta Catenin
  •  go-up   go-down


15. Hannemann J, Velds A, Halfwerk JB, Kreike B, Peterse JL, van de Vijver MJ: Classification of ductal carcinoma in situ by gene expression profiling. Breast Cancer Res; 2006;8(5):R61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Ductal carcinoma in situ (DCIS) is characterised by the intraductal proliferation of malignant epithelial cells.
  • Using two-dimensional hierarchical clustering, the basal-like type, ERB-B2 type, and the luminal-type tumours originally described for invasive breast cancer could also be identified in DCIS.
  • [MeSH-major] Breast Neoplasms / genetics. Carcinoma, Ductal, Breast / genetics. Carcinoma, Intraductal, Noninfiltrating / genetics. Gene Expression Profiling

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 1999 Dec;81(8):1410-8 [10604741.001]
  • [Cites] Mol Cancer Res. 2003 Mar;1(5):362-75 [12651909.001]
  • [Cites] Endocr Relat Cancer. 2001 Mar;8(1):47-61 [11350726.001]
  • [Cites] Nat Med. 2001 Jun;7(6):673-9 [11385503.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74 [11553815.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 May 13;100(10):5974-9 [12714683.001]
  • [Cites] Lancet. 2003 May 10;361(9369):1590-6 [12747878.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8418-23 [12829800.001]
  • [Cites] Anticancer Res. 2003 May-Jun;23(3A):2043-51 [12894577.001]
  • [Cites] Breast Cancer Res. 2003;5(5):254-7 [12927035.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 2;100(18):10393-8 [12917485.001]
  • [Cites] Clin Exp Metastasis. 2003;20(5):459-70 [14524536.001]
  • [Cites] Breast Cancer Res. 2003;5(6):313-9 [14580249.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15901-5 [14665696.001]
  • [Cites] Tumori. 2004 Mar-Apr;90(2):233-8 [15237588.001]
  • [Cites] Cancer Cell. 2004 Jul;6(1):17-32 [15261139.001]
  • [Cites] N Engl J Med. 1988 Nov 10;319(19):1239-45 [2903446.001]
  • [Cites] J Clin Pathol. 1993 Feb;46(2):189-90 [8459046.001]
  • [Cites] Semin Diagn Pathol. 1994 Aug;11(3):167-80 [7831528.001]
  • [Cites] Am J Pathol. 1997 Jul;151(1):161-8 [9212742.001]
  • [Cites] Br J Cancer. 1997;76(9):1131-3 [9365159.001]
  • [Cites] Hum Pathol. 1999 Mar;30(3):257-62 [10088542.001]
  • [Cites] J Pathol. 1999 Mar;187(4):396-402 [10398097.001]
  • [Cites] J Pathol. 1999 Feb;187(3):272-8 [10398078.001]
  • [Cites] N Engl J Med. 2004 Dec 30;351(27):2817-26 [15591335.001]
  • [Cites] Lancet. 2005 Feb 19-25;365(9460):671-9 [15721472.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3331-42 [15908647.001]
  • [Cites] Oncogene. 2006 Apr 13;25(16):2328-38 [16314837.001]
  • [Cites] Cancer Res. 2006 May 15;66(10):5278-86 [16707453.001]
  • [Cites] Breast Cancer Res. 2006;8(5):R61 [17069663.001]
  • [Cites] Nature. 2002 Jan 31;415(6871):530-6 [11823860.001]
  • [Cites] Bioinformatics. 2002 Jan;18(1):207-8 [11836235.001]
  • [Cites] Pathol Oncol Res. 2002;8(1):26-30 [11994759.001]
  • [Cites] J Natl Cancer Inst. 2002 Oct 16;94(20):1546-54 [12381707.001]
  • [Cites] Cancer Res. 2002 Nov 15;62(22):6740-9 [12438275.001]
  • [Cites] Clin Cancer Res. 2002 Dec;8(12):3788-95 [12473591.001]
  • [Cites] J Natl Cancer Inst. 2003 Jan 1;95(1):14-8 [12509396.001]
  • [Cites] J Clin Oncol. 2003 Mar 15;21(6):1022-8 [12637466.001]
  • [Cites] Nature. 2000 Aug 17;406(6797):747-52 [10963602.001]
  • (PMID = 17069663.001).
  • [ISSN] 1465-542X
  • [Journal-full-title] Breast cancer research : BCR
  • [ISO-abbreviation] Breast Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1779498
  •  go-up   go-down


16. Amnuaykanjanasin A, Punya J, Paungmoung P, Rungrod A, Tachaleat A, Pongpattanakitshote S, Cheevadhanarak S, Tanticharoen M: Diversity of type I polyketide synthase genes in the wood-decay fungus Xylaria sp. BCC 1067. FEMS Microbiol Lett; 2005 Oct 1;251(1):125-36
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The finding of 11 distinct PKS genes solely by means of PCR cloning supports that PKS genes are highly diverse in fungi.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • StrainInfo. culture/stock collections - online strain list (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] FEMS Microbiol Lett. 2006 Jan;254(2):333
  • (PMID = 16112817.001).
  • [ISSN] 0378-1097
  • [Journal-full-title] FEMS microbiology letters
  • [ISO-abbreviation] FEMS Microbiol. Lett.
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ AF395534/ AY445825/ AY965071/ AY971512/ AY971872/ DQ003485/ DQ011042/ DQ011043/ DQ011045/ DQ011595/ DQ011596
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA Primers; 0 / DNA, Fungal; 0 / Fungal Proteins; 79956-01-7 / Polyketide Synthases
  •  go-up   go-down


17. Davidchack RL, Laird BB: Crystal structure and interaction dependence of the crystal-melt interfacial free energy. Phys Rev Lett; 2005 Mar 4;94(8):086102
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Crystal structure and interaction dependence of the crystal-melt interfacial free energy.
  • We examine via molecular simulation the dependence of the crystal-melt interfacial free energy gamma on molecular interaction and crystal structure (fcc vs bcc) for systems interacting with inverse-power repulsive potentials, u(r)=epsilon(sigma/r)(n), 6< or =n< or =100.
  • Both the magnitude and anisotropy of gamma are found to increase as the range of the potential increases.
  • Also we find that gamma(bcc)<gamma(fcc), consistent with recent observations that some fcc forming fluids nucleate via formation of metastable bcc nuclei.
  • The anisotropy in gamma is also seen to be smaller in the bcc systems.
  • By extrapolation, we also obtain an improved estimate of gamma for hard spheres.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15783906.001).
  • [ISSN] 0031-9007
  • [Journal-full-title] Physical review letters
  • [ISO-abbreviation] Phys. Rev. Lett.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Bath-Hextall FJ, Perkins W, Bong J, Williams HC: Interventions for basal cell carcinoma of the skin. Cochrane Database Syst Rev; 2007;(1):CD003412
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interventions for basal cell carcinoma of the skin.
  • BACKGROUND: Basal cell carcinoma (BCC) is the commonest skin cancer.
  • OBJECTIVES: To assess the effects of treatments for basal cell carcinoma.
  • SELECTION CRITERIA: Inclusion criteria were adults with one or more histologically proven, primary basal cell carcinoma.
  • An ongoing study comparing imiquimod to surgery should clarify whether imiquimod is a useful option.
  • [MeSH-major] Carcinoma, Basal Cell / therapy. Skin Neoplasms / therapy


19. Kwon S, Kim TS, Yu GH, Jung JH, Park HD: Bacterial community composition and diversity of a full-scale integrated fixed-film activated sludge system as investigated by pyrosequencing. J Microbiol Biotechnol; 2010 Dec;20(12):1717-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bacterial community composition and diversity of a full-scale integrated fixed-film activated sludge system as investigated by pyrosequencing.
  • The integrated fixed-film activated sludge (IFAS) system is a variation of the activated sludge wastewater treatment process, in which hybrid suspended and attached biomass is used to treat wastewater.
  • Although the function and performance of the IFAS system are well studied, little is known about its microbial community structure.
  • In this study, the composition and diversity of the bacterial community of suspended and attached biomass samples were investigated in a full-scale IFAS system using a highthroughput pyrosequencing technology.
  • Distinct bacterial community compositions were examined for each sample and appeared to be important for its features different from conventional activated sludge processes.
  • The abundant bacterial groups were Betaproteobacteria (59.3%), Gammaproteobacteria (8.1%), Bacteroidetes (5.2%), Alphaproteobacteria (3.9%), and Actinobacteria (3.2%) in the suspended sample, whereas Actinobacteria (14.6%), Firmicutes (13.6%), Bacteroidetes (11.6%), Betaproteobacteria (9.9%), Gammaproteobacteria (9.25%), and Alphaproteobacteria (7.4%) were major bacterial groups in the attached sample.
  • Regarding the diversity, totals of 3,034 and 1,451 operational taxonomic units were identified at the 3% cutoff for the suspended and attached samples, respectively.
  • Rank abundance and community analyses demonstrated that most of the diversity was originated from rare species in the samples.
  • Taken together, the information obtained in this study will be a base for further studies relating to the microbial community structure and function of the IFAS system.
  • [MeSH-major] Bacteria / classification. Bacteria / genetics. Biodiversity. Sewage / microbiology
  • [MeSH-minor] Cluster Analysis. DNA, Bacterial / chemistry. DNA, Bacterial / genetics. DNA, Ribosomal / chemistry. DNA, Ribosomal / genetics. Molecular Sequence Data. Phylogeny. RNA, Ribosomal, 16S / genetics. Sequence Analysis, DNA. Water Purification

  • SILVA. SILVA SSU Database .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21193829.001).
  • [ISSN] 1738-8872
  • [Journal-full-title] Journal of microbiology and biotechnology
  • [ISO-abbreviation] J. Microbiol. Biotechnol.
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ GU539392/ GU539393/ GU539394/ GU539395/ GU539396/ GU539397/ GU539398/ GU539399/ GU539400/ GU539401/ GU539402/ GU539403/ GU539404/ GU539405/ GU539406/ GU539407/ GU539408/ GU539409/ GU539410/ GU539411/ GU539412/ GU539413/ GU539414/ GU539415/ GU539416/ GU539417/ GU539418/ GU539419/ GU539420/ GU539421/ GU539422/ GU539423/ GU539424/ GU539425/ GU539426/ GU539427/ GU539428/ GU539429/ GU539430/ GU539431/ GU539432/ GU539433/ GU539434/ GU539435/ GU539436/ GU539437/ GU539438/ GU539439/ GU539440/ GU539441/ GU539442/ GU539443/ GU539444/ GU539445/ GU539446/ GU539447/ GU539448/ GU539449/ GU539450/ GU539451/ GU539452/ GU539453/ GU539454/ GU539455/ GU539456/ GU539457/ GU539458/ GU539459/ GU539460/ GU539461/ GU539462/ GU539463/ GU539464/ GU539465/ GU539466/ GU539467/ GU539468/ GU539469/ GU539470/ GU539471/ GU539472/ GU539473/ GU539474/ GU539475/ GU539476/ GU539477/ GU539478/ GU539479/ GU539480/ GU539481/ GU539482/ GU539483/ GU539484/ GU539485/ GU539486/ GU539487/ GU539488/ GU539489/ GU539490/ GU539491/ GU539492/ GU539493/ GU539494/ GU539495/ GU539496/ GU539497/ GU539498/ GU539499/ GU539500/ GU539501/ GU539502/ GU539503/ GU539504/ GU539505/ GU539506/ GU539507/ GU539508/ GU539509/ GU539510/ GU539511/ GU539512/ GU539513/ GU539514/ GU539515/ GU539516/ GU539517/ GU539518/ GU539519/ GU539520/ GU539521/ GU539522/ GU539523/ GU539524/ GU539525/ GU539526/ GU539527/ GU539528/ GU539529/ GU539530/ GU539531/ GU539532/ GU539533/ GU539534/ GU539535/ GU539536/ GU539537/ GU539538/ GU539539/ GU539540/ GU539541/ GU539542/ GU539543/ GU539544/ GU539545/ GU539546/ GU539547/ GU539548/ GU539549/ GU539550/ GU539551/ GU539552/ GU539553/ GU539554/ GU539555/ GU539556/ GU539557/ GU539558/ GU539559/ GU539560/ GU539561/ GU539562/ GU539563/ GU539564/ GU539565/ GU539566/ GU539567/ GU539568/ GU539569/ GU539570/ GU539571/ GU539572/ GU539573/ GU539574/ GU539575/ GU539576/ GU539577/ GU539578/ GU539579/ GU539580/ GU539581/ GU539582/ GU539583/ GU539584/ GU539585/ GU539586/ GU539587/ GU539588/ GU539589/ GU539590/ GU539591/ GU539592/ GU539593/ GU539594/ GU539595/ GU539596/ GU539597/ GU539598/ GU539599/ GU539600/ GU539601/ GU539602/ GU539603/ GU539604/ GU539605/ GU539606/ GU539607/ GU539608/ GU539609/ GU539610/ GU539611/ GU539612/ GU539613/ GU539614/ GU539615/ GU539616/ GU539617/ GU539618/ GU539619/ GU539620/ GU539621/ GU539622/ GU539623/ GU539624/ GU539625/ GU539626/ GU539627/ GU539628/ GU539629/ GU539630/ GU539631/ GU539632/ GU539633/ GU539634/ GU539635/ GU539636/ GU539637/ GU539638/ GU539639/ GU539640/ GU539641/ GU539642/ GU539643/ GU539644/ GU539645/ GU539646/ GU539647/ GU539648/ GU539649/ GU539650/ GU539651/ GU539652/ GU539653/ GU539654/ GU539655/ GU539656/ GU539657/ GU539658/ GU539659/ GU539660/ GU539661/ GU539662/ GU539663/ GU539664/ GU539665/ GU539666/ GU539667/ GU539668/ GU539669/ GU539670/ GU539671/ GU539672/ GU539673/ GU539674/ GU539675/ GU539676/ GU539677/ GU539678/ GU539679/ GU539680/ GU539681/ GU539682/ GU539683/ GU539684/ GU539685/ GU539686/ GU539687/ GU539688/ GU539689/ GU539690/ GU539691/ GU539692/ GU539693/ GU539694/ GU539695/ GU539696/ GU539697/ GU539698/ GU539699/ GU539700/ GU539701/ GU539702/ GU539703/ GU539704/ GU539705/ GU539706/ GU539707/ GU539708/ GU539709/ GU539710/ GU539711/ GU539712/ GU539713/ GU539714/ GU539715/ GU539716/ GU539717/ GU539718/ GU539719/ GU539720/ GU539721/ GU539722/ GU539723/ GU539724/ GU539725/ GU539726/ GU539727/ GU539728/ GU539729/ GU539730/ GU539731/ GU539732/ GU539733/ GU539734/ GU539735/ GU539736/ GU539737/ GU539738/ GU539739/ GU539740/ GU539741/ GU539742/ GU539743/ GU539744/ GU539745/ GU539746/ GU539747/ GU539748/ GU539749/ GU539750/ GU539751/ GU539752/ GU539753/ GU539754/ GU539755/ GU539756/ GU539757/ GU539758/ GU539759/ GU539760/ GU539761/ GU539762/ GU539763/ GU539764/ GU539765/ GU539766/ GU539767/ GU539768/ GU539769/ GU539770/ GU539771/ GU539772/ GU539773/ GU539774/ GU539775/ GU539776/ GU539777/ GU539778/ GU539779/ GU539780/ GU539781/ GU539782/ GU539783/ GU539784/ GU539785/ GU539786/ GU539787/ GU539788/ GU539789/ GU539790/ GU539791/ GU539792/ GU539793/ GU539794/ GU539795/ GU539796/ GU539797/ GU539798/ GU539799/ GU539800/ GU539801/ GU539802/ GU539803/ GU539804/ GU539805/ GU539806/ GU539807/ GU539808/ GU539809/ GU539810/ GU539811/ GU539812/ GU539813/ GU539814/ GU539815/ GU539816/ GU539817/ GU539818/ GU539819/ GU539820/ GU539821/ GU539822/ GU539823/ GU539824/ GU539825/ GU539826/ GU539827/ GU539828/ GU539829/ GU539830/ GU539831/ GU539832/ GU539833/ GU539834/ GU539835/ GU539836/ GU539837/ GU539838/ GU539839/ GU539840/ GU539841/ GU539842/ GU539843/ GU539844/ GU539845/ GU539846/ GU539847/ GU539848/ GU539849/ GU539850/ GU539851/ GU539852/ GU539853/ GU539854/ GU539855/ GU539856/ GU539857/ GU539858/ GU539859/ GU539860/ GU539861/ GU539862/ GU539863/ GU539864/ GU539865/ GU539866/ GU539867/ GU539868/ GU539869/ GU539870/ GU539871/ GU539872/ GU539873/ GU539874/ GU539875/ GU539876/ GU539877/ GU539878/ GU539879/ GU539880/ GU539881/ GU539882/ GU539883/ GU539884/ GU539885/ GU539886/ GU539887/ GU539888/ GU539889/ GU539890/ GU539891/ GU539892/ GU539893/ GU539894/ GU539895/ GU539896/ GU539897/ GU539898/ GU539899/ GU539900/ GU539901/ GU539902/ GU539903/ GU539904/ GU539905/ GU539906/ GU539907/ GU539908/ GU539909/ GU539910/ GU539911/ GU539912/ GU539913/ GU539914/ GU539915/ GU539916/ GU539917/ GU539918/ GU539919/ GU539920/ GU539921/ GU539922/ GU539923/ GU539924/ GU539925/ GU539926/ GU539927/ GU539928/ GU539929/ GU539930/ GU539931/ GU539932/ GU539933/ GU539934/ GU539935/ GU539936/ GU539937/ GU539938/ GU539939/ GU539940/ GU539941/ GU539942/ GU539943/ GU539944/ GU539945/ GU539946/ GU539947/ GU539948/ GU539949/ GU539950/ GU539951/ GU539952/ GU539953/ GU539954/ GU539955/ GU539956/ GU539957/ GU539958/ GU539959/ GU539960/ GU539961/ GU539962/ GU539963/ GU539964/ GU539965/ GU539966/ GU539967/ GU539968/ GU539969/ GU539970/ GU539971/ GU539972/ GU539973/ GU539974/ GU539975/ GU539976/ GU539977/ GU539978/ GU539979/ GU539980/ GU539981/ GU539982/ GU539983/ GU539984/ GU539985/ GU539986/ GU539987/ GU539988/ GU539989/ GU539990/ GU539991/ GU539992/ GU539993/ GU539994/ GU539995/ GU539996/ GU539997/ GU539998/ GU539999/ GU540000/ GU540001/ GU540002/ GU540003/ GU540004/ GU540005/ GU540006/ GU540007/ GU540008/ GU540009/ GU540010/ GU540011/ GU540012/ GU540013/ GU540014/ GU540015/ GU540016/ GU540017/ GU540018/ GU540019/ GU540020/ GU540021/ GU540022/ GU540023/ GU540024/ GU540025/ GU540026/ GU540027/ GU540028/ GU540029/ GU540030/ GU540031/ GU540032/ GU540033/ GU540034/ GU540035/ GU540036/ GU540037/ GU540038/ GU540039/ GU540040/ GU540041/ GU540042/ GU540043/ GU540044/ GU540045/ GU540046/ GU540047/ GU540048/ GU540049/ GU540050/ GU540051/ GU540052/ GU540053/ GU540054/ GU540055/ GU540056/ GU540057/ GU540058/ GU540059/ GU540060/ GU540061/ GU540062/ GU540063/ GU540064/ GU540065/ GU540066/ GU540067/ GU540068/ GU540069/ GU540070/ GU540071/ GU540072/ GU540073/ GU540074/ GU540075/ GU540076/ GU540077/ GU540078/ GU540079/ GU540080/ GU540081/ GU540082/ GU540083/ GU540084/ GU540085/ GU540086/ GU540087/ GU540088/ GU540089/ GU540090/ GU540091/ GU540092/ GU540093/ GU540094/ GU540095/ GU540096/ GU540097/ GU540098/ GU540099/ GU540100/ GU540101/ GU540102/ GU540103/ GU540104/ GU540105/ GU540106/ GU540107/ GU540108/ GU540109/ GU540110/ GU540111/ GU540112/ GU540113/ GU540114/ GU540115/ GU540116/ GU540117/ GU540118/ GU540119/ GU540120/ GU540121/ GU540122/ GU540123/ GU540124/ GU540125/ GU540126/ GU540127/ GU540128/ GU540129/ GU540130/ GU540131/ GU540132/ GU540133/ GU540134/ GU540135/ GU540136/ GU540137/ GU540138/ GU540139/ GU540140/ GU540141/ GU540142/ GU540143/ GU540144/ GU540145/ GU540146/ GU540147/ GU540148/ GU540149/ GU540150/ GU540151/ GU540152/ GU540153/ GU540154/ GU540155/ GU540156/ GU540157/ GU540158/ GU540159/ GU540160/ GU540161/ GU540162/ GU540163/ GU540164/ GU540165/ GU540166/ GU540167/ GU540168/ GU540169/ GU540170/ GU540171/ GU540172/ GU540173/ GU540174/ GU540175/ GU540176/ GU540177/ GU540178/ GU540179/ GU540180/ GU540181/ GU540182/ GU540183/ GU540184/ GU540185/ GU540186/ GU540187/ GU540188/ GU540189/ GU540190/ GU540191/ GU540192/ GU540193/ GU540194/ GU540195/ GU540196/ GU540197/ GU540198/ GU540199/ GU540200/ GU540201/ GU540202/ GU540203/ GU540204/ GU540205/ GU540206/ GU540207/ GU540208/ GU540209/ GU540210/ GU540211/ GU540212/ GU540213/ GU540214/ GU540215/ GU540216/ GU540217/ GU540218/ GU540219/ GU540220/ GU540221/ GU540222/ GU540223/ GU540224/ GU540225/ GU540226/ GU540227/ GU540228/ GU540229/ GU540230/ GU540231/ GU540232/ GU540233/ GU540234/ GU540235/ GU540236/ GU540237/ GU540238/ GU540239/ GU540240/ GU540241/ GU540242/ GU540243/ GU540244/ GU540245/ GU540246/ GU540247/ GU540248/ GU540249/ GU540250/ GU540251/ GU540252/ GU540253/ GU540254/ GU540255/ GU540256/ GU540257/ GU540258/ GU540259/ GU540260/ GU540261/ GU540262/ GU540263/ GU540264/ GU540265/ GU540266/ GU540267/ GU540268/ GU540269/ GU540270/ GU540271/ GU540272/ GU540273/ GU540274/ GU540275/ GU540276/ GU540277/ GU540278/ GU540279/ GU540280/ GU540281/ GU540282/ GU540283/ GU540284/ GU540285/ GU540286/ GU540287/ GU540288/ GU540289/ GU540290/ GU540291/ GU540292/ GU540293/ GU540294/ GU540295/ GU540296/ GU540297/ GU540298/ GU540299/ GU540300/ GU540301/ GU540302/ GU540303/ GU540304/ GU540305/ GU540306/ GU540307/ GU540308/ GU540309/ GU540310/ GU540311/ GU540312/ GU540313/ GU540314/ GU540315/ GU540316/ GU540317/ GU540318/ GU540319/ GU540320/ GU540321/ GU540322/ GU540323/ GU540324/ GU540325/ GU540326/ GU540327/ GU540328/ GU540329/ GU540330/ GU540331/ GU540332/ GU540333/ GU540334/ GU540335/ GU540336/ GU540337/ GU540338/ GU540339/ GU540340/ GU540341/ GU540342/ GU540343/ GU540344/ GU540345/ GU540346/ GU540347/ GU540348/ GU540349/ GU540350/ GU540351/ GU540352/ GU540353/ GU540354/ GU540355/ GU540356/ GU540357/ GU540358/ GU540359/ GU540360/ GU540361/ GU540362/ GU540363/ GU540364/ GU540365/ GU540366/ GU540367/ GU540368/ GU540369/ GU540370/ GU540371/ GU540372/ GU540373/ GU540374/ GU540375/ GU540376/ GU540377/ GU540378/ GU540379/ GU540380/ GU540381/ GU540382/ GU540383/ GU540384/ GU540385/ GU540386/ GU540387/ GU540388/ GU540389/ GU540390/ GU540391
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / DNA, Bacterial; 0 / DNA, Ribosomal; 0 / RNA, Ribosomal, 16S; 0 / Sewage
  •  go-up   go-down


20. Sopel M: The myoepithelial cell: its role in normal mammary glands and breast cancer. Folia Morphol (Warsz); 2010 Feb;69(1):1-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The myoepithelial cell: its role in normal mammary glands and breast cancer.
  • Mammary gland epithelium is composed of an inner layer of secretory cells (luminal) and an outer layer of myoepithelial cells (MEC) bordering the basal lamina which separates the epithelial layer from the extracellular matrix.
  • The majority of malignant breast cancers are derived from luminal cells, whereas neoplasms of MEC origin are the most seldom and usually benign form of breast tumours.
  • MECs are markedly resistant to malignant transformation and they are able to suppress the transformation of neighboring luminal cells.
  • [MeSH-major] Breast Neoplasms. Mammary Glands, Animal. Mammary Glands, Human. Mammary Neoplasms, Animal. Myeloid Cells

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20235044.001).
  • [ISSN] 0015-5659
  • [Journal-full-title] Folia morphologica
  • [ISO-abbreviation] Folia Morphol. (Warsz)
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Poland
  • [Number-of-references] 84
  •  go-up   go-down


21. Liu Y, Nie H, Bansil R, Steinhart M, Bang J, Lodge TP: Kinetics of disorder-to-fcc phase transition via an intermediate bcc state. Phys Rev E Stat Nonlin Soft Matter Phys; 2006 Jun;73(6 Pt 1):061803
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Kinetics of disorder-to-fcc phase transition via an intermediate bcc state.
  • Time-resolved small-angle x-ray scattering measurements reveal that a long-lived intermediate bcc state forms when a poly(styrene-b-isoprene) diblock copolymer solution in an isoprene selective solvent is rapidly cooled from the disordered micellar fluid at high temperature to an equilibrium fcc state.
  • The kinetics of the epitaxial growth of the [111] fcc peak from the [110] bcc peak was obtained by fitting the scattering data to a simple model of the transformation.
  • The growth of the [111] fcc peak agrees with the Avrami model of nucleation and growth kinetics with an exponent n=1.4, as does the initial decay of the [110] bcc peak, with an exponent n=1.3.
  • The data were also found to be in good agreement with the Cahn model of grain boundary nucleation and growth.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16906856.001).
  • [ISSN] 1539-3755
  • [Journal-full-title] Physical review. E, Statistical, nonlinear, and soft matter physics
  • [ISO-abbreviation] Phys Rev E Stat Nonlin Soft Matter Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Zanetti R, Rosso S, Martinez C, Nieto A, Miranda A, Mercier M, Loria DI, Østerlind A, Greinert R, Navarro C, Fabbrocini G, Barbera C, Sancho-Garnier H, Gafà L, Chiarugi A, Mossotti R: Comparison of risk patterns in carcinoma and melanoma of the skin in men: a multi-centre case-case-control study. Br J Cancer; 2006 Mar 13;94(5):743-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We directly compared risk factors between 214 histologically confirmed melanomas (CMM), 215 basal-cell carcinomas (BCC) and 139 squamous-cell carcinomas (SCC) in a multiple case-case-control study with 349 controls from patients without dermatological disease admitted to the same hospitals.
  • [MeSH-major] Carcinoma, Basal Cell / etiology. Carcinoma, Squamous Cell / etiology. Melanoma / etiology. Skin Neoplasms / etiology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 1995 Feb 8;60(4):489-94 [7829262.001]
  • [Cites] Int J Cancer. 1995 Feb 8;60(4):482-8 [7829261.001]
  • [Cites] Arch Dermatol. 1995 Feb;131(2):164-9 [7857112.001]
  • [Cites] Int J Cancer. 1995 Aug 9;62(4):367-76 [7635560.001]
  • [Cites] Br J Cancer. 1996 Jun;73(11):1440-6 [8645595.001]
  • [Cites] Br J Cancer. 1996 Jun;73(11):1447-54 [8645596.001]
  • [Cites] Int J Cancer. 1997 Oct 9;73(2):198-203 [9335442.001]
  • [Cites] Int J Cancer. 1998 Jul 29;77(3):347-53 [9663594.001]
  • [Cites] Melanoma Res. 1998 Dec;8(6):573-83 [9918420.001]
  • [Cites] Eur J Cancer. 2005 Jan;41(1):28-44 [15617989.001]
  • [Cites] Eur J Cancer. 2005 Jan;41(1):45-60 [15617990.001]
  • [Cites] Cancer Causes Control. 2001 Jan;12(1):69-82 [11227927.001]
  • [Cites] Melanoma Res. 2001 Dec;11(6):551-7 [11725201.001]
  • [Cites] Int J Epidemiol. 2002 Apr;31(2):439-46 [11980813.001]
  • [Cites] Br J Cancer. 1982 Dec;46(6):955-60 [7150488.001]
  • [Cites] J Dermatol Surg Oncol. 1983 Dec;9(12):981-6 [6643817.001]
  • [Cites] Br J Cancer. 1985 Mar;51(3):393-7 [3970815.001]
  • [Cites] Int J Cancer. 1985 Apr 15;35(4):427-33 [3988369.001]
  • [Cites] J Natl Cancer Inst. 1986 Mar;76(3):403-14 [3456458.001]
  • [Cites] Stat Med. 1986 Jan-Feb;5(1):49-60 [3961315.001]
  • [Cites] Am J Epidemiol. 1986 Jun;123(6):1101-17 [3706280.001]
  • [Cites] J Am Acad Dermatol. 1987 Sep;17(3):459-68 [3655025.001]
  • [Cites] Int J Cancer. 1988 Aug 15;42(2):200-6 [3403065.001]
  • [Cites] Rev Epidemiol Sante Publique. 1988;36(4-5):309-17 [3217570.001]
  • [Cites] Int J Epidemiol. 1990 Dec;19(4):801-10 [2084006.001]
  • [Cites] Int J Cancer. 1991 Jul 9;48(5):650-62 [2071226.001]
  • [Cites] Eur J Cancer. 1992;28A(6-7):1172-6 [1627390.001]
  • [Cites] Arch Dermatol. 1995 Feb;131(2):157-63 [7857111.001]
  • (PMID = 16495934.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2361214
  •  go-up   go-down


23. Broers S, Smets E, Bindels P, Evertsz' FB, Calff M, de Haes H: Training general practitioners in behavior change counseling to improve asthma medication adherence. Patient Educ Couns; 2005 Sep;58(3):279-87
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Training general practitioners in behavior change counseling to improve asthma medication adherence.
  • OBJECTIVE: Adherence to asthma medication regimens is problematic in general practice.
  • We developed and evaluated a communication training for general practitioners (GPs) to help them address medication adherence during routine consultations.
  • This paper describes the development of the training and evaluation results of a pilot study.
  • METHODS: The training was based on behavior change counseling (BCC), a technique derived from motivational interviewing.
  • We developed a five phases BCC consultation model.
  • Participating GPs answered questions at baseline (T0), directly after (T1) and 4-10 months after (T2) the training that assessed their attitudes and confidence regarding adherence communication.
  • They completed evaluation forms at T1 and T2.
  • RESULTS: The 19 participating GPs were positive about the course and the feasibility of BCC in GP consultations.
  • Also, after the training, their attitudes and confidence had improved (p<0.05) and all reported to use BCC skills at least sometimes 4-10 months after the training.
  • CONCLUSION: These positive effects provide us with some hope that the training positively influenced the GP's communication behavior.
  • PRACTICE IMPLICATIONS: If further data on physician behavior and patient outcomes justify implementation of the training, it would then be worthwhile to also involve practice nurses.
  • [MeSH-major] Asthma / drug therapy. Counseling / education. Education, Medical, Continuing. Family Practice / education. Patient Compliance
  • [MeSH-minor] Adult. Female. Humans. Male. Middle Aged. Netherlands. Pilot Projects. Statistics, Nonparametric

  • Genetic Alliance. consumer health - Asthma.
  • MedlinePlus Health Information. consumer health - Asthma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16024211.001).
  • [ISSN] 0738-3991
  • [Journal-full-title] Patient education and counseling
  • [ISO-abbreviation] Patient Educ Couns
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  •  go-up   go-down


24. Hansen CR, Pressler T, Nielsen KG, Jensen PØ, Bjarnsholt T, Høiby N: Inflammation in Achromobacter xylosoxidans infected cystic fibrosis patients. J Cyst Fibros; 2010 Jan;9(1):51-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adolescent. Adult. Anti-Bacterial Agents / therapeutic use. Biofilms. Breath Tests. Child. Drug Resistance, Bacterial. Female. Forced Expiratory Volume. Granulocyte Colony-Stimulating Factor / metabolism. Humans. Interferon-gamma / blood. Interferon-gamma / metabolism. Interleukin-10 / metabolism. Interleukin-1beta / metabolism. Interleukin-6 / blood. Interleukin-6 / metabolism. Interleukin-8 / metabolism. Male. Pneumonia, Bacterial / complications. Pneumonia, Bacterial / drug therapy. Pneumonia, Bacterial / immunology. Retrospective Studies. Sputum / metabolism. Sputum / microbiology. Tumor Necrosis Factor-alpha / metabolism. Young Adult

  • Genetic Alliance. consumer health - BabysFirstTest - Cystic Fibrosis.
  • Genetic Alliance. consumer health - Cystic Fibrosis.
  • MedlinePlus Health Information. consumer health - Cystic Fibrosis.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19939747.001).
  • [ISSN] 1873-5010
  • [Journal-full-title] Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
  • [ISO-abbreviation] J. Cyst. Fibros.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / IL10 protein, human; 0 / IL6 protein, human; 0 / Interleukin-1beta; 0 / Interleukin-6; 0 / Interleukin-8; 0 / Tumor Necrosis Factor-alpha; 130068-27-8 / Interleukin-10; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


25. Kim JM, Cho EN, Kwon YE, Bae SJ, Kim M, Seol JH: CHFR functions as a ubiquitin ligase for HLTF to regulate its stability and functions. Biochem Biophys Res Commun; 2010 May 14;395(4):515-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CHFR is frequently silenced by hypermethylation in human cancers, indicating that CHFR is a tumor suppressor.
  • HLTF modulates basal expression of PAI-1 involved in regulation of cell migration.
  • Consistently, overexpression of CHFR inhibits cell migration, resulting from reduced HLTF followed by decreased PAI-1 expression.
  • [MeSH-major] Cell Cycle Proteins / physiology. DNA-Binding Proteins / metabolism. Neoplasm Proteins / physiology. Neoplasms / enzymology. Transcription Factors / metabolism. Ubiquitin-Protein Ligases / physiology
  • [MeSH-minor] Cell Line, Tumor. HeLa Cells. Humans. Plasminogen Activator Inhibitor 1 / metabolism. Proteasome Endopeptidase Complex / metabolism. Protein Stability

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20388495.001).
  • [ISSN] 1090-2104
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CHFR protein, human; 0 / Cell Cycle Proteins; 0 / DNA-Binding Proteins; 0 / HLTF protein, human; 0 / Neoplasm Proteins; 0 / Plasminogen Activator Inhibitor 1; 0 / SERPINE1 protein, human; 0 / Transcription Factors; EC 3.4.25.1 / Proteasome Endopeptidase Complex; EC 6.3.2.19 / Ubiquitin-Protein Ligases
  •  go-up   go-down


26. Knower KC, To SQ, Simpson ER, Clyne CD: Epigenetic mechanisms regulating CYP19 transcription in human breast adipose fibroblasts. Mol Cell Endocrinol; 2010 Jun 10;321(2):123-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In post-menopausal women, adipose becomes the major site for estrogen production, where basal CYP19 transcription is driven by distal promoter I.4.
  • In breast adipose fibroblasts (BAFs), CYP19 expression is elevated in the presence of tumour-derived factors through use of promoters I.3 and II.
  • We show for the first time that DNA methylation contributes to CYP19 regulation in BAFs and breast cell lines.
  • However, inhibition of DNA methylation with 5-aza-2'-deoxycytidine resulted in a significant approximately 40-fold induction in CYP19 mRNA expression in BAFs and breast cell lines.
  • [MeSH-major] Aromatase / metabolism. Breast Neoplasms / metabolism. Epigenesis, Genetic. Fibroblasts / metabolism. Gene Expression Regulation. Promoter Regions, Genetic
  • [MeSH-minor] Adipose Tissue / cytology. Adipose Tissue / metabolism. Cell Line, Tumor. CpG Islands / genetics. DNA Methylation / physiology. DNA-Cytosine Methylases / metabolism. Female. Humans. RNA, Messenger / metabolism

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published by Elsevier Ireland Ltd.
  • (PMID = 20211687.001).
  • [ISSN] 1872-8057
  • [Journal-full-title] Molecular and cellular endocrinology
  • [ISO-abbreviation] Mol. Cell. Endocrinol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / RNA, Messenger; EC 1.14.14.1 / Aromatase; EC 2.1.1.- / DNA modification methylase SssI; EC 2.1.1.- / DNA-Cytosine Methylases
  •  go-up   go-down


27. Raaby L, Otkjær K, Salvskov-Iversen ML, Johansen C, Iversen L: A Characterization of the expression of 14-3-3 isoforms in psoriasis, basal cell carcinoma, atopic dermatitis and contact dermatitis. Dermatol Reports; 2010 Aug 31;2(2):e14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A Characterization of the expression of 14-3-3 isoforms in psoriasis, basal cell carcinoma, atopic dermatitis and contact dermatitis.
  • 14-3-3 is a highly conserved protein involved in a number of cellular processes including cell signalling, cell cycle regulation and gene transcription.
  • To investigate the expression of the seven 14-3-3 isoforms in involved and uninvolved skin from psoriasis, basal cell carcinoma (BCC), atopic dermatitis and nickel induced allergic contact dermatitis.
  • These results demonstrate a disease specific expression profile of the 14-3-3τ and 14-3-3σ iso-forms.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 25386251.001).
  • [ISSN] 2036-7392
  • [Journal-full-title] Dermatology reports
  • [ISO-abbreviation] Dermatol Reports
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC4211473
  • [Keywords] NOTNLM ; 14-3-3 proteins / allergic contact dermatitis / atopic dermatitis. / basal cell carcinoma / psoriasis
  •  go-up   go-down


28. Brasanac D, Boricic I, Todorovic V, Tomanovic N, Radojevic S: Cyclin A and beta-catenin expression in actinic keratosis, Bowen's disease and invasive squamous cell carcinoma of the skin. Br J Dermatol; 2005 Dec;153(6):1166-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyclin A and beta-catenin expression in actinic keratosis, Bowen's disease and invasive squamous cell carcinoma of the skin.
  • BACKGROUND: Actinic keratosis (AK) has been defined as a precancerous lesion or an early phase in the evolution of squamous cell carcinoma (SCC) and histological changes seen in the individual cells of an AK are indistinguishable from those seen in SCC, which invade the dermis.
  • Cyclin A is an increasingly utilized proliferation marker that has functions in both S phase (DNA replication) and initiation of mitosis, whereas alterations of beta-catenin, the molecule involved in cell-cell adhesion and in signalling transduction, could promote invasive and proliferative capacities of malignant tumours.
  • OBJECTIVES: To determine cyclin A and beta-catenin expression pattern in cutaneous SCC and in in situ lesions classified as keratinocytic intraepidermal neoplasia (KIN) and, using traditional terms, as AK and Bowen's disease (BD), and to analyse it in relation to SCC differentiation, diameter and thickness.
  • Aberrant beta-catenin cellular localization demonstrated 28 lesions (25.5%), most often in the basal or peripheral parts and in the lesions with diffuse beta-catenin loss (P = 0.009), but revealed no correlation with the histological type, SCC level of differentiation or KIN grades.
  • Diffuse loss of membranous beta-catenin staining was found to be significantly more frequent in SCC thicker than 4 mm (P = 0.03), while all other comparisons between cyclin A or beta-catenin with the tumour size remained nonsignificant.
  • Diffuse pattern of loss of membranous beta-catenin staining correlated better with the type of lesion, SCC differentiation and tumour size than reduced expression in general or aberrant cellular localization of beta-catenin.
  • [MeSH-major] Carcinoma, Squamous Cell / metabolism. Cyclin A / metabolism. Keratosis / metabolism. Skin Neoplasms / metabolism. beta Catenin / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Bowen's Disease / metabolism. Bowen's Disease / pathology. Disease Progression. Female. Humans. Immunoenzyme Techniques. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Proteins / metabolism. Precancerous Conditions / metabolism. Precancerous Conditions / pathology


29. Elmets CA, Viner JL, Pentland AP, Cantrell W, Lin HY, Bailey H, Kang S, Linden KG, Heffernan M, Duvic M, Richmond E, Elewski BE, Umar A, Bell W, Gordon GB: Chemoprevention of nonmelanoma skin cancer with celecoxib: a randomized, double-blind, placebo-controlled trial. J Natl Cancer Inst; 2010 Dec 15;102(24):1835-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We evaluated the efficacy and safety of celecoxib, a cyclooxygenase 2 inhibitor, as a chemopreventive agent for actinic keratoses, the premalignant precursor of nonmelanoma skin cancers, and for nonmelanoma skin cancers, including cutaneous squamous cell carcinomas (SCCs) and basal cell carcinomas (BCCs).
  • However, at 11 months after randomization, there were fewer nonmelanoma skin cancers in the celecoxib arm than in the placebo arm (mean cumulative tumor number per patient 0.14 vs 0.35; rate ratio [RR] = .43, 95% confidence interval [CI] = 0.24 to 0.75; P = .003).

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • Hazardous Substances Data Bank. CELECOXIB .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2000 Jun 29;342(26):1946-52 [10874062.001]
  • [Cites] J Am Acad Dermatol. 1994 May;30(5 Pt 1):774-8 [8176018.001]
  • [Cites] J Invest Dermatol. 1994 Jun;102(6):4S-5S [8006434.001]
  • [Cites] J Invest Dermatol. 2000 Aug;115(2):273-7 [10951246.001]
  • [Cites] Int J Cancer. 2001 Jan 20;95(1):7-11 [11241303.001]
  • [Cites] Lancet. 2001 Mar 24;357(9260):926-9 [11289350.001]
  • [Cites] Arch Dermatol. 2001 Aug;137(8):1055-8 [11493098.001]
  • [Cites] Oncology (Williston Park). 2002 May;16(5 Suppl 4):37-51 [12102579.001]
  • [Cites] Photochem Photobiol. 2002 Jul;76(1):73-80 [12126310.001]
  • [Cites] N Engl J Med. 2003 Mar 6;348(10):891-9 [12621133.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Oct;12(10):1105-8 [14578151.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Jun;13(6):920-7 [15184247.001]
  • [Cites] J Drugs Dermatol. 2004 Jul-Aug;3(4):401-7 [15303784.001]
  • [Cites] Br J Dermatol. 1994 Oct;131(4):455-64 [7947197.001]
  • [Cites] Arch Dermatol. 1995 Feb;131(2):170-5 [7857113.001]
  • [Cites] Int J Cancer. 1995 Jul 17;62(2):165-9 [7622291.001]
  • [Cites] Br J Cancer. 1996 Oct;74(8):1302-7 [8883422.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1997 Nov;6(11):957-61 [9367070.001]
  • [Cites] Carcinogenesis. 1998 May;19(5):723-9 [9635856.001]
  • [Cites] Br J Dermatol. 1998 Dec;139(6):1033-9 [9990367.001]
  • [Cites] Mol Carcinog. 1999 Aug;25(4):231-40 [10449029.001]
  • [Cites] Lancet. 1999 Aug 28;354(9180):723-9 [10475183.001]
  • [Cites] Carcinogenesis. 1999 Oct;20(10):1939-44 [10506108.001]
  • [Cites] N Engl J Med. 2005 Mar 17;352(11):1071-80 [15713944.001]
  • [Cites] Br J Dermatol. 2005 Mar;152(3):518-23 [15787821.001]
  • [Cites] JAMA. 2005 Aug 10;294(6):681-90 [16091570.001]
  • [Cites] J Exp Med. 2005 Oct 3;202(7):931-9 [16186186.001]
  • [Cites] J Am Acad Dermatol. 2005 Dec;53(6):966-72 [16310056.001]
  • [Cites] Int J Cancer. 2006 Aug 1;119(3):682-6 [16496410.001]
  • [Cites] J Am Acad Dermatol. 2006 Sep;55(3):490-500 [16908356.001]
  • [Cites] N Engl J Med. 2006 Aug 31;355(9):873-84 [16943400.001]
  • [Cites] N Engl J Med. 2006 Aug 31;355(9):885-95 [16943401.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Dec;15(12):2546-8 [17132769.001]
  • [Cites] N Engl J Med. 2007 Jul 26;357(4):360-9 [17652651.001]
  • [Cites] Mol Carcinog. 2007 Aug;46(8):692-8 [17443745.001]
  • [Cites] Mol Carcinog. 2007 Dec;46(12):981-92 [17583568.001]
  • [Cites] Photochem Photobiol. 2008 Mar-Apr;84(2):463-76 [18248498.001]
  • [Cites] J Am Acad Dermatol. 2008 May;58(5 Suppl 2):S129-32 [18410798.001]
  • [Cites] Circulation. 2008 Apr 22;117(16):2104-13 [18378608.001]
  • [Cites] Crit Rev Oncol Hematol. 2008 Jun;66(3):208-17 [18304833.001]
  • [Cites] Mol Cancer Res. 2008 Jun;6(6):1003-16 [18567804.001]
  • [Cites] Cancer Prev Res (Phila). 2008 Jun;1(1):21-31 [19138933.001]
  • [Cites] J Invest Dermatol. 2009 Apr;129(4):1016-25 [18843292.001]
  • [Cites] Pharmacoepidemiol Drug Saf. 2009 Apr;18(4):276-83 [19226541.001]
  • [Cites] Cancer Prev Res (Phila). 2010 Jan;3(1):25-34 [20051370.001]
  • [Cites] Cancer Prev Res (Phila). 2010 Jan;3(1):35-47 [20051371.001]
  • [Cites] Arch Dermatol. 2010 Mar;146(3):283-7 [20231499.001]
  • [Cites] Arch Dermatol. 2010 Apr;146(4):388-95 [20157019.001]
  • [Cites] Australas J Dermatol. 1983 Aug;24(2):79-82 [6661117.001]
  • [Cites] N Engl J Med. 1988 Jun 23;318(25):1633-7 [3287161.001]
  • [Cites] J Natl Cancer Inst. 1992 Mar 4;84(5):328-32 [1738183.001]
  • [Cites] JAMA. 1992 Jun 24;267(24):3305-10 [1597912.001]
  • [Cites] N Engl J Med. 1993 Oct 14;329(16):1147-51 [8377777.001]
  • [Cites] N Engl J Med. 1994 May 5;330(18):1272-5 [8145782.001]
  • [CommentIn] J Natl Cancer Inst. 2010 Dec 15;102(24):1815-7 [21115881.001]
  • [CommentIn] Arch Dermatol. 2012 May;148(5):638-40 [22782153.001]
  • (PMID = 21115882.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CN / N01-CN-85183; United States / NIAMS NIH HHS / AR / P30 AR050948; United States / NCI NIH HHS / CA / P30 CA013148
  • [Publication-type] Clinical Trial, Phase II; Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Cyclooxygenase 2 Inhibitors; 0 / Pyrazoles; 0 / Sulfonamides; JCX84Q7J1L / Celecoxib
  • [Other-IDs] NLM/ PMC3001966
  •  go-up   go-down


30. Wenzel J, Tomiuk S, Zahn S, Küsters D, Vahsen A, Wiechert A, Mikus S, Birth M, Scheler M, von Bubnoff D, Baron JM, Merk HF, Mauch C, Krieg T, Bieber T, Bosio A, Hofmann K, Tüting T, Peters B: Transcriptional profiling identifies an interferon-associated host immune response in invasive squamous cell carcinoma of the skin. Int J Cancer; 2008 Dec 1;123(11):2605-15
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transcriptional profiling identifies an interferon-associated host immune response in invasive squamous cell carcinoma of the skin.
  • Squamous cell carcinoma (SCC) and basal cell carcinoma (BCC) represent the 2 most common types of nonmelanoma skin cancer.
  • Here we present transcriptional profiling data of a large cohort of tumor patients (SCC, n = 42; BCC, n = 114).
  • Differentially expressed genes reflect known features of SCC and BCC including the typical cytokeratin pattern as well as upregulation of characteristic cell proliferation genes.
  • The expression of IFN-regulated genes correlated with the extent of the lesional immune-cell infiltrate.
  • Collectively, our findings support the concept that IFN-associated host responses play an important role in tumor immunosurveillance in the skin.
  • [MeSH-major] Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / immunology. Gene Expression Regulation, Neoplastic / genetics. Interferons / immunology. Skin Neoplasms / genetics. Skin Neoplasms / immunology. Transcription, Genetic / genetics
  • [MeSH-minor] Aged. Aged, 80 and over. Cell Differentiation. Cell Proliferation. Female. Gene Expression Profiling. Humans. Immunohistochemistry. Keratins / genetics. Male. Middle Aged. Neoplasm Invasiveness / genetics. Neoplasm Invasiveness / immunology. Neoplasm Invasiveness / pathology. Neoplasms, Basal Cell / genetics. Neoplasms, Basal Cell / immunology. Neoplasms, Basal Cell / pathology


31. Kwon GT, Cho HJ, Chung WY, Park KK, Moon A, Park JH: Isoliquiritigenin inhibits migration and invasion of prostate cancer cells: possible mediation by decreased JNK/AP-1 signaling. J Nutr Biochem; 2009 Sep;20(9):663-76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • ISL inhibited basal and EGF-induced cell migration, invasion and adhesion dose dependently.
  • In addition, ISL decreased the protein levels of integrin-alpha2, intercellular adhesion molecule (ICAM) and vascular cell adhesion molecule (VCAM), and mRNA levels of uPA, MMP-9, VEGF, ICAM and integrin-alpha2.
  • Furthermore, basal and EGF-induced activator protein (AP)-1 binding activity and phosphorylation of Jun N-terminal kinase (JNK), c-Jun and Akt were decreased after ISL treatment.
  • The JNK inhibitor SP600125 inhibited basal and EGF-induced secretion of uPA, VEGF, MMP-9 and TIMP-1, as well as AP-1 DNA binding activity and cell migration.
  • The inhibition of JNK/AP-1 signaling may be one of the mechanisms by which ISL inhibits cancer cell invasion and migration.
  • [MeSH-major] Cell Movement / drug effects. Chalcones / pharmacology. Enzyme Inhibitors / pharmacology. JNK Mitogen-Activated Protein Kinases / metabolism. Prostatic Neoplasms / pathology. Transcription Factor AP-1 / metabolism
  • [MeSH-minor] Androgens / physiology. Cell Adhesion / drug effects. Cell Line. Cell Line, Tumor. Dose-Response Relationship, Drug. Epidermal Growth Factor / physiology. Humans. Male. Matrix Metalloproteinase 9 / secretion. Neoplasm Invasiveness. Neoplasm Metastasis / drug therapy. Proto-Oncogene Proteins c-akt / metabolism. Signal Transduction / drug effects. Tissue Inhibitor of Metalloproteinase-2 / secretion. Vascular Endothelial Growth Factors / secretion


32. Basyuk E, Coulon V, Le Digarcher A, Coisy-Quivy M, Moles JP, Gandarillas A, Journot L: The candidate tumor suppressor gene ZAC is involved in keratinocyte differentiation and its expression is lost in basal cell carcinomas. Mol Cancer Res; 2005 Sep;3(9):483-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The candidate tumor suppressor gene ZAC is involved in keratinocyte differentiation and its expression is lost in basal cell carcinomas.
  • ZAC is a zinc finger transcription factor that induces apoptosis and cell cycle arrest in various cell lines.
  • The corresponding gene is maternally imprinted and localized on chromosome 6q24-q25, a region harboring an unidentified tumor suppressor gene for a variety of solid neoplasms.
  • ZAC expression is lost or down-regulated in some breast, ovary, and pituitary tumors and in an in vitro model of ovary epithelial cell transformation.
  • In the present study, we examined ZAC expression in normal skin and found a high expression level in basal keratinocytes and a lower, more heterogeneous, expression in the first suprabasal differentiating layers of epidermis.
  • Interestingly, we found a dramatic loss of ZAC expression in basal cell carcinoma, a neoplasm characterized by a relatively undifferentiated morphology.
  • In contrast, ZAC expression was maintained in squamous cell carcinomas that retain the squamous differentiated phenotype.
  • [MeSH-major] Cell Cycle Proteins / metabolism. Cell Differentiation. Keratinocytes / cytology. Skin Neoplasms / metabolism. Transcription Factors / metabolism
  • [MeSH-minor] Carcinoma, Basal Cell / genetics. Carcinoma, Basal Cell / metabolism. Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Cells, Cultured. Genes, Tumor Suppressor. Humans. In Situ Hybridization. RNA Probes. Tumor Suppressor Proteins. Zinc Fingers

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16179495.001).
  • [ISSN] 1541-7786
  • [Journal-full-title] Molecular cancer research : MCR
  • [ISO-abbreviation] Mol. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / PLAGL1 protein, human; 0 / RNA Probes; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


33. Kishikawa M, Koyama K, Iseki M, Kobuke T, Yonehara S, Soda M, Ron E, Tokunaga M, Preston DL, Mabuchi K, Tokuoka S: Histologic characteristics of skin cancer in Hiroshima and Nagasaki: background incidence and radiation effects. Int J Cancer; 2005 Nov 10;117(3):363-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Skin tumor incident cases diagnosed between 1958 and 1987 were ascertained by linkage to the Hiroshima and Nagasaki tumor registries augmented by searches of other data sources.
  • Study pathologists reviewed tumor specimens and pathology reports and classified tumors using the World Health Organization classification scheme.
  • They identified 274 primary incident skin cancers, of which 106 were basal cell carcinoma (BCC), 81 were squamous cell carcinoma (SCC), and 14 were malignant melanomas.
  • [MeSH-major] Nuclear Warfare. Skin Neoplasms / epidemiology. Skin Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Cohort Studies. Female. Humans. Incidence. Japan / epidemiology. Male. Middle Aged. Neoplasms, Radiation-Induced. Radioactive Fallout

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley-Liss, Inc.
  • (PMID = 15900592.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CP / N01-CP-31012; United States / NCI NIH HHS / CP / N01-CP-71015
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radioactive Fallout
  •  go-up   go-down


34. Bobadilla F, Wortsman X, Muñoz C, Segovia L, Espinoza M, Jemec GB: Pre-surgical high resolution ultrasound of facial basal cell carcinoma: correlation with histology. Cancer Imaging; 2008;8:163-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pre-surgical high resolution ultrasound of facial basal cell carcinoma: correlation with histology.
  • The aim of this study was to analyze the scope of pre-surgical high resolution ultrasound in basal cell carcinoma (BCC).
  • Pre-operative imaging may aid surgical planning by identifying the extent and location of a neoplasm, which can be interesting at zones with higher risk of recurrences such as the face.
  • Ultrasound reported the morphology and thickness of the tumors.
  • Ultrasound identified 29 suspicious facial lesions that were removed with tumor-free borders at the first surgery and confirmed by histology.
  • The intraclass correlation coefficient (ICC) value was used to compare tumor thickness measurements between ultrasound and histology.
  • It has a good thickness correlation with histology and may be used as a technique to monitor disease changes following non-invasive medical treatments in the future.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Carcinoma, Basal Cell / ultrasonography. Skin Neoplasms / pathology. Skin Neoplasms / ultrasonography. Ultrasonography, Doppler, Color

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Dermatol. 2000 Aug;10(6):492-7 [10980479.001]
  • [Cites] J Cancer Res Ther. 2006 Jul-Sep;2(3):140-3 [17998694.001]
  • [Cites] Ann Plast Surg. 2001 Feb;46(2):192-3 [11216624.001]
  • [Cites] J Radiol. 2001 May;82(5):563-71 [11416794.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2003 Mar;17(2):167-70 [12705745.001]
  • [Cites] BMJ. 2003 Oct 4;327(7418):794-8 [14525881.001]
  • [Cites] Clin Exp Dermatol. 2003 Nov;28(6):632-8 [14616832.001]
  • [Cites] Skin Res Technol. 2004 Feb;10(1):23-31 [14731245.001]
  • [Cites] Dermatol Surg. 2004 Feb;30(2 Pt 2):301-10 [14871225.001]
  • [Cites] Acta Derm Venereol. 2004;84(1):44-7 [15040477.001]
  • [Cites] J Biomed Opt. 2004 Mar-Apr;9(2):292-8 [15065894.001]
  • [Cites] J Am Acad Dermatol. 1990 Mar;22(3):413-7 [2312827.001]
  • [Cites] J Am Acad Dermatol. 1991 Jan;24(1):1-13 [1999506.001]
  • [Cites] Radiology. 1993 Oct;189(1):69-76 [8372222.001]
  • [Cites] Cutis. 1994 Jan;53(1):44-8 [8119078.001]
  • [Cites] Dermatol Surg. 1996 Feb;22(2):131-6 [8608374.001]
  • [Cites] Radiographics. 1997 Nov-Dec;17(6):1559-65 [9397463.001]
  • [Cites] Eur J Radiol. 1998 May;27 Suppl 2:S215-23 [9652525.001]
  • [Cites] Ophthalmologica. 1998;212 Suppl 1:40-1 [9730747.001]
  • [Cites] Ann Dermatol Venereol. 1998 Aug;125(8):500-4 [9747315.001]
  • [Cites] Br J Plast Surg. 1999 Jan;52(1):24-8 [10343586.001]
  • [Cites] Arch Dermatol. 1999 Oct;135(10):1177-83 [10522664.001]
  • [Cites] Arch Dermatol. 2005 Feb;141(2):217-24 [15724019.001]
  • [Cites] Arch Dermatol. 2006 Feb;142(2):187-94 [16490846.001]
  • [Cites] Otolaryngol Head Neck Surg. 2006 Mar;134(3):471-5 [16500447.001]
  • [Cites] Radiol Med. 2006 Aug;111(5):702-8 [16791462.001]
  • [Cites] Eur J Dermatol. 2006 Sep-Oct;16(5):543-7 [17101476.001]
  • [Cites] J Radiol. 2006 Dec;87(12 Pt 2):1946-61 [17211309.001]
  • [Cites] Bull Cancer. 2007 Jan;94(1):93-8 [17237009.001]
  • [Cites] J Cutan Med Surg. 2006 May-Jun;10(3):122-7 [17241587.001]
  • [Cites] Acta Derm Venereol. 2007;87(4):330-4 [17598036.001]
  • [Cites] Plast Reconstr Surg. 2007 Oct;120(5):1240-8 [17898596.001]
  • [Cites] Dermatol Surg. 2007 Oct;33(10):1158-74 [17903149.001]
  • [Cites] Dermatol Surg. 2007 Oct;33(10):1207-14 [17903153.001]
  • [Cites] Dermatol Surg. 2007 Oct;33(10):1215-9 [17903154.001]
  • [Cites] Dermatol Surg. 2007 Oct;33(10):1220-7; discussion 1226-7 [17903155.001]
  • [Cites] Dermatol Surg. 2007 Nov;33(11):1340-2 [17958586.001]
  • [Cites] Br J Plast Surg. 2000 Oct;53(7):563-6 [11000071.001]
  • (PMID = 18812268.001).
  • [ISSN] 1470-7330
  • [Journal-full-title] Cancer imaging : the official publication of the International Cancer Imaging Society
  • [ISO-abbreviation] Cancer Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2556504
  •  go-up   go-down


35. Guldner L, Multigner L, Héraud F, Monfort C, Thomé JP, Giusti A, Kadhel P, Cordier S: Pesticide exposure of pregnant women in Guadeloupe: ability of a food frequency questionnaire to estimate blood concentration of chlordecone. Environ Res; 2010 Feb;110(2):146-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pesticide exposure of pregnant women in Guadeloupe: ability of a food frequency questionnaire to estimate blood concentration of chlordecone.
  • CONTEXT: Chlordecone, an environmentally persistent organochlorine insecticide used intensively in banana culture in the French West Indies until 1993, has permanently polluted soils and contaminated foodstuffs.
  • Consumption of contaminated food is the main source of exposure nowadays.
  • We sought to identify main contributors to blood chlordecone concentration (BCC) and to validate an exposure indicator based on food intakes.
  • MATERIAL AND METHODS: We used a food frequency questionnaire (FFQ) completed by a sample of 194 pregnant women to estimate their dietary exposure to chlordecone and compared it to blood levels.
  • In a first approach, chlordecone daily intake was estimated as the product of daily eaten quantity of 214 foodstuffs, multiplied by their chlordecone content, and summed over all items.
  • We then predicted individual blood chlordecone concentration with empirical weight regression models based on frequency of food consumption, and without contamination data.
  • RESULTS: Among the 191 subjects who had BCC determination, 146 (76%) had detectable values and mean BCC was 0.86 ng/mL (range < LOD-13.2).
  • Mean per capita dietary intake of chlordecone was estimated at 3.3 microg/day (range: 0.1-22.2).
  • Blood chlordecone levels were significantly correlated with food exposure predicted from the empirical weight models (r=0.47, p<0.0001) and, to a lesser extent, with chlordecone intake estimated from food consumption and food contamination data (r=0.20, p=0.007).
  • Main contributors to chlordecone exposure included seafood, root vegetables, and Cucurbitaceous.
  • CONCLUSION: These results show that the Timoun FFQ provides valid estimates of chlordecone exposure.
  • Estimates from empirical weight models correlated better with blood levels of chlordecone than did estimates from the dietary intake assessment.
  • [MeSH-major] Chlordecone / blood. Food Contamination. Pesticides / blood. Pregnancy / blood. Soil Pollutants / blood
  • [MeSH-minor] Adolescent. Adult. Cohort Studies. Diet. Environmental Exposure. Female. Guadeloupe. Humans. Middle Aged. Prospective Studies. Regression Analysis. Socioeconomic Factors. Surveys and Questionnaires. Young Adult

  • MedlinePlus Health Information. consumer health - Foodborne Illness.
  • MedlinePlus Health Information. consumer health - Pesticides.
  • MedlinePlus Health Information. consumer health - Pregnancy.
  • HAL archives ouvertes. Full text from .
  • Hazardous Substances Data Bank. KEPONE .
  • ORBi (University of Liege). Free full Text at ORBi .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Elsevier Inc. All rights reserved.
  • (PMID = 20003965.001).
  • [ISSN] 1096-0953
  • [Journal-full-title] Environmental research
  • [ISO-abbreviation] Environ. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Pesticides; 0 / Soil Pollutants; RG5XJ88UDF / Chlordecone
  •  go-up   go-down


36. Allison AS, McIntyre MA, McArdle C, Habib FK: The insulin-like growth factor type 1 receptor and colorectal neoplasia: insights into invasion. Hum Pathol; 2007 Nov;38(11):1590-602
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The insulin-like growth factor type 1 receptor and colorectal neoplasia: insights into invasion.
  • This study examines the expression of the insulin-like growth factor type 1 receptor (IGF-1R) in colorectal neoplasia.
  • We show for the first time that (1) in normal colorectal crypts, epithelial stem cells in the basal crypt region express high IGF-1R levels, which decrease to low levels when these cells migrate to and differentiate in the mid and upper crypt regions;.
  • (2) in tumor initiation in aberrant crypt foci, all of the transformed cells express high levels of the IGF-1R at stem cell levels throughout the crypt axis;.
  • (3) in tumor progression in adenomatous and cancerous crypts, tumor cells of an epithelial type morphology express high levels of the IGF-1R;.
  • (4) in advanced cancers, low levels of the IGF-1R are expressed in invasive foci where cancer cells dedifferentiate to a mesenchymal-type morphology and show a loss of cell adhesion.
  • Interestingly, these cells can form an alternating pattern with mesenchymal type cells that show cell adhesion and high levels of IGF-1R expression.
  • In summary, this study shows that high-level IGF-1R expression in colorectal neoplasia is initiated by an abnormality of stem cell programmed differentiation in the aberrant crypt focus.
  • However, low-level IGF-1R expression is found in some invasive cancers where it is consequent to cancer cell dedifferentiation to a mesenchymal type morphology with loss of cell adhesion.
  • [MeSH-major] Colorectal Neoplasms / pathology. Neoplasm Invasiveness / physiopathology. Receptor, IGF Type 1

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17651787.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, IGF Type 1
  •  go-up   go-down


37. Bogdanić B, Smud S, Bagatin D, Nola M, Mijatović D, Majerović M: Giant basal cell carcinoma of the back: a case report and review of the literature. Coll Antropol; 2009 Mar;33(1):315-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant basal cell carcinoma of the back: a case report and review of the literature.
  • Basal cell carcinoma (BCC) is the most common cutaneous malignancy and the most common human malignancy in general.
  • Out of all basal cell carcinomas, giant basal cell carcinoma represents less than 1%.
  • Only 10% of all basal cell carcinomas are located on the trunk and majority is located on the head and neck.
  • We describe a patient with a exophytic giant basal cell carcinoma of the back size 8.5 x 8 x 6 cm, infiltrating skin 1.5 cm.
  • Review of the literature that refers to giant basal cell carcinoma was carried out.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19408644.001).
  • [ISSN] 0350-6134
  • [Journal-full-title] Collegium antropologicum
  • [ISO-abbreviation] Coll Antropol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Croatia
  •  go-up   go-down


38. Soulairol R, Fu CC, Barreteau C: Structure and magnetism of bulk Fe and Cr: from plane waves to LCAO methods. J Phys Condens Matter; 2010 Jul 28;22(29):295502
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Structure and magnetism of bulk Fe and Cr: from plane waves to LCAO methods.
  • Magnetic, structural and energetic properties of bulk Fe and Cr were studied using first-principles calculations within density functional theory (DFT).
  • We aimed to identify the dependence of these properties on key approximations of DFT, namely the exchange-correlation functional, the pseudopotential and the basis set.
  • We found a smaller effect of pseudopotentials (PPs) on Fe than on Cr.
  • For instance, the local magnetism of Cr was shown to be particularly sensitive to the potentials representing the core electrons, i.e. projector augmented wave and Vanderbilt ultrasoft PPs predict similar results, whereas standard norm-conserving PPs tend to overestimate the local magnetic moments of Cr in bcc Cr and in dilute bcc FeCr alloys.
  • This drawback is suggested to be closely correlated to the overestimation of Cr solution energy in the latter system.
  • On the other hand, we point out that DFT methods with very reduced localized basis sets (LCAO: linear combination of atomic orbitals) give satisfactory results compared with more robust plane-wave approaches.
  • A minimal-basis representation of '3d' electrons comes to be sufficient to describe non-trivial magnetic phases including spin spirals in both fcc Fe and bcc Cr, as well as the experimental magnetic ground state of bcc Cr showing a spin density wave (SDW) state.
  • In addition, a magnetic 'spd' tight binding model within the Stoner formalism was proposed and validated for Fe and Cr.
  • The respective Stoner parameters were obtained by fitting to DFT data.
  • This efficient semiempirical approach was shown to be accurate enough for studying various collinear and non-collinear phases of bulk Fe and Cr.
  • It also enabled a detailed investigation of different polarization states of SDW in bcc Cr, where the longitudinal state was suggested to be the ground state, consistent with existing experimental data.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21399309.001).
  • [ISSN] 1361-648X
  • [Journal-full-title] Journal of physics. Condensed matter : an Institute of Physics journal
  • [ISO-abbreviation] J Phys Condens Matter
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


39. de Longueville F, Lacroix M, Barbuto AM, Bertholet V, Gallo D, Larsimont D, Marcq L, Zammatteo N, Boffe S, Leclercq G, Remacle J: Molecular characterization of breast cancer cell lines by a low-density microarray. Int J Oncol; 2005 Oct;27(4):881-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular characterization of breast cancer cell lines by a low-density microarray.
  • We designed a low-density microarray carrying 132 DNA capture sequences highly specific for genes known to be differentially expressed among breast tumors and BCC lines or associated with specific tumor properties (cell-cycle alteration, proteolysis, adhesion, hormone sensitivity, etc).
  • Some data obtained were verified or extended by real-time polymerase chain reaction (real-time PCR), Northern blotting, Western blotting, immunohistochemistry and cell growth studies.
  • A few genes that are highly and specifically expressed in one cell line were identified, such as MGB1 (mammaglobin 1) in Evsa-T cells, and PIP (prolactin-inducible protein) in MDA-MB-453 BCC, suggesting an apocrine origin for these latter cells.
  • In conclusion, our results support the utility of a low-density microarray approach in cases where the cost and exhaustiveness of high-density microarrays may constitute a drawback; for instance, in obtaining a rapid phenotype evaluation in cell populations freshly isolated from breast tumors.
  • [MeSH-major] Breast Neoplasms / genetics. Breast Neoplasms / metabolism. Gene Expression Regulation, Neoplastic. Oligonucleotide Array Sequence Analysis
  • [MeSH-minor] Biotinylation. Blotting, Northern. Blotting, Western. Cell Adhesion. Cell Line, Tumor. Cell Proliferation. Cluster Analysis. DNA, Complementary / metabolism. Estrogen Receptor alpha / metabolism. Humans. Image Processing, Computer-Assisted. Immunohistochemistry. Mammaglobin A. Neoplasm Proteins / metabolism. Nucleic Acid Hybridization. Phenotype. Polymerase Chain Reaction. RNA / metabolism. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Time Factors. Uteroglobin / metabolism

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Cellosaurus - a cell line knowledge resource. culture/stock collections - Cell lines described in this publication .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16142302.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / DNA, Complementary; 0 / Estrogen Receptor alpha; 0 / Mammaglobin A; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / SCGB2A2 protein, human; 63231-63-0 / RNA; 9060-09-7 / Uteroglobin
  •  go-up   go-down


40. Chen J, Wang L, Thompson LU: Flaxseed and its components reduce metastasis after surgical excision of solid human breast tumor in nude mice. Cancer Lett; 2006 Mar 28;234(2):168-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Flaxseed and its components reduce metastasis after surgical excision of solid human breast tumor in nude mice.
  • This study determined the effect of 10% flaxseed (FS) and its components, secoisolariciresinol diglycoside (SDG) and flaxseed oil (FO) alone or in combination (SDG+FO), on the metastasis and recurrence of human breast tumor after excision in nude mice.
  • Mice were injected orthotopically with human breast cancer cells (MDA-MB-435) and fed basal diet (BD).
  • There was no significant difference in tumor recurrence among groups.
  • In conclusion, FS and its components inhibited tumor metastasis but not tumor recurrence after surgical excision of the primary tumor.
  • [MeSH-major] Butylene Glycols / therapeutic use. Glucosides / therapeutic use. Linseed Oil / therapeutic use. Mammary Neoplasms, Experimental / drug therapy. Neoplasm Metastasis / prevention & control
  • [MeSH-minor] Animals. Cell Line, Tumor. Female. Humans. Mice. Mice, Nude. Neoplasm Transplantation

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. LINSEED OIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15913884.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Butylene Glycols; 0 / Glucosides; 148244-82-0 / secoisolariciresinol diglucoside; 8001-26-1 / Linseed Oil
  •  go-up   go-down


41. Lorentzen HF, Eefsen RL, Weismann K: Comparison of classical dermatoscopy and acrylic globe magnifier dermatoscopy. Acta Derm Venereol; 2008;88(2):139-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sensitivity for melanoma, benign melanocytic naevi and basal cell carcinoma was 100%, 98% and 85%, respectively.
  • Specificity was 95%, 94% and 100% for melanoma, naevi and basal cell carcinoma.
  • [MeSH-major] Dermoscopy. Skin Neoplasms / pathology
  • [MeSH-minor] Carcinoma, Basal Cell / pathology. Hemangioma / pathology. Humans. Keratosis, Seborrheic / pathology. Nevus / pathology. Observer Variation. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18311441.001).
  • [ISSN] 0001-5555
  • [Journal-full-title] Acta dermato-venereologica
  • [ISO-abbreviation] Acta Derm. Venereol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Sweden
  •  go-up   go-down


42. Li Q, Bagchi MK, Bagchi IC: Identification of a signaling pathway involving progesterone receptor, calcitonin, and tissue tranglutaminase in Ishikawa endometrial cells. Endocrinology; 2006 May;147(5):2147-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To gain insight into the molecular events underlying CT action in the endometrium, we performed gene expression profiling in response to CT in a human endometrial adenocarcinoma cell line, Ishikawa.
  • Other studies revealed that regulation of the tTGase gene by CT occurs via its cell surface receptor and uses both cAMP and Ca(2+) signaling pathways.
  • We also noted that tTGase protein is expressed in human endometrium during the P-dominated midsecretory phase of the menstrual cycle, and it is localized at the basal membrane of glandular epithelium and the surrounding stroma.
  • [MeSH-major] Adenocarcinoma / metabolism. Calcitonin / metabolism. Endometrial Neoplasms / metabolism. Endometrium / cytology. Gene Expression Regulation, Neoplastic. Receptors, Progesterone / metabolism. Signal Transduction. Transglutaminases / metabolism. Uterus / metabolism
  • [MeSH-minor] Blotting, Northern. Calcium / metabolism. Cell Membrane / metabolism. Cells, Cultured. Cyclic AMP / metabolism. Epithelial Cells / metabolism. Female. GTP-Binding Proteins. Homeostasis. Humans. Immunohistochemistry. Microscopy, Fluorescence. Oligonucleotide Array Sequence Analysis. Progesterone / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Steroids / metabolism. Time Factors

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. PROGESTERONE .
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • Hazardous Substances Data Bank. Calcitonin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16439457.001).
  • [ISSN] 0013-7227
  • [Journal-full-title] Endocrinology
  • [ISO-abbreviation] Endocrinology
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / R01-HD-34527; United States / NICHD NIH HHS / HD / R01-HD-44611; United States / NICHD NIH HHS / HD / R01-HD-43381; United States / NICHD NIH HHS / HD / R01 HD043381; United States / NICHD NIH HHS / HD / R01-HD-39291; United States / NCRR NIH HHS / RR / C06 RR
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Progesterone; 0 / Steroids; 4G7DS2Q64Y / Progesterone; 9007-12-9 / Calcitonin; E0399OZS9N / Cyclic AMP; EC 2.3.2.- / transglutaminase 2; EC 2.3.2.13 / Transglutaminases; EC 3.6.1.- / GTP-Binding Proteins; SY7Q814VUP / Calcium
  •  go-up   go-down


43. Siegfried JM, Gubish CT, Rothstein ME, Queiroz de Oliveira PE, Stabile LP: Signaling pathways involved in cyclooxygenase-2 induction by hepatocyte growth factor in non small-cell lung cancer. Mol Pharmacol; 2007 Sep;72(3):769-79
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Signaling pathways involved in cyclooxygenase-2 induction by hepatocyte growth factor in non small-cell lung cancer.
  • We examined four c-Met-positive non-small-cell lung cancer (NSCLC) cell lines for effects of HGF on COX-2.
  • HGF increased COX-2 protein expression 3-fold over basal levels.
  • HGF stimulation resulted in a 4-fold increase in PGE(2) secretion, and treatment of NSCLC cells with exogenous PGE(2) significantly increased cell proliferation.


44. Sathyanarayana UG, Moore AY, Li L, Padar A, Majmudar K, Stastny V, Makarla P, Suzuki M, Minna JD, Feng Z, Gazdar AF: Sun exposure related methylation in malignant and non-malignant skin lesions. Cancer Lett; 2007 Jan 8;245(1-2):112-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sun exposure related methylation in malignant and non-malignant skin lesions.
  • We investigated the aberrant promoter methylation status of 12 genes in skin lesions, both malignant (basal cell carcinomas (BCCs), n=68 and squamous cell carcinomas (SCCs), n=35) and non-malignant (tags, n=58) skin lesions and compared the results of lesions from sun exposed (SE) and sun protected (SP) regions.
  • In this report, we found high frequencies of methylation of several known or suspected tumor suppressor genes in tags and skin cancers.
  • We investigated whether methylation was tumor related.
  • [MeSH-major] DNA Methylation / radiation effects. Skin / radiation effects. Skin Neoplasms / genetics. Sunlight
  • [MeSH-minor] Aged. Cadherins / genetics. Carcinoma, Basal Cell / genetics. Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / pathology. Claudins. Cyclin D2. Cyclin-Dependent Kinase Inhibitor p16 / genetics. Cyclins / genetics. Environmental Exposure. Extracellular Matrix Proteins / genetics. Female. Humans. Laminin / genetics. Male. Membrane Proteins / genetics. Middle Aged. Polymerase Chain Reaction / methods. Transforming Growth Factor beta / genetics. Tumor Suppressor Proteins / genetics. Zonula Occludens-2 Protein

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16494996.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / CCND2 protein, human; 0 / CLDN7 protein, human; 0 / Cadherins; 0 / Claudins; 0 / Cyclin D2; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Cyclins; 0 / Extracellular Matrix Proteins; 0 / Laminin; 0 / Membrane Proteins; 0 / RASSF1 protein, human; 0 / TJP2 protein, human; 0 / Transforming Growth Factor beta; 0 / Tumor Suppressor Proteins; 0 / Zonula Occludens-2 Protein; 148710-76-3 / betaIG-H3 protein
  •  go-up   go-down


45. Janković-Velicković L, Katić V, Ignjatović I: [Morphological markers of secretory activity in prostatic adenocarcinoma]. Vojnosanit Pregl; 2007 Sep;64(9):617-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histological diagnosis of prostate cancer relies on the infiltrative growth pattern, presence of macronucleoli, and absence of basal cell layer.
  • [MeSH-major] Adenocarcinoma / secretion. Prostatic Neoplasms / secretion

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17969817.001).
  • [ISSN] 0042-8450
  • [Journal-full-title] Vojnosanitetski pregled
  • [ISO-abbreviation] Vojnosanit Pregl
  • [Language] srp
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Serbia and Montenegro
  • [Chemical-registry-number] 0 / Mucins
  •  go-up   go-down


46. [Item no 149: epithelial and melanoma skin tumors: skin carcinoma]. Ann Dermatol Venereol; 2005 Oct;132(10 Suppl):7S127-7S133
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Item no 149: tumeurs cutanées épithéliales et mélaniques: carcinomes cutanés.
  • [MeSH-major] Carcinoma, Basal Cell / diagnosis. Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / pathology. Skin Neoplasms / diagnosis. Skin Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Disease Progression. Humans. Incidence. Prognosis

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16419534.001).
  • [ISSN] 0151-9638
  • [Journal-full-title] Annales de dermatologie et de vénéréologie
  • [ISO-abbreviation] Ann Dermatol Venereol
  • [Language] fre
  • [Publication-type] Journal Article
  • [Publication-country] France
  •  go-up   go-down


47. Tai KP, Dai XD, Shen YX, Liu BX: Formation and structural anomaly of the metastable phases in an immiscible Ag-Mo system studied by ion beam mixing and molecular dynamics simulation. J Phys Chem B; 2006 Jan 12;110(1):595-606
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Formation and structural anomaly of the metastable phases in an immiscible Ag-Mo system studied by ion beam mixing and molecular dynamics simulation.
  • For the equilibrium immiscible Ag-Mo system characterized by a large positive heat of formation, the nanosized Ag-Mo multilayered samples are designed and prepared to include sufficient interfacial free energy to elevate their initial energetic states to be higher than that of either the amorphous phase or solid solution and then subject to 200 keV xenon ion irradiation.
  • The results show that a uniform amorphous alloy can be obtained within a composition range, at least, from 25 to 88 atom % of Mo.
  • Interestingly, in the intermediate stage of ion irradiation, a bcc phase, an amorphous phase, and an order (bcc)-disorder coexisting state appear simultaneously in the Ag12Mo88 multilayered sample and extend over the entire bright field image with unanimously homogeneous composition.
  • In thermodynamic modeling, a Gibbs free energy diagram of the Ag-Mo system is constructed, based on Miedema's model, and suggests that within a narrow composition regime of 85-90 atom % of Mo, the energy difference between the bcc and the amorphous phases is extremely small, which is probably the very reason for the order-disorder coexisting state to appear.
  • In atomistic modeling, an ab initio derived Ag-Mo potential is applied to perform molecular dynamics simulations.
  • The simulations not only determine an intrinsic glass-forming ability/range (GFA/GFR) of the Ag-Mo system to be from 10 to 88 atom % of Mo but also reveal the possibility of the formation/appearance of a crystalline and amorphous mixture in a narrow composition regime of 88-92 atom % of Mo.
  • Apparently, the theoretical results are in excellent agreement and/or compatible with the experimental observations in ion beam mixing.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16471572.001).
  • [ISSN] 1520-6106
  • [Journal-full-title] The journal of physical chemistry. B
  • [ISO-abbreviation] J Phys Chem B
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


48. Madan V, Lear JT, Szeimies RM: Non-melanoma skin cancer. Lancet; 2010 Feb 20;375(9715):673-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Whereas the role of cumulative sun exposure in pathogenesis of squamous-cell carcinoma seems clear, the relation between sun-exposure patterns and subtypes of basal-cell carcinoma remains undetermined.
  • Unlike basal-cell carcinoma, squamous-cell carcinomas can arise from precursor lesions.
  • Prevention strategies aim at reduction of sun exposure, but are of unproven benefit, especially for basal-cell carcinoma.
  • Surgical excision with predetermined margins is the mainstay of treatment for squamous-cell carcinoma and for most basal-cell carcinomas.
  • Of the new non-invasive treatments, only photodynamic therapy and topical imiquimod have become established treatments for specific subtypes of basal-cell carcinoma, and the search for more effective and tissue-salvaging therapies continues.
  • [MeSH-major] Carcinoma, Basal Cell. Carcinoma, Squamous Cell. Skin Neoplasms. Sunlight / adverse effects
  • [MeSH-minor] Age Distribution. Age Factors. Environmental Exposure. Female. Humans. Incidence. Male. Neoplasm Staging. Population Surveillance. Prognosis. Registries. Risk. Risk Factors. Sex Factors


49. Depianto D, Kerns ML, Dlugosz AA, Coulombe PA: Keratin 17 promotes epithelial proliferation and tumor growth by polarizing the immune response in skin. Nat Genet; 2010 Oct;42(10):910-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Keratin 17 promotes epithelial proliferation and tumor growth by polarizing the immune response in skin.
  • Basaloid skin tumors, including basal cell carcinoma (BCC) and basaloid follicular hamartoma, are associated with aberrant Hedgehog (Hh) signaling and, in the case of BCC, an expanding set of genetic variants including keratin 5 (encoded by KRT5), an intermediate filament-forming protein.
  • We here show that genetic ablation of keratin 17 (Krt17) protein, which is induced in basaloid skin tumors and co-polymerizes with Krt5 in vivo, delays basaloid follicular hamartoma tumor initiation and growth in mice with constitutive Hh signaling in epidermis.
  • Our findings establish an immunomodulatory role for Krt17 in Hh driven basaloid skin tumors that could impact additional tumor settings, psoriasis and wound repair.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • SciCrunch. OMIM: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Genet. 2000 Mar;24(3):216-7 [10700170.001]
  • [Cites] Nat Rev Immunol. 2009 Nov;9(11):778-88 [19855404.001]
  • [Cites] Genes Dev. 2002 Jun 1;16(11):1412-22 [12050118.001]
  • [Cites] Immunogenetics. 2002 Nov;54(8):599-603 [12439624.001]
  • [Cites] J Invest Dermatol. 2002 Nov;119(5):1137-49 [12445204.001]
  • [Cites] Am J Pathol. 2002 Dec;161(6):1991-6 [12466114.001]
  • [Cites] Am J Dermatopathol. 2003 Apr;25(2):130-7 [12652194.001]
  • [Cites] EMBO J. 2003 Jun 2;22(11):2741-51 [12773389.001]
  • [Cites] Exp Mol Pathol. 2003 Jun;74(3):230-7 [12782009.001]
  • [Cites] J Investig Dermatol Symp Proc. 2003 Oct;8(2):188-94 [14582671.001]
  • [Cites] J Invest Dermatol. 2004 Jul;123(1):23-33 [15191538.001]
  • [Cites] J Invest Dermatol. 1982 Mar;78(3):206-9 [6276474.001]
  • [Cites] Br J Dermatol. 1992 Feb;126(2):154-60 [1371396.001]
  • [Cites] Cancer Res. 1994 Mar 1;54(5):1178-89 [8118803.001]
  • [Cites] Clin Exp Immunol. 1995 Jul;101(1):177-82 [7621586.001]
  • [Cites] Development. 1998 Apr;125(8):1541-52 [9502735.001]
  • [Cites] J Cell Biol. 1998 Oct 19;143(2):469-86 [9786956.001]
  • [Cites] Biochim Biophys Acta. 1999 Jul 7;1446(1-2):167-72 [10395932.001]
  • [Cites] J Immunol. 1999 Oct 1;163(7):3976-84 [10491000.001]
  • [Cites] Genes Dev. 2004 Nov 15;18(22):2724-9 [15545630.001]
  • [Cites] J Invest Dermatol. 2004 Dec;123(6):1169-75 [15610530.001]
  • [Cites] Methods Cell Biol. 2004;78:453-87 [15646628.001]
  • [Cites] J Invest Dermatol. 2005 Jul;125(1):9-13 [15982297.001]
  • [Cites] Cancer Res. 2006 Apr 15;66(8):4279-84 [16618752.001]
  • [Cites] Genes Dev. 2006 May 15;20(10):1353-64 [16702408.001]
  • [Cites] Nature. 2006 May 18;441(7091):362-5 [16710422.001]
  • [Cites] Nat Med. 2007 Feb;13(2):139-45 [17290272.001]
  • [Cites] Nat Med. 2007 Mar;13(3):242-4 [17342112.001]
  • [Cites] J Immunol. 2007 Jun 1;178(11):7097-109 [17513759.001]
  • [Cites] Am J Clin Pathol. 2007 Aug;128(2):255-9 [17638659.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Sep 4;104(36):14460-5 [17724334.001]
  • [Cites] FASEB J. 2008 May;22(5):1404-15 [18162489.001]
  • [Cites] J Invest Dermatol. 2008 Jul;128(7):1797-805 [18200053.001]
  • [Cites] Nat Rev Cancer. 2008 Oct;8(10):743-54 [18813320.001]
  • [Cites] Cancer Res. 2009 Jan 1;69(1):319-28 [19118017.001]
  • [Cites] PLoS Biol. 2009 May 19;7(5):e1000067 [19557146.001]
  • [Cites] Nat Genet. 2009 Aug;41(8):909-14 [19578363.001]
  • [Cites] Curr Opin Allergy Clin Immunol. 2009 Oct;9(5):437-46 [19550302.001]
  • [Cites] Am J Pathol. 2010 May;176(5):2435-46 [20228225.001]
  • [Cites] BMJ. 2000 Aug 12;321(7258):424 [10938051.001]
  • (PMID = 20871598.001).
  • [ISSN] 1546-1718
  • [Journal-full-title] Nature genetics
  • [ISO-abbreviation] Nat. Genet.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA160255; United States / NIAMS NIH HHS / AR / R01 AR044232-14; United States / NCI NIH HHS / CA / CA123530-02; United States / NCI NIH HHS / CA / R21 CA123530; United States / NCI NIH HHS / CA / T32 CA009110; United States / NCI NIH HHS / CA / CA123530; United States / NIAMS NIH HHS / AR / AR44232; United States / NCI NIH HHS / CA / R21 CA123530-02; United States / NCI NIH HHS / CA / F32 CA110618; United States / NIAMS NIH HHS / AR / R01 AR044232; United States / NCI NIH HHS / CA / R01 CA087837; United States / NCI NIH HHS / CA / CA087837; United States / NIAMS NIH HHS / AR / AR044232-14
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gli2 protein; 0 / Hedgehog Proteins; 0 / KRT1-17 protein, mouse; 0 / Kruppel-Like Transcription Factors; 0 / RNA, Messenger; 68238-35-7 / Keratins
  • [Other-IDs] NLM/ NIHMS231459; NLM/ PMC2947596
  •  go-up   go-down


50. Edwards L: Pigmented vulvar lesions. Dermatol Ther; 2010 Sep-Oct;23(5):449-57
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pigmented lesions represent an enormous range of conditions, from benign to malignant tumors, and from infectious to post-inflammatory.
  • [MeSH-major] Nevus, Pigmented / pathology. Pigmentation Disorders / pathology. Skin Neoplasms / pathology. Vulva / pathology
  • [MeSH-minor] Acanthosis Nigricans / pathology. Angiokeratoma / pathology. Bowen's Disease / pathology. Carcinoma, Basal Cell / pathology. Condylomata Acuminata / pathology. Dysplastic Nevus Syndrome / pathology. Female. Humans. Keratosis, Seborrheic / pathology. Melanoma / pathology. Melanosis / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Skin Pigmentation Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Wiley Periodicals, Inc.
  • (PMID = 20868400.001).
  • [ISSN] 1529-8019
  • [Journal-full-title] Dermatologic therapy
  • [ISO-abbreviation] Dermatol Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


51. Rosenfeldt MT, Ryan KM: The role of autophagy in tumour development and cancer therapy. Expert Rev Mol Med; 2009 Dec 02;11:e36
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of autophagy in tumour development and cancer therapy.
  • It is executed at basal levels in every cell and promotes cellular homeostasis by regulating organelle and protein turnover.
  • In nutrient-deprived states, for example, autophagy can be activated to degrade cargoes for cell-autonomous energy production to promote cell survival.
  • In other contexts, in contrast, autophagy has been shown to contribute to cell death.
  • Given these dual effects in regulating cell viability, it is no surprise that autophagy has implications in both the genesis and treatment of malignant disease.
  • In this review, we provide a comprehensive appraisal of the way in which oncogenes and tumour suppressor genes regulate autophagy.
  • In addition, we address the current evidence from human cancer and animal models that has aided our understanding of the role of autophagy in tumour progression.
  • Finally, the potential for targeting autophagy therapeutically is discussed in light of the functions of autophagy at different stages of tumour progression and in normal tissues.

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 2005 Sep 23;122(6):927-39 [16179260.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Mar 28;103(13):4952-7 [16547133.001]
  • [Cites] Mol Cell. 2006 May 19;22(4):463-75 [16713577.001]
  • [Cites] Nature. 2006 May 25;441(7092):424-30 [16724053.001]
  • [Cites] Nature. 2006 Jun 15;441(7095):885-9 [16625204.001]
  • [Cites] Nature. 2006 Jun 15;441(7095):880-4 [16625205.001]
  • [Cites] Cancer Res. 2006 Jul 1;66(13):6861-70 [16818664.001]
  • [Cites] Nat Cell Biol. 2006 Jul;8(7):688-99 [16799551.001]
  • [Cites] Cell. 2006 Jul 14;126(1):121-34 [16839881.001]
  • [Cites] Cancer Cell. 2006 Jul;10(1):51-64 [16843265.001]
  • [Cites] Autophagy. 2005 Apr;1(1):1-10 [16874026.001]
  • [Cites] Nat Cell Biol. 2006 Oct;8(10):1124-32 [16998475.001]
  • [Cites] Mol Biol Cell. 2006 Dec;17(12):5094-104 [17021250.001]
  • [Cites] Autophagy. 2006 Apr-Jun;2(2):74-9 [17139808.001]
  • [Cites] Cancer Cell. 2006 Dec;10(6):459-72 [17157787.001]
  • [Cites] Int J Oncol. 2007 Feb;30(2):429-36 [17203225.001]
  • [Cites] Autophagy. 2007 Jan-Feb;3(1):28-31 [16969128.001]
  • [Cites] Autophagy. 2007 Jan-Feb;3(1):72-4 [17102582.001]
  • [Cites] Nat Cell Biol. 2007 Feb;9(2):218-24 [17237771.001]
  • [Cites] J Clin Invest. 2007 Feb;117(2):326-36 [17235397.001]
  • [Cites] Cell. 2007 Mar 9;128(5):931-46 [17350577.001]
  • [Cites] EMBO J. 2007 May 16;26(10):2527-39 [17446862.001]
  • [Cites] Cell Death Differ. 2007 Jun;14(6):1071-9 [17304243.001]
  • [Cites] Genes Dev. 2007 Jun 1;21(11):1367-81 [17510285.001]
  • [Cites] J Biol Chem. 2007 Jun 22;282(25):18573-83 [17442669.001]
  • [Cites] Nature. 2007 Jun 28;447(7148):1121-5 [17589504.001]
  • [Cites] Genes Dev. 2007 Jul 1;21(13):1621-35 [17606641.001]
  • [Cites] Cell. 2008 Aug 8;134(3):451-60 [18692468.001]
  • [Cites] EMBO Rep. 2008 Sep;9(9):859-64 [18704115.001]
  • [Cites] Oncogene. 2008 Sep 18;27(41):5497-510 [18794884.001]
  • [Cites] Autophagy. 2008 Oct;4(7):851-65 [18670193.001]
  • [Cites] Mol Cell Biol. 2008 Oct;28(19):5951-64 [18678646.001]
  • [Cites] APMIS. 2008 Jul-Aug;116(7-8):742-53 [18834416.001]
  • [Cites] Cell Cycle. 2008 Oct;7(19):3056-61 [18818522.001]
  • [Cites] Nat Rev Mol Cell Biol. 2008 Dec;9(12):1004-10 [18971948.001]
  • [Cites] J Clin Invest. 2008 Dec;118(12):3917-29 [19033662.001]
  • [Cites] Mol Biol Cell. 2008 Dec;19(12):5360-72 [18843052.001]
  • [Cites] J Biol Chem. 2008 Dec 12;283(50):34495-9 [18945681.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Dec 9;105(49):19211-6 [19050071.001]
  • [Cites] Cell Death Differ. 2009 Jan;16(1):87-93 [18806760.001]
  • [Cites] J Biol Chem. 2009 Jan 2;284(1):334-44 [18974095.001]
  • [Cites] J Biol Chem. 2009 Jan 30;284(5):2803-10 [19049976.001]
  • [Cites] Cell Cycle. 2009 Feb 1;8(3):403-13 [19177005.001]
  • [Cites] Cell Signal. 2009 May;21(5):656-64 [19166931.001]
  • [Cites] Curr Opin Genet Dev. 2009 Feb;19(1):12-7 [19185485.001]
  • [Cites] EMBO Rep. 2009 Mar;10(3):285-92 [19180116.001]
  • [Cites] Apoptosis. 2009 Apr;14(4):376-91 [19172397.001]
  • [Cites] J Pathol. 2009 Apr;217(5):702-6 [19197948.001]
  • [Cites] Mol Biol Cell. 2009 Apr;20(7):1992-2003 [19225151.001]
  • [Cites] Nat Cell Biol. 2009 Apr;11(4):468-76 [19270693.001]
  • [Cites] Nat Cell Biol. 2009 Apr;11(4):385-96 [19270696.001]
  • [Cites] Genes Dev. 2009 Apr 1;23(7):798-803 [19279323.001]
  • [Cites] J Biol Chem. 2009 May 1;284(18):12297-305 [19258318.001]
  • [Cites] Cell Cycle. 2009 May 15;8(10):1571-6 [19377293.001]
  • [Cites] Cell. 2009 May 15;137(4):721-35 [19427028.001]
  • [Cites] Genes Dev. 2009 Jun 1;23(11):1283-8 [19487569.001]
  • [Cites] Cell. 2009 May 29;137(5):873-86 [19446321.001]
  • [Cites] Cell. 2009 Jun 12;137(6):1001-4 [19524504.001]
  • [Cites] Cell. 2009 Jun 12;137(6):1062-75 [19524509.001]
  • [Cites] Cell Cycle. 2009 Jul 15;8(14):2260-5 [19556885.001]
  • [Cites] J Biol Chem. 2009 Aug 7;284(32):21412-24 [19520853.001]
  • [Cites] Biochim Biophys Acta. 2009 Sep;1793(9):1524-32 [19371598.001]
  • [Cites] Nature. 2009 Oct 1;461(7264):654-8 [19794493.001]
  • [Cites] Autophagy. 2009 Oct;5(7):1068-9 [19738440.001]
  • [Cites] Adv Cancer Res. 2000;77:81-137 [10549356.001]
  • [Cites] Nature. 1999 Dec 9;402(6762):672-6 [10604474.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] EMBO J. 2000 Nov 1;19(21):5720-8 [11060023.001]
  • [Cites] J Biol Chem. 2000 Dec 15;275(50):39090-5 [10993892.001]
  • [Cites] Cell. 2002 Jul 26;110(2):163-75 [12150925.001]
  • [Cites] Ann N Y Acad Sci. 2003 Mar;983:268-77 [12724231.001]
  • [Cites] J Biol Chem. 2003 May 9;278(19):16667-74 [12609989.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15077-82 [14657337.001]
  • [Cites] J Clin Invest. 2003 Dec;112(12):1809-20 [14638851.001]
  • [Cites] Science. 2004 Apr 23;304(5670):596-600 [15105503.001]
  • [Cites] Oncogene. 2004 May 13;23(22):3898-904 [15064741.001]
  • [Cites] Genes Dev. 2004 Jun 1;18(11):1272-82 [15145826.001]
  • [Cites] Science. 2004 Jun 4;304(5676):1500-2 [15131264.001]
  • [Cites] Semin Cell Dev Biol. 2004 Apr;15(2):231-6 [15209383.001]
  • [Cites] Cancer Cell. 2007 Jul;12(1):9-22 [17613433.001]
  • [Cites] Nat Rev Mol Cell Biol. 2007 Sep;8(9):741-52 [17717517.001]
  • [Cites] Nat Cell Biol. 2007 Oct;9(10):1142-51 [17891140.001]
  • [Cites] Nat Cell Biol. 2007 Oct;9(10):1102-9 [17909521.001]
  • [Cites] Genes Dev. 2007 Oct 15;21(20):2525-38 [17938238.001]
  • [Cites] Nat Rev Cancer. 2007 Dec;7(12):961-7 [17972889.001]
  • [Cites] Cell. 2007 Dec 14;131(6):1137-48 [18083103.001]
  • [Cites] Clin Cancer Res. 2007 Dec 15;13(24):7271-9 [18094407.001]
  • [Cites] J Clin Invest. 2008 Jan;118(1):79-88 [18097482.001]
  • [Cites] Cell. 2008 Jan 11;132(1):27-42 [18191218.001]
  • [Cites] Genes Dev. 2008 Jan 15;22(2):239-51 [18198340.001]
  • [Cites] Cancer Res. 2008 Jan 15;68(2):352-7 [18199527.001]
  • [Cites] Autophagy. 2008 Feb;4(2):151-75 [18188003.001]
  • [Cites] Biochimie. 2008 Feb;90(2):313-23 [17928127.001]
  • [Cites] Clin Cancer Res. 2008 Feb 15;14(4):1167-71 [18281551.001]
  • [Cites] Nature. 2008 Feb 28;451(7182):1069-75 [18305538.001]
  • [Cites] Cancer Cell. 2008 Apr;13(4):343-54 [18394557.001]
  • [Cites] Curr Opin Cell Biol. 2008 Apr;20(2):150-5 [18353625.001]
  • [Cites] J Cell Biol. 2008 May 5;181(3):497-510 [18443221.001]
  • [Cites] Nat Cell Biol. 2008 Jun;10(6):676-87 [18454141.001]
  • [Cites] Autophagy. 2008 Jul;4(5):600-6 [18497563.001]
  • [Cites] Hum Pathol. 2008 Jul;39(7):1059-63 [18495205.001]
  • [Cites] Nat Cell Biol. 2008 Jul;10(7):776-87 [18552835.001]
  • [Cites] Mol Biol Cell. 2008 Aug;19(8):3290-8 [18508918.001]
  • [Cites] Curr Biol. 2004 Jul 27;14(14):1296-302 [15268862.001]
  • [Cites] Genomics. 1999 Jul 1;59(1):59-65 [10395800.001]
  • [Cites] Nat Cell Biol. 2004 Dec;6(12):1221-8 [15558033.001]
  • [Cites] Genes Dev. 2004 Dec 1;18(23):2893-904 [15545625.001]
  • [Cites] Biochim Biophys Acta. 2004 Dec 10;1705(1):3-15 [15585169.001]
  • [Cites] Nature. 2004 Dec 23;432(7020):1032-6 [15525940.001]
  • [Cites] Cell. 2005 Jan 28;120(2):237-48 [15680329.001]
  • [Cites] Science. 2005 Feb 18;307(5712):1098-101 [15718470.001]
  • [Cites] Curr Opin Cell Biol. 2005 Apr;17(2):158-66 [15780592.001]
  • [Cites] J Cell Biol. 2005 May 9;169(3):425-34 [15866887.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 Jun;6(6):439-48 [15928708.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jun 7;102(23):8204-9 [15928081.001]
  • [Cites] Nat Rev Cancer. 2005 Sep;5(9):726-34 [16148885.001]
  • (PMID = 19951459.001).
  • [ISSN] 1462-3994
  • [Journal-full-title] Expert reviews in molecular medicine
  • [ISO-abbreviation] Expert Rev Mol Med
  • [Language] ENG
  • [Grant] United Kingdom / Cancer Research UK / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2811398
  •  go-up   go-down


52. Papadopoulos O, Konofaos P, Tsantoulas Z, Chrisostomidis C, Frangoulis M, Karakitsos P: Lip defects due to tumor excision: apropos of 899 cases. Oral Oncol; 2007 Feb;43(2):204-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lip defects due to tumor excision: apropos of 899 cases.
  • In the last five-years, we have performed preoperative fine needle aspiration (FNA) biopsy of the tumor.
  • In our series, from the 550 patients who had a five-year follow-up we observed 62 recurrences of the primary tumor.
  • [MeSH-major] Lip / surgery. Lip Neoplasms / surgery. Reconstructive Surgical Procedures / methods
  • [MeSH-minor] Adult. Aged. Biopsy, Fine-Needle. Carcinoma, Basal Cell / pathology. Carcinoma, Basal Cell / surgery. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Epidemiologic Methods. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Sex Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16857414.001).
  • [ISSN] 1368-8375
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  •  go-up   go-down


53. Bunyapaiboonsri T, Yoiprommarat S, Khonsanit A, Komwijit S: Phenolic glycosides from the filamentous fungus Acremonium sp. BCC 14080. J Nat Prod; 2008 May;71(5):891-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phenolic glycosides from the filamentous fungus Acremonium sp. BCC 14080.
  • New phenolic mono- and digalactopyranosides (1 and 2), their aglycone KS-501a (3), and a new phenolic 4-O-methylglucopyranoside (4) were isolated from the filamentous fungus Acremonium sp. BCC 14080.
  • Structures of these compounds were elucidated by extensive MS and NMR spectroscopic analyses.
  • Compound 1 displayed anti-HSV-1 activity with an IC(50) value of 7.2 microM.
  • Compound 3 exhibited activity against Plasmodium falciparum K1 with an IC(50) value of 9.9 microM.
  • [MeSH-major] Acremonium / chemistry. Antiviral Agents / isolation & purification. Antiviral Agents / pharmacology. Glycosides / isolation & purification. Glycosides / pharmacology. Herpesvirus 1, Human / drug effects. Phenols / isolation & purification. Phenols / pharmacology. Plasmodium falciparum / drug effects
  • [MeSH-minor] Animals. Cercopithecus aethiops. Drug Screening Assays, Antitumor. Humans. Hydroxybenzoates / chemistry. Hydroxybenzoates / isolation & purification. Hydroxybenzoates / pharmacology. Inhibitory Concentration 50. Molecular Structure

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18363379.001).
  • [ISSN] 0163-3864
  • [Journal-full-title] Journal of natural products
  • [ISO-abbreviation] J. Nat. Prod.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Glycosides; 0 / Hydroxybenzoates; 0 / Phenols; 120634-86-8 / KS 501
  •  go-up   go-down


54. Xie J: Molecular biology of basal and squamous cell carcinomas. Adv Exp Med Biol; 2008;624:241-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular biology of basal and squamous cell carcinomas.
  • Basal cell carcinomas and Squamous cell carcinomas are the two most common human cancers.
  • For example, identification of hedgehog signaling activation has opened up many opportunities for targeted therapy and prevention of basal cell carcinomas.
  • Significant progress has also been made in our understanding of squamous cell carcinomas of the skin.
  • In this chapter, we will focus on major recent developments in our understanding of basal cell carcinomas and squamous cell carcinomas at the molecular levels and their clinical implications.
  • [MeSH-major] Carcinoma, Basal Cell / genetics. Carcinoma, Squamous Cell / genetics. Molecular Biology. Mutation / genetics. Skin Neoplasms / genetics
  • [MeSH-minor] Animals. Chromosome Aberrations. Disease Models, Animal. Humans. Mice

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18348461.001).
  • [ISSN] 0065-2598
  • [Journal-full-title] Advances in experimental medicine and biology
  • [ISO-abbreviation] Adv. Exp. Med. Biol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01-CA94160
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] United States
  • [Number-of-references] 85
  •  go-up   go-down


55. Hobisch A, Fritzer A, Comuzzi B, Fiechtl M, Malinowska K, Steiner H, Bartsch G, Culig Z: The androgen receptor pathway is by-passed in prostate cancer cells generated after prolonged treatment with bicalutamide. Prostate; 2006 Mar 1;66(4):413-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Experimental work in various prostate cancer models revealed that the androgen receptor is frequently upregulated and implicated in tumor progression.
  • Proliferation of LNCaP-Bic cells in the absence or presence of androgen, tocopherol succinate, and/or bicalutamide was assessed by cell counting.
  • RESULTS: In basal conditions, proliferation of LNCaP-Bic cells increased more than threefold over that of control LNCaP cells.
  • Androgen receptor expression did not differ between the cell subline generated in the presence of bicalutamide and parental LNCaP cells.
  • Tocopherol succinate caused inhibition of proliferation only in the parental cell line although the androgen receptor and prostate-specific antigen were down regulated by the vitamin E derivative in both parental LNCaP and LNCaP-Bic cells.
  • [MeSH-major] Androgen Antagonists / pharmacology. Anilides / pharmacology. Prostatic Neoplasms / pathology. Receptors, Androgen / biosynthesis. Receptors, Androgen / drug effects
  • [MeSH-minor] Blotting, Western. Cell Proliferation. Disease Progression. Drug Resistance, Neoplasm. Humans. Male. Nitriles. Signal Transduction. Tosyl Compounds. Tumor Cells, Cultured. Up-Regulation

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. BICALUTAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley-Liss, Inc.
  • (PMID = 16302272.001).
  • [ISSN] 0270-4137
  • [Journal-full-title] The Prostate
  • [ISO-abbreviation] Prostate
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0 / Anilides; 0 / Nitriles; 0 / Receptors, Androgen; 0 / Tosyl Compounds; A0Z3NAU9DP / bicalutamide
  •  go-up   go-down


56. Iijima M, Brantley WA, Baba N, Alapati SB, Yuasa T, Ohno H, Mizoguchi I: Micro-XRD study of beta-titanium wires and infrared soldered joints. Dent Mater; 2007 Sep;23(9):1051-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Micro-XRD study of beta-titanium wires and infrared soldered joints.
  • OBJECTIVE: The purpose of this study was to investigate the metallurgical phases in beta-titanium soldered joints prepared by infrared soldering, using the Micro X-ray diffraction technique (Micro-XRD), and to characterize the Vickers hardness in the soldered beta-titanium wires.
  • METHODS: Beta-titanium wires with cross-section dimensions of 0.032in.x0.032in. (TMA, Ormco), and both titanium-based solder (Ti-30Ni-20Cu, Selec) and silver-based solder (Ag-22Cu-17Zn-5Sn, Tomy) were selected.
  • Soldering was performed using infrared radiation (RS-1, Morita) under argon atmosphere.
  • Micro-XRD analyses were performed at room temperature.
  • Micro-XRD spectra were obtained for the boundary region of the soldered beta-titanium wires using 50microm and 10microm diameter analysis regions.
  • Hardness was measured at 30microm intervals from boundary of the diffusion layer and beta-titanium wire.
  • The Kruskal-Wallis test with the Bonferroni and Wilcoxson Mann-Whitney tests for nonparametric means were employed as statistical methods (P<0.05).
  • RESULTS: For both types of soldered beta-titanium samples, the Micro-XRD spectra contained four major peaks for body-centered cubic (bcc) beta-titanium.
  • Additional peaks at about 41 and 45 degrees are attributed to Cu-Ti intermetallic phase(s), which may be metastable under soldering conditions.
  • The diffusion layer had greater hardness than bulk beta-titanium for both types of soldered specimens (P<0.05).
  • SIGNIFICANCE: Soldering of beta-titanium orthodontic wire by infrared radiation may be acceptable for clinical use, since Micro-XRD spectra revealed that both types of soldered specimens largely retained the bcc beta-titanium structure.
  • Further research is needed to investigate the mechanical properties and corrosion behavior of infrared-soldered beta-titanium wire.
  • [MeSH-major] Dental Soldering. Orthodontic Wires. Titanium / chemistry
  • [MeSH-minor] Alloys / chemistry. Copper / chemistry. Diffusion. Electron Probe Microanalysis. Hardness. Humans. Infrared Rays. Materials Testing. Mechanics. Metallurgy. Microspectrophotometry. Nickel / chemistry. Silver / chemistry. Surface Properties. Tin / chemistry. X-Ray Diffraction. Zinc / chemistry

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. NICKEL, ELEMENTAL .
  • Hazardous Substances Data Bank. SILVER, ELEMENTAL .
  • Hazardous Substances Data Bank. TIN .
  • Hazardous Substances Data Bank. TITANIUM .
  • Hazardous Substances Data Bank. COPPER, ELEMENTAL .
  • Hazardous Substances Data Bank. ZINC, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17178150.001).
  • [ISSN] 0109-5641
  • [Journal-full-title] Dental materials : official publication of the Academy of Dental Materials
  • [ISO-abbreviation] Dent Mater
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Alloys; 3M4G523W1G / Silver; 7440-31-5 / Tin; 789U1901C5 / Copper; 7OV03QG267 / Nickel; D1JT611TNE / Titanium; J41CSQ7QDS / Zinc
  •  go-up   go-down


57. Bertheau P, Turpin E, Rickman DS, Espié M, de Reyniès A, Feugeas JP, Plassa LF, Soliman H, Varna M, de Roquancourt A, Lehmann-Che J, Beuzard Y, Marty M, Misset JL, Janin A, de Thé H: Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen. PLoS Med; 2007 Mar;4(3):e90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen.
  • In cell lines or animal models, tumor protein p53 (TP53) plays a critical role in modulating the response to genotoxic drugs.
  • TP53 is activated in response to DNA damage and triggers either apoptosis or cell-cycle arrest, which have opposite effects on cell fate.
  • Breast cancers with a TP53 mutation were repeatedly shown to have a poor outcome, but whether this reflects poor response to treatment or greater intrinsic aggressiveness of the tumor is unknown.
  • Tumor diagnoses were performed on pretreatment biopsies, and the patients then received six cycles of a dose-dense regimen of 75 mg/m(2) epirubicin and 1,200 mg/m(2) cyclophosphamide, given every 14 days.
  • Furthermore, among the TP53-mutant tumors, nine out of ten of the highly aggressive basal subtypes (defined by basal cytokeratin [KRT] immunohistochemical staining) experienced complete pathological responses, and only TP53 status and basal subtype were independent predictors of a complete response.
  • Expression analysis identified many mutant TP53-associated genes, including CDC20, TTK, CDKN2A, and the stem cell gene PROM1, but failed to identify a transcriptional profile associated with complete responses among TP53 mutant tumors.
  • CONCLUSIONS: This study demonstrates that, in noninflammatory breast cancers, TP53 status is a key predictive factor for response to this dose-dense epirubicin-cyclophosphamide regimen and further suggests that the basal subtype is exquisitely sensitive to this association.
  • Given the well-established predictive value of complete responses for long-term survival and the poor prognosis of basal and TP53-mutant tumors treated with other regimens, this chemotherapy could be particularly suited for breast cancer patients with a mutant TP53, particularly those with basal features.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Breast Neoplasms / drug therapy. Breast Neoplasms / genetics. Tumor Suppressor Protein p53 / genetics

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • SciCrunch. ArrayExpress: Data: Microarray .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 1999 Dec 22;84(6):587-93 [10567903.001]
  • [Cites] Ann Oncol. 2006 Oct;17(10):1504-11 [16968874.001]
  • [Cites] Nature. 2000 Aug 17;406(6797):747-52 [10963602.001]
  • [Cites] Breast Cancer Res Treat. 2001 May;67(1):61-70 [11518467.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74 [11553815.001]
  • [Cites] Breast Cancer Res Treat. 2001 Dec;70(3):205-12 [11804184.001]
  • [Cites] Lancet. 2002 Sep 14;360(9336):852-4 [12243922.001]
  • [Cites] Am J Pathol. 2002 Dec;161(6):1991-6 [12466114.001]
  • [Cites] J Clin Oncol. 2003 Apr 15;21(8):1431-9 [12668651.001]
  • [Cites] J Clin Oncol. 2003 Jul 1;21(13):2600-8 [12829681.001]
  • [Cites] Lancet. 2003 Aug 2;362(9381):362-9 [12907009.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 2;100(18):10393-8 [12917485.001]
  • [Cites] Breast. 2003 Dec;12(6):522-8 [14659130.001]
  • [Cites] Blood. 2004 Sep 1;104(5):1428-34 [15138159.001]
  • [Cites] Clin Cancer Res. 2004 Aug 15;10(16):5367-74 [15328174.001]
  • [Cites] Oncogene. 2004 Aug 26;23(39):6548-58 [15221012.001]
  • [Cites] Clin Cancer Res. 2004 Oct 1;10(19):6418-31 [15475428.001]
  • [Cites] Eur J Cancer. 1971 Feb;7(1):11-6 [5576726.001]
  • [Cites] Histopathology. 1991 Nov;19(5):403-10 [1757079.001]
  • [Cites] Blood. 1995 Mar 15;85(6):1580-9 [7888675.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Apr 25;92(9):3963-7 [7732013.001]
  • [Cites] Nat Med. 1996 Jul;2(7):811-4 [8673929.001]
  • [Cites] Oncogene. 1997 Jan 16;14(2):163-9 [9010218.001]
  • [Cites] Br J Cancer. 1998 Dec;78(12):1661-8 [9862580.001]
  • [Cites] J Clin Oncol. 1999 Feb;17(2):460-9 [10080586.001]
  • [Cites] J Clin Invest. 1999 Aug;104(3):223-5 [10430602.001]
  • [Cites] J Clin Invest. 1999 Aug;104(3):263-9 [10430607.001]
  • [Cites] Ann Oncol. 1999 Jul;10(7):795-801 [10470426.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):307-15 [15549092.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):396-401 [15549107.001]
  • [Cites] Ann Oncol. 2005 May;16(5):743-8 [15802278.001]
  • [Cites] Oncol Rep. 2005 Aug;14(2):513-20 [16012739.001]
  • [Cites] Cancer Cell. 2005 Jul;8(1):7-12 [16023594.001]
  • [Cites] Clin Cancer Res. 2005 Aug 15;11(16):5678-85 [16115903.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 20;102(38):13550-5 [16141321.001]
  • [Cites] Clin Cancer Res. 2006 Feb 15;12(4):1157-67 [16489069.001]
  • [Cites] Breast Cancer Res Treat. 2006 Feb;95(3):229-33 [16322899.001]
  • [Cites] J Clin Oncol. 2006 Apr 20;24(12):1940-9 [16622270.001]
  • [Cites] J Clin Oncol. 2006 Jun 1;24(16):2428-36 [16682728.001]
  • [Cites] J Clin Pathol. 2006 Jul;59(7):729-35 [16556664.001]
  • [Cites] Eur J Cancer. 2006 Jul;42(10):1369-79 [16766179.001]
  • [Cites] Nature. 2006 Sep 14;443(7108):153-4 [16971934.001]
  • [Cites] Clin Cancer Res. 2000 Jan;6(1):50-6 [10656431.001]
  • (PMID = 17388661.001).
  • [ISSN] 1549-1676
  • [Journal-full-title] PLoS medicine
  • [ISO-abbreviation] PLoS Med.
  • [Language] eng
  • [Databank-accession-numbers] RefSeq/ NM/ 000077/ NM/ 000125/ NM/ 000389/ NM/ 000422/ NM/ 000424/ NM/ 000546/ NM/ 001005862/ NM/ 001067/ NM/ 001124/ NM/ 001255/ NM/ 001809/ NM/ 001827/ NM/ 003311/ NM/ 003318/ NM/ 004336/ NM/ 004701/ NM/ 005556/ NM/ 006017/ NM/ 010755/ NM/ 014417/ NM/ 021992/ NM/ 031966/ NM/ 057212/ NM/ 058195/ NM/ 080747/ NM/ 138763/ NP/ 000068/ NP/ 000116/ NP/ 000380/ NP/ 000413/ NP/ 000415/ NP/ 001005862/ NP/ 001115/ NP/ 001246/ NP/ 001800/ NP/ 003302/ NP/ 003309/ NP/ 004692/ NP/ 005547/ NP/ 006008/ NP/ 006133/ NP/ 034885/ NP/ 055232/ NP/ 068832/ NP/ 114172/ NP/ 476560/ NP/ 478102/ NP/ 542785/ NP/ 620118
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; 3Z8479ZZ5X / Epirubicin; 8N3DW7272P / Cyclophosphamide
  • [Other-IDs] NLM/ PMC1831731
  •  go-up   go-down


58. Cos S, Martínez-Campa C, Mediavilla MD, Sánchez-Barceló EJ: Melatonin modulates aromatase activity in MCF-7 human breast cancer cells. J Pineal Res; 2005 Mar;38(2):136-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The objective of this work was to study whether melatonin may modify the aromatase activity in MCF-7 breast cancer cells thus modulating the local estrogen biosynthesis.
  • In MCF-7 cells cultured with testosterone in estradiol-free media, melatonin (1 nM) counteracts the testosterone-induced cell proliferation dependent on the local biosynthesis of estrogens from testosterone by the aromatase activity of the cells.
  • We found that melatonin reduces the aromatase activity (measured by the tritiated water release assay) of MCF-7 cells both at basal conditions and when aromatase activity was stimulated by cAMP or cortisol.
  • This aromatase inhibitory effect of melatonin, together with its already known antiestrogenic properties interacting with the estrogen-receptor, makes this indoleamine an interesting tool to be considered in the prevention and treatment of hormone-dependent mammary neoplasias.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Aromatase / metabolism. Breast Neoplasms / drug therapy. Melatonin / pharmacology
  • [MeSH-minor] Androgens / pharmacology. Androstenedione / metabolism. Cell Proliferation / drug effects. Female. Humans. RNA, Messenger / metabolism. Testosterone / pharmacology. Tritium / metabolism

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. TRITIUM, RADIOACTIVE .
  • Hazardous Substances Data Bank. TESTOSTERONE .
  • Hazardous Substances Data Bank. ANDROSTENEDIONE .
  • Hazardous Substances Data Bank. MELATONIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15683469.001).
  • [ISSN] 0742-3098
  • [Journal-full-title] Journal of pineal research
  • [ISO-abbreviation] J. Pineal Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Androgens; 0 / Antineoplastic Agents; 0 / RNA, Messenger; 10028-17-8 / Tritium; 3XMK78S47O / Testosterone; 409J2J96VR / Androstenedione; EC 1.14.14.1 / Aromatase; JL5DK93RCL / Melatonin
  •  go-up   go-down


59. Lawson DA, Zong Y, Memarzadeh S, Xin L, Huang J, Witte ON: Basal epithelial stem cells are efficient targets for prostate cancer initiation. Proc Natl Acad Sci U S A; 2010 Feb 9;107(6):2610-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal epithelial stem cells are efficient targets for prostate cancer initiation.
  • Prevailing theories suggest that luminal cells are the origin of prostate cancer because it is histologically defined by basal cell loss and malignant luminal cell expansion.
  • We introduced a series of genetic alterations into prospectively identified populations of murine basal/stem and luminal cells in an in vivo prostate regeneration assay.
  • Combination of activated PI3K signaling and heightened androgen receptor signaling, which is associated with disease progression to androgen independence, was also performed.
  • Even though luminal cells fail to respond, basal/stem cells demonstrate efficient capacity for cancer initiation and can produce luminal-like disease characteristic of human prostate cancer in multiple models.
  • This finding provides evidence in support of basal epithelial stem cells as one target cell for prostate cancer initiation and demonstrates the propensity of primitive cells for tumorigenesis.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Prostate. 1998 Mar 1;34(4):292-301 [9496904.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1993;422(1):35-8 [8438556.001]
  • [Cites] Cancer Cell. 2004 Dec;6(6):587-96 [15607963.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 May 10;102(19):6942-7 [15860580.001]
  • [Cites] Science. 2005 Oct 28;310(5748):644-8 [16254181.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jan 31;103(5):1480-5 [16432235.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 May 16;103(20):7789-94 [16682621.001]
  • [Cites] N C Med J. 2006 Mar-Apr;67(2):122-7 [16752715.001]
  • [Cites] Nature. 2006 Aug 17;442(7104):818-22 [16862118.001]
  • [Cites] Cancer Res. 2006 Nov 1;66(21):10513-6 [17079473.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jan 2;104(1):181-6 [17185413.001]
  • [Cites] J Pathol. 2007 May;212(1):91-101 [17385188.001]
  • [Cites] Cancer Res. 2007 Jun 15;67(12):5683-90 [17553900.001]
  • [Cites] Cancer Cell. 2007 Dec;12(6):572-85 [18068633.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Feb 12;105(6):2105-10 [18245377.001]
  • [Cites] Neoplasia. 2008 Feb;10(2):177-88 [18283340.001]
  • [Cites] Nature. 2009 Jan 29;457(7229):608-11 [19092804.001]
  • [Cites] PLoS One. 2009;4(5):e5662 [19461893.001]
  • [Cites] Cold Spring Harb Symp Quant Biol. 2008;73:529-38 [19150960.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Jul 28;106(30):12465-70 [19592505.001]
  • [Cites] Nature. 2009 Sep 24;461(7263):495-500 [19741607.001]
  • [Cites] Cancer Res. 2009 Nov 15;69(22):8555-62 [19887604.001]
  • [Cites] Endocr Relat Cancer. 2000 Jun;7(2):115-29 [10903528.001]
  • [Cites] Lab Invest. 2000 Aug;80(8):1251-8 [10950116.001]
  • [Cites] Cancer Res. 2000 Dec 15;60(24):6841-5 [11156376.001]
  • [Cites] Nat Rev Cancer. 2001 Oct;1(1):34-45 [11900250.001]
  • [Cites] J Cell Biol. 2002 Jun 24;157(7):1257-65 [12082083.001]
  • [Cites] Bioessays. 2002 Oct;24(10):937-48 [12325126.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jun 24;100(13):7841-6 [12799464.001]
  • [Cites] Dev Biol. 2003 Sep 1;261(1):39-54 [12941620.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 30;100 Suppl 1:11896-903 [12909713.001]
  • [Cites] Genes Dev. 2003 Dec 15;17(24):3029-35 [14701873.001]
  • [Cites] Prostate. 1987;11(3):229-42 [3684783.001]
  • [Cites] Endocrinology. 1988 Feb;122(2):552-62 [2828003.001]
  • [Cites] Prostate. 1990;17(4):293-300 [1701248.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1992;421(2):157-61 [1381129.001]
  • [Cites] J Endocrinol. 1999 Sep;162(3):341-50 [10467225.001]
  • (PMID = 20133806.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R00 CA125937-03; United States / NCI NIH HHS / CA / 1K99/R00 CA125937; United States / NCI NIH HHS / PC / PC061456; United States / NCI NIH HHS / CA / R00 CA125937; United States / NICHD NIH HHS / HD / K12 HD001400; United States / NCI NIH HHS / CA / K99 CA125937; United States / Howard Hughes Medical Institute / / ; United States / NCI NIH HHS / CA / CA125937-03; United States / NICHD NIH HHS / HD / 5 K12HD001400
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Fibroblast Growth Factor 10; 0 / Fli1 protein, mouse; 0 / Proto-Oncogene Protein c-fli-1; 0 / Receptors, Androgen; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.11.1 / Akt1 protein, mouse; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt
  • [Other-IDs] NLM/ PMC2823887
  •  go-up   go-down


60. Samaratunga H, Letizia B: Prostatic ductal adenocarcinoma presenting as a urethral polyp: a clinicopathological study of eight cases of a lesion with the potential to be misdiagnosed as a benign prostatic urethral polyp. Pathology; 2007 Oct;39(5):476-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostatic ductal adenocarcinoma presenting as a urethral polyp: a clinicopathological study of eight cases of a lesion with the potential to be misdiagnosed as a benign prostatic urethral polyp.
  • AIMS: Centrally located prostatic ductal adenocarcinoma can present as a single urethral polyp mimicking a benign polyp.
  • Single small polyps were seen on cystourethroscopy with a clinical diagnosis of benign polyps.
  • Five cases had mild cytological atypia, three of which were initially diagnosed as benign prostatic urethral polyps.
  • CONCLUSIONS: Centrally located prostatic ductal adenocarcinoma has the propensity to mimic benign urethral polyps clinically and histopathologically.
  • Basal cell immunostaining may not help with this distinction but AMACR is useful.
  • [MeSH-major] Adenocarcinoma / pathology. Polyps / pathology. Prostatic Neoplasms / pathology. Urethra / pathology


61. Gilmore JL, Scott JA, Bouizar Z, Robling A, Pitfield SE, Riese DJ 2nd, Foley J: Amphiregulin-EGFR signaling regulates PTHrP gene expression in breast cancer cells. Breast Cancer Res Treat; 2008 Aug;110(3):493-505
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It has been previously shown that EGFR signaling induces the production of PTHrP in several primary and transformed epithelial cell types.
  • Of a panel of 7 breast epithelial and cancer cell lines, the osteolytic, EGFR- positive lines (MDA-MB-231 and NS2T2A1) exhibited higher levels of PTHrP transcript expression.
  • In the EGFR bearing lines, the receptor was phosphorylated at tyrosine 992 under basal conditions, and the addition of 100 nM amphiregulin did not lead to the phosphorylation of other tyrosine residues typically phosphorylated by the prototypical ligand EGF.
  • Stable EGFR expression in the MCF7 line failed to increase basal PTHrP mRNA levels; however, treatment of this cell line with exogenous EGF or amphiregulin increased PTHrP transcription 3-fold.
  • Taken together, it appears that autocrine stimulation of EGFR signaling by amphiregulin is coupled to PTHrP gene expression via EGFR Tyr992 and MAPK, and that this pathway may contribute to PTHrP expression by breast tumor cells.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Respir Cell Mol Biol. 1998 Nov;19(5):786-98 [9806743.001]
  • [Cites] Int J Cancer. 1998 Jul 3;77(1):128-37 [9639404.001]
  • [Cites] J Bone Miner Res. 2000 Nov;15(11):2129-39 [11092394.001]
  • [Cites] J Natl Cancer Inst. 2001 Feb 7;93(3):234-7 [11158193.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Apr;86(4):1788-94 [11297619.001]
  • [Cites] Ann Oncol. 2001 Jun;12(6):841-6 [11484962.001]
  • [Cites] J Biol Chem. 2001 Dec 7;276(49):46661-70 [11590145.001]
  • [Cites] J Endocrinol. 2001 Dec;171(3):403-16 [11739006.001]
  • [Cites] Breast Cancer Res Treat. 2002 Jan;71(1):67-75 [11859875.001]
  • [Cites] Mol Cell Endocrinol. 2002 Feb 25;188(1-2):37-46 [11911944.001]
  • [Cites] Int J Surg Pathol. 2002 Apr;10(2):91-9 [12075402.001]
  • [Cites] J Biol Chem. 2002 Jul 5;277(27):24571-8 [11964407.001]
  • [Cites] Curr Opin Investig Drugs. 2002 Sep;3(9):1385-95 [12498017.001]
  • [Cites] Cancer. 2003 Feb 1;97(3 Suppl):779-84 [12548575.001]
  • [Cites] Int J Oncol. 2003 Apr;22(4):799-805 [12632071.001]
  • [Cites] Exp Cell Res. 2003 Mar 10;284(1):31-53 [12648464.001]
  • [Cites] J Clin Pathol. 2003 Apr;56(4):300-4 [12663644.001]
  • [Cites] J Biol Chem. 2003 May 30;278(22):19723-31 [12644456.001]
  • [Cites] Biochem J. 2003 Jun 15;372(Pt 3):787-97 [12628005.001]
  • [Cites] Mol Cell Endocrinol. 2003 Jun 30;204(1-2):155-68 [12850290.001]
  • [Cites] Mol Cell Biol. 2003 Nov;23(21):7875-86 [14560030.001]
  • [Cites] Curr Cancer Drug Targets. 2004 Mar;4(2):125-46 [15032665.001]
  • [Cites] J Endocrinol. 2004 Apr;181(1):179-90 [15072578.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Jun 18;319(1):1-11 [15158434.001]
  • [Cites] Endocrinology. 2004 Sep;145(9):4232-43 [15192046.001]
  • [Cites] Br J Cancer. 1989 Aug;60(2):185-92 [2548558.001]
  • [Cites] J Submicrosc Cytol Pathol. 1989 Jul;21(3):489-99 [2551482.001]
  • [Cites] Cancer Res. 1990 Dec 1;50(23):7710-6 [2253214.001]
  • [Cites] EMBO J. 1992 Feb;11(2):559-67 [1537335.001]
  • [Cites] Mol Cell Biol. 1992 Oct;12(10):4643-53 [1406654.001]
  • [Cites] J Bone Miner Res. 1992 Aug;7(8):971-9 [1442211.001]
  • [Cites] FEBS Lett. 1992 Jul 6;305(3):228-32 [1299622.001]
  • [Cites] J Biol Chem. 1993 Nov 5;268(31):23634-9 [7693694.001]
  • [Cites] J Bone Miner Res. 1994 May;9(5):639-44 [8053392.001]
  • [Cites] Biochem J. 1995 Apr 1;307 ( Pt 1):159-67 [7717970.001]
  • [Cites] J Biol Chem. 1995 Apr 28;270(17):9809-12 [7730360.001]
  • [Cites] Breast Cancer Res Treat. 1995;33(2):103-14 [7749138.001]
  • [Cites] Mol Cell Endocrinol. 1995 Jun;111(2):225-32 [7556886.001]
  • [Cites] J Clin Invest. 1999 Jan;103(2):197-206 [9916131.001]
  • [Cites] J Bone Miner Res. 1999 Mar;14(3):406-14 [10027905.001]
  • [Cites] Development. 1999 Jun;126(12):2739-50 [10331984.001]
  • [Cites] Endocrinology. 1999 Oct;140(10):4451-8 [10499498.001]
  • [Cites] Oncol Res. 2004;14(11-12):589-602 [15667000.001]
  • [Cites] J Biol Chem. 2005 Feb 4;280(5):3974-81 [15509566.001]
  • [Cites] J Biol Chem. 2005 Apr 15;280(15):14597-604 [15708852.001]
  • [Cites] Endocr Relat Cancer. 2005 Jun;12(2):471-82 [15947117.001]
  • [Cites] J Immunol Methods. 2005 May;300(1-2):136-45 [15907331.001]
  • [Cites] Front Biosci. 2005;10:2611-7 [15970523.001]
  • [Cites] Crit Rev Eukaryot Gene Expr. 2005;15(2):115-32 [16022632.001]
  • [Cites] Exp Cell Res. 2005 Sep 10;309(1):149-60 [15979068.001]
  • [Cites] Cancer Res. 2006 Feb 15;66(4):2250-6 [16489028.001]
  • [Cites] Mol Cell Proteomics. 2006 Sep;5(9):1610-27 [16799092.001]
  • [Cites] J Biol Chem. 2006 Dec 8;281(49):37728-37 [17035230.001]
  • [Cites] Endocr Relat Cancer. 2006 Dec;13(4):1033-67 [17158753.001]
  • [Cites] Br J Cancer. 2007 Jul 16;97(2):183-93 [17533397.001]
  • [Cites] Breast Cancer Res Treat. 1995 Sep;35(3):293-7 [7579500.001]
  • [Cites] Prostate. 1996 Jul;29(1):20-9 [8685051.001]
  • [Cites] J Clin Invest. 1996 Oct 1;98(7):1544-9 [8833902.001]
  • [Cites] Carcinogenesis. 1997 Jan;18(1):23-9 [9054585.001]
  • [Cites] Br J Cancer. 1997;76(8):1095-8 [9376272.001]
  • [Cites] J Invest Dermatol. 1999 Nov;113(5):860 [10571748.001]
  • (PMID = 17882547.001).
  • [ISSN] 0167-6806
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] ENG
  • [Grant] United States / NIAMS NIH HHS / AR / AR45585; United States / NCI NIH HHS / CA / R01 CA114209-02; None / None / / R01 CA114209-01A2; None / None / / R01 CA114209-02; United States / NCI NIH HHS / CA / R01 CA114209-01A2; United States / NCI NIH HHS / CA / R01 CA114209-03; None / None / / R01 CA114209-03; United States / NIDDK NIH HHS / DK / R21 DK067875; United States / NIDDK NIH HHS / DK / DK067875
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / AREG protein, human; 0 / Amphiregulin; 0 / EGF Family of Proteins; 0 / Glycoproteins; 0 / Intercellular Signaling Peptides and Proteins; 0 / Parathyroid Hormone-Related Protein; 0 / RNA, Messenger; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.11.24 / Mitogen-Activated Protein Kinases
  • [Other-IDs] NLM/ NIHMS123023; NLM/ PMC2730887
  •  go-up   go-down


62. Wang L, Chen J, Thompson LU: The inhibitory effect of flaxseed on the growth and metastasis of estrogen receptor negative human breast cancer xenograftsis attributed to both its lignan and oil components. Int J Cancer; 2005 Sep 20;116(5):793-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aims of our study were to determine (i) whether the tumor inhibitory effect of FS was due to its oil (FO), lignan secoisolariciresinol diglycoside (SDG), or both components, and (ii) whether the effect on tumor growth was related to increased lipid peroxidation.
  • Athymic nude mice were orthotopically injected with ER- breast cancer cells (MDA-MB-435) and 8 weeks later were fed either the basal diet (BD) or BD supplemented with 10% FS, SDG, FO, or combined SDG and FO (SDG + FO) for 6 weeks.
  • Compared to the BD group, the tumor growth rate was significantly lower (p < 0.05) in the FS, FO, and SDG + FO groups, in concordance with decreased cell proliferation and increased apoptosis; however, these did not significantly relate to the lipid peroxidation, indexed as malonaldehyde (MDA), in the primary tumors.
  • [MeSH-major] Breast Neoplasms / drug therapy. Flax. Lignans / therapeutic use. Linseed Oil / therapeutic use. Receptors, Estrogen / analysis
  • [MeSH-minor] Animals. Cell Line, Tumor. Female. Humans. Mice. Neoplasm Metastasis. Neoplasm Transplantation. Transplantation, Heterologous

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. LINSEED OIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley-Liss, Inc.
  • (PMID = 15849746.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Lignans; 0 / Receptors, Estrogen; 8001-26-1 / Linseed Oil
  •  go-up   go-down


63. Jin HR, Jeong WJ: Reconstruction of nasal cutaneous defects in Asians. Auris Nasus Larynx; 2009 Oct;36(5):560-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Majority of the defects (36/40) resulted from resection of a neoplasm.
  • Among tumors, basal cell carcinoma accounted for 75% (27/36) followed by squamous cell carcinoma 8% (3/36).
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Carcinoma, Basal Cell / surgery. Carcinoma, Squamous Cell / surgery. Cartilage / transplantation. Child. Female. Humans. Male. Middle Aged. Retrospective Studies. Skin / pathology. Skin Neoplasms / surgery. Surgical Flaps. Surgical Procedures, Operative / adverse effects. Young Adult

  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19269755.001).
  • [ISSN] 1879-1476
  • [Journal-full-title] Auris, nasus, larynx
  • [ISO-abbreviation] Auris Nasus Larynx
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


64. Piesold JU, Vent S, Krüger R, Pistner H: [Treatment results after surgery for basal cell carcinomas of the head and neck region taking into consideration various reconstruction techniques]. Mund Kiefer Gesichtschir; 2005 May;9(3):143-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment results after surgery for basal cell carcinomas of the head and neck region taking into consideration various reconstruction techniques].
  • BACKGROUND: Basal cell carcinomas are the most frequently occurring malignant tumors in the white population.
  • PATIENTS AND METHOD: All cases of basal cell carcinoma treated at the department for oral and maxillofacial and regional plastic surgery of the HELIOS hospital in Erfurt between 1976 and 2003 were analyzed and partly reexamined in a retrospective study.
  • RESULTS: A total of 648 patients with 765 basal cell carcinomas were treated.
  • In 64% of the cases the basal cell carcinomas were nodular, in 16% infiltrative.
  • DISCUSSION: If an infiltrative basal cell carcinoma is suspected or insufficient radical primary surgery is presumed, plastic reconstruction should be postponed until free margins can be confirmed histologically.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Head and Neck Neoplasms / surgery. Neoplasms, Radiation-Induced / surgery. Skin Neoplasms / surgery. Sunlight / adverse effects
  • [MeSH-minor] Aged. Dermatologic Surgical Procedures. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Neoplasm Staging. Orbit Evisceration. Outcome and Process Assessment (Health Care). Retrospective Studies. Skin / pathology. Surgical Flaps

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Facial Plast Surg. 1997 Apr;13(2):79-82 [9243982.001]
  • [Cites] J Am Acad Dermatol. 1992 Jan;26(1):117-20 [1732317.001]
  • [Cites] Aust J Public Health. 1994 Jun;18(2):218-21 [7948343.001]
  • [Cites] Nat Rev Cancer. 2004 Jan;4(1):23-35 [14681688.001]
  • [Cites] Medicine (Baltimore). 1987 Mar;66(2):98-113 [3547011.001]
  • [Cites] Br J Dermatol. 2003 Nov;149 Suppl 66:50-2 [14616351.001]
  • [Cites] Br J Dermatol. 2003 Dec;149(6):1200-6 [14674897.001]
  • [Cites] Br J Dermatol. 2003 Dec;149(6):1242-9 [14674903.001]
  • [Cites] Br J Dermatol. 2003 Dec;149(6):1221-6 [14674900.001]
  • [Cites] Br J Dermatol. 2003 Nov;149 Suppl 66:57-8 [14616353.001]
  • (PMID = 15719264.001).
  • [ISSN] 1432-9417
  • [Journal-full-title] Mund-, Kiefer- und Gesichtschirurgie : MKG
  • [ISO-abbreviation] Mund Kiefer Gesichtschir
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


65. Kampkötter A, Wiegand C, Timpel C, Röhrdanz E, Chovolou Y, Kahl R, Wätjen W: Increased expression of catalase in human hepatoma cells by the soy isoflavone, daidzein. Basic Clin Pharmacol Toxicol; 2008 May;102(5):437-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The present study was undertaken in order to test the antioxidative potential of daidzein and to examine the effect of daidzein treatment on the expression of the antioxidant enzyme catalase in the human hepatoma cell lines Huh-7 and HepG2.
  • Huh-7 cells were much more susceptible to daidzein cytotoxicity than HepG2 cells and showed much lower basal activity in luciferase reporter gene assays with the 3.2 kb fragment of the human catalase promoter.
  • However, treatment with daidzein at a non-toxic concentration resulted in a similar induction of promoter activity in both cell lines.
  • Reporter gene studies with different promoter constructs in HepG2 cells restrict the potential localization of the main regulatory elements for basal and inducible activity of the catalase promoter to a region approximately 120 bp to 300 bp upstream of the start codon of the catalase gene.
  • [MeSH-minor] Carcinoma, Hepatocellular. Cell Line, Tumor. Cell-Free System. Humans. Liver Neoplasms. Promoter Regions, Genetic. Soybeans. Transcription, Genetic

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Basic Clin Pharmacol Toxicol. 2008 May;102(5):489
  • (PMID = 18047476.001).
  • [ISSN] 1742-7843
  • [Journal-full-title] Basic & clinical pharmacology & toxicology
  • [ISO-abbreviation] Basic Clin. Pharmacol. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Isoflavones; 6287WC5J2L / daidzein; EC 1.11.1.6 / Catalase
  •  go-up   go-down


66. Amatya VJ, Naumann U, Weller M, Ohgaki H: TP53 promoter methylation in human gliomas. Acta Neuropathol; 2005 Aug;110(2):178-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Methylation of the promoter region of tumor suppressor genes may be associated with transcriptional silencing and tumor progression.
  • The 5' region of the TP53 gene does not contain a CpG island, but a basal promoter region of 85 bp is essential for its full promoter activity.
  • In the present study, we assessed whether TP53 promoter methylation is present in malignant glioma cells and whether this is associated with reduced TP53 expression.
  • Methylation-specific PCR revealed TP53 promoter methylation in three (U87MG, LNT-229, T98G) out of six malignant glioma cell lines studied.
  • Treatment with 5-aza-2'-deoxycytidine (5-aza-dC) led to up-regulated expression of TP53 mRNA and protein in U87MG and T98G cells, suggesting that promoter methylation is associated with reduced expression in some malignant glioma cells.
  • [MeSH-major] Brain Neoplasms / genetics. DNA Methylation. Genes, p53 / genetics. Glioma / genetics. Promoter Regions, Genetic / genetics
  • [MeSH-minor] Base Sequence. Cell Line, Tumor. Female. Humans. Male. Molecular Sequence Data. RNA, Messenger / analysis. Reverse Transcriptase Polymerase Chain Reaction. Tumor Suppressor Protein p14ARF / genetics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16025287.001).
  • [ISSN] 0001-6322
  • [Journal-full-title] Acta neuropathologica
  • [ISO-abbreviation] Acta Neuropathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Tumor Suppressor Protein p14ARF
  •  go-up   go-down


67. Tucker SB, Polasek JW, Perri AJ, Goldsmith EA: Long-term follow-up of basal cell carcinomas treated with perilesional interferon alfa 2b as monotherapy. J Am Acad Dermatol; 2006 Jun;54(6):1033-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term follow-up of basal cell carcinomas treated with perilesional interferon alfa 2b as monotherapy.
  • BACKGROUND: Interferon alfa-2b (IFN) may be used to treat basal cell carcinoma (BCC) as an alternative to surgical or destructive methods.
  • In addition, on the basis of this study, results of IFN treatment for BCC are comparable to most other methods of tumor destruction.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Carcinoma, Basal Cell / drug therapy. Interferon-alpha / administration & dosage. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16713458.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Recombinant Proteins; 99210-65-8 / interferon alfa-2b
  •  go-up   go-down


68. Cole GW Jr, Alleva AM, Zuo JT, Sehgal SS, Yeow WS, Schrump DS, Nguyen DM: Suppression of pro-metastasis phenotypes expression in malignant pleural mesothelioma by the PI3K inhibitor LY294002 or the MEK inhibitor UO126. Anticancer Res; 2006 Mar-Apr;26(2A):809-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Suppression of pro-metastasis phenotypes expression in malignant pleural mesothelioma by the PI3K inhibitor LY294002 or the MEK inhibitor UO126.
  • BACKGROUND: This study aimed to evaluate the impact of selective abrogation of either the MEK/ERK1/2 (UO126 or PD98059) or the PI3K/AKT (LY294002) signaling cascade on cell proliferation, motility and invasion and production of VEGF (collectively termed pro-metastasis phenotypes) in cultured malignant pleural mesothelioma (MPM) cells.
  • Cell motility was assessed by wound healing and Matrigel invasion assays.
  • RESULTS: LY294002 and UO126 significantly inhibited cell proliferation and clonogenicity of MPM cells in vitro.
  • A substantial reduction of cell motility, Matrigel invasion as well as inhibition of basal or EGF-induced VEGF production were observed in drug-treated cells.
  • CONCLUSION: The selective MEK or PI3K kinase inhibitors are equally effective in down-regulating the expression of pro-metastasis phenotypes, suggesting that MEK or PI3K are appropriate targets for the development of molecular therapeutics for malignant pleural mesothelioma.
  • [MeSH-major] Butadienes / pharmacology. Chromones / pharmacology. MAP Kinase Kinase Kinases / antagonists & inhibitors. Mesothelioma / drug therapy. Mesothelioma / secondary. Morpholines / pharmacology. Nitriles / pharmacology. Phosphatidylinositol 3-Kinases / antagonists & inhibitors. Pleural Neoplasms / drug therapy. Pleural Neoplasms / pathology
  • [MeSH-minor] Cell Line, Tumor. Cell Movement / drug effects. Enzyme Activation / drug effects. Enzyme Inhibitors / pharmacology. Humans. Interleukin-8 / biosynthesis. Neoplasm Metastasis. Neovascularization, Pathologic / drug therapy. Neovascularization, Pathologic / enzymology. Neovascularization, Pathologic / pathology. Proto-Oncogene Proteins c-akt / antagonists & inhibitors. Quinazolines / pharmacology. Vascular Endothelial Growth Factor A / biosynthesis

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16619474.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline; 0 / Butadienes; 0 / Chromones; 0 / Enzyme Inhibitors; 0 / Interleukin-8; 0 / Morpholines; 0 / Nitriles; 0 / Quinazolines; 0 / U 0126; 0 / Vascular Endothelial Growth Factor A; 154447-36-6 / 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 2.7.11.25 / MAP Kinase Kinase Kinases
  •  go-up   go-down


69. Turan A, Turkaslan T, Kul Z, Isler C, Ozsoy Z: Reconstruction of the anterior surface of the ear using a postauricular pull-through neurovascular island flap. Ann Plast Surg; 2006 Jun;56(6):609-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Ear Neoplasms / surgery. Ear, External / surgery. Reconstructive Surgical Procedures / methods. Surgical Flaps

  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16721071.001).
  • [ISSN] 0148-7043
  • [Journal-full-title] Annals of plastic surgery
  • [ISO-abbreviation] Ann Plast Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


70. Inoue S, Inoue M, Takahashi H, Inoue A, Kunitomo K, Fujii H: [Two advanced/recurrent breast cancer cases effectively treated by trastuzumab/capecitabine combination therapy]. Gan To Kagaku Ryoho; 2008 Feb;35(2):319-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Trastuzumab/capecitabine combination therapy was performed for two advanced/recurrent breast cancer cases with acute deterioration of the disease.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Breast Neoplasms / pathology. Deoxycytidine / analogs & derivatives. Fluorouracil / analogs & derivatives
  • [MeSH-minor] Antibodies, Monoclonal, Humanized. Biomarkers, Tumor / blood. Bone Neoplasms / blood. Bone Neoplasms / drug therapy. Bone Neoplasms / radiography. Bone Neoplasms / secondary. Capecitabine. Female. Humans. Immunotherapy. Liver Neoplasms / blood. Liver Neoplasms / drug therapy. Liver Neoplasms / radiography. Liver Neoplasms / secondary. Middle Aged. Neoplasm Staging. Recurrence. Tomography, X-Ray Computed. Trastuzumab

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. Trastuzumab .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18281774.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Biomarkers, Tumor; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; P188ANX8CK / Trastuzumab; U3P01618RT / Fluorouracil
  •  go-up   go-down


71. Zhou J, Liu M, Zhai Y, Xie W: The antiapoptotic role of pregnane X receptor in human colon cancer cells. Mol Endocrinol; 2008 Apr;22(4):868-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Certain bile acids are known to promote colonic carcinogenesis by inducing colon cancer cell apoptosis.
  • However, whether and how PXR plays a role in colon cancer apoptosis has not been reported.
  • Interestingly, activation of PXR also protected HCT116 cells from adriamycin-induced cell death, suggesting that the antiapoptotic effect of PXR was not bile acid specific.
  • Moreover, the antiapoptotic effect of PXR in HCT116 cells appeared to be independent of xenobiotic enzyme regulation, because these cells had little basal and inducible expression of bile acid-detoxifying enzymes.
  • Treatment with rifampicin in colon cancer LS180 cells, a cell line known to express endogenous PXR, also inhibited apoptosis.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RIFAMPIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEOXYCHOLIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Lett. 2000 Apr 28;152(1):107-13 [10754212.001]
  • [Cites] J Invest Dermatol. 2006 Feb;126(2):374-85 [16374467.001]
  • [Cites] J Biol Chem. 2000 May 19;275(20):15090-8 [10748108.001]
  • [Cites] Nature. 2000 Jul 27;406(6794):435-9 [10935643.001]
  • [Cites] Carcinogenesis. 2001 Jan;22(1):35-41 [11159738.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3369-74 [11248085.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3375-80 [11248086.001]
  • [Cites] Nat Med. 2001 May;7(5):584-90 [11329060.001]
  • [Cites] J Biol Chem. 2006 Mar 3;281(9):5750-9 [16380381.001]
  • [Cites] Mol Endocrinol. 2006 Feb;20(2):279-90 [16195250.001]
  • [Cites] J Biol Chem. 2006 May 26;281(21):15013-20 [16556603.001]
  • [Cites] Oncogene. 2006 Aug 7;25(34):4725-43 [16892086.001]
  • [Cites] J Clin Invest. 2006 Aug;116(8):2280-2289 [16841097.001]
  • [Cites] Hepatology. 2007 Feb;45(2):422-32 [17256725.001]
  • [Cites] Mol Pharmacol. 2007 Oct;72(4):1045-53 [17636047.001]
  • [Cites] Carcinogenesis. 2001 Jun;22(6):957-64 [11375905.001]
  • [Cites] J Biol Chem. 2001 Nov 30;276(48):45120-7 [11571294.001]
  • [Cites] J Biol Chem. 2002 Jan 25;277(4):2908-15 [11706036.001]
  • [Cites] Biochim Biophys Acta. 2002 Jun 13;1583(1):108-16 [12069855.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Oct 15;99(21):13801-6 [12370413.001]
  • [Cites] Am J Med. 2002 Dec 30;113 Suppl 9B:63S-70S [12566141.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2003 Mar;284(3):G349-56 [12576301.001]
  • [Cites] Carcinogenesis. 2003 Feb;24(2):307-15 [12584182.001]
  • [Cites] Cell. 2003 Apr 18;113(2):159-70 [12705865.001]
  • [Cites] Genes Dev. 2003 Jun 15;17(12):1475-86 [12783855.001]
  • [Cites] Annu Rev Biochem. 2003;72:137-74 [12543708.001]
  • [Cites] Genes Dev. 2003 Dec 1;17(23):2922-32 [14633975.001]
  • [Cites] Mol Pharmacol. 2004 Feb;65(2):292-300 [14742670.001]
  • [Cites] Drug Discov Today. 2004 May 15;9(10):442-9 [15109949.001]
  • [Cites] Int J Biochem Cell Biol. 2005 Feb;37(2):267-71 [15474972.001]
  • [Cites] Cancer Res. 1979 May;39(5):1521-4 [427796.001]
  • [Cites] Carcinogenesis. 1988 Jan;9(1):187-90 [2826033.001]
  • [Cites] Nature. 1989 Dec 7;342(6250):705-8 [2531845.001]
  • [Cites] Jpn J Cancer Res. 1992 Aug;83(8):830-4 [1399820.001]
  • [Cites] Cell. 1993 Nov 19;75(4):631-9 [8242739.001]
  • [Cites] Nature. 1994 Jan 20;367(6460):277-81 [8121493.001]
  • [Cites] J Virol. 1994 Apr;68(4):2521-8 [8139034.001]
  • [Cites] Nature. 1994 Jul 21;370(6486):220-3 [8028670.001]
  • [Cites] Cancer Res. 1996 Apr 1;56(7):1480-3 [8603388.001]
  • [Cites] Gastroenterology. 1997 Feb;112(2):594-642 [9024315.001]
  • [Cites] J Gastroenterol. 1997 Jun;32(3):306-11 [9213242.001]
  • [Cites] Oncogene. 1997 Aug 18;15(8):887-98 [9285684.001]
  • [Cites] Surg Oncol. 1997 Nov;6(3):143-56 [9576630.001]
  • [Cites] Nutr Cancer. 1998;31(2):81-9 [9770718.001]
  • [Cites] J Biol Chem. 1999 Jan 8;274(2):781-6 [9873016.001]
  • [Cites] Oncogene. 1998 Dec 24;17(25):3247-59 [9916987.001]
  • [Cites] Cancer Res. 1999 May 15;59(10):2353-7 [10344743.001]
  • [Cites] Mol Pharmacol. 2004 Dec;66(6):1415-20 [15340041.001]
  • [Cites] Oncogene. 1999 Nov 4;18(46):6183-90 [10597216.001]
  • [Cites] Biochim Biophys Acta. 2000 Mar 27;1470(2):M69-78 [10722929.001]
  • [Cites] Hepatology. 2005 Jan;41(1):168-76 [15619241.001]
  • [Cites] Mol Endocrinol. 2005 Jun;19(6):1646-53 [15831521.001]
  • [Cites] Genes Dev. 2005 Jun 1;19(11):1263-8 [15937216.001]
  • [Cites] Hepatology. 2005 Aug;42(2):420-30 [15986414.001]
  • [Cites] Biochim Biophys Acta. 2005 Aug 15;1745(1):48-58 [16085054.001]
  • [Cites] J Biochem. 2005 Aug;138(2):151-7 [16091589.001]
  • [Cites] Carcinogenesis. 2000 May;21(5):999-1005 [10783324.001]
  • (PMID = 18096695.001).
  • [ISSN] 0888-8809
  • [Journal-full-title] Molecular endocrinology (Baltimore, Md.)
  • [ISO-abbreviation] Mol. Endocrinol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA107011; United States / NIEHS NIH HHS / ES / R01 ES012479; United States / NCI NIH HHS / CA / CA107011; United States / NIEHS NIH HHS / ES / ES012479
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Apoptosis Regulatory Proteins; 0 / BAG3 protein, human; 0 / BAK1 protein, human; 0 / BIRC2 protein, human; 0 / Dimethylhydrazines; 0 / Inhibitor of Apoptosis Proteins; 0 / Mcl1 protein, mouse; 0 / Myeloid Cell Leukemia Sequence 1 Protein; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Receptors, Steroid; 0 / bcl-2 Homologous Antagonist-Killer Protein; 0 / pregnane X receptor; 005990WHZZ / Deoxycholic Acid; 80168379AG / Doxorubicin; EC 6.3.2.19 / Ubiquitin-Protein Ligases; VJT6J7R4TR / Rifampin
  • [Other-IDs] NLM/ PMC2276464
  •  go-up   go-down


72. Torrens R, Swan BA: Promoting prevention and early recognition of malignant melanoma. Dermatol Nurs; 2009 May-Jun;21(3):115-22; quiz 123
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Promoting prevention and early recognition of malignant melanoma.
  • Research continues to support several of the traditional risk factors for melanoma: a personal history of melanoma, basal or squamous cell carcinomas, the presence of moles, sun sensitivity, occupational exposure to certain substances, or a depressed immune system (ACS, 2007; Batailee et al., 2007; Batistatou et al., 2007).
  • In addition, current pathology and pharmacology studies point towards an endogenous origin for malignant melanomas.
  • Malignant melanoma's profile is expanding on a genotypic and phenotypic level.
  • This finding underscores Pender's theory that if practitioners have a perceived higher confidence in their ability to perform cutaneous exams, then they are more likely to perform routine full skin exams and sun-protection education (Pender et al., 2002).
  • If practitioners can skillfully utilize these tools, then a significant achievement against the progression of malignant

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19554842.001).
  • [ISSN] 1060-3441
  • [Journal-full-title] Dermatology nursing
  • [ISO-abbreviation] Dermatol Nurs
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 24
  •  go-up   go-down


73. Weyers W, Hörster S, Diaz-Cascajo C: Tumor of follicular infundibulum is Basal cell carcinoma. Am J Dermatopathol; 2009 Oct;31(7):634-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor of follicular infundibulum is Basal cell carcinoma.
  • Tumor of follicular infundibulum (TFI) is currently thought to be a benign epithelial neoplasm with follicular differentiation.
  • It is encountered commonly in association with basal cell carcinoma (BCC), often as an incidental finding.
  • [MeSH-major] Carcinoma, Basal Cell / classification. Carcinoma, Basal Cell / pathology. Skin Neoplasms / classification. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19652582.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


74. Ogawa R, Akaishi S, Hyakusoku H: Differential and exclusive diagnosis of diseases that resemble keloids and hypertrophic scars. Ann Plast Surg; 2009 Jun;62(6):660-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Previous articles suggested the presence of various kinds of malignant tumors that resemble keloid or hypertrophic scar, including dermatofibrosarcoma protuberans, trichilemmal carcinoma, and keloidal basal cell carcinoma.
  • All tumors were benign: apocrine cystadenoma, adult-onset juvenile xanthogranuloma, mixed tumor, and chronic folliculitis.
  • (1) biopsy should be conducted in anomalous cases because malignant disease may be the original or secondary problem, (2) steroid injection should be performed only after careful consideration because malignancy or infections may be present, (3) careful differential diagnosis is particularly challenging in African-Americans because skin and tumor color are often similar, and (4) the presence of bacterial or fungal infection should be investigated.
  • [MeSH-minor] Adenoma, Pleomorphic / pathology. Adult. Cystadenoma / pathology. Diagnosis, Differential. Folliculitis / pathology. Humans. Male. Middle Aged. Sweat Gland Neoplasms / pathology. Xanthogranuloma, Juvenile / pathology. Young Adult

  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19461281.001).
  • [ISSN] 1536-3708
  • [Journal-full-title] Annals of plastic surgery
  • [ISO-abbreviation] Ann Plast Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


75. Yan H, Blackburn AC, McLary SC, Tao L, Roberts AL, Xavier EA, Dickinson ES, Seo JH, Arenas RB, Otis CN, Cao QJ, Lawlor RG, Osborne BA, Kittrell FS, Medina D, Jerry DJ: Pathways contributing to development of spontaneous mammary tumors in BALB/c-Trp53+/- mice. Am J Pathol; 2010 Mar;176(3):1421-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Expression of biomarkers was retained when tumor fragments were transplanted to syngeneic hosts.
  • Tumors expressing solely luminal or basal keratins were also observed (27 and 11%, respectively), but the largest class of tumors expressed both luminal and basal keratins (62%).
  • Overall, this panel of transplantable tumors provides a resource for detailed evaluation of the cell lineages undergoing transformation and preclinical testing of therapeutic agents targeting a variety of oncogenic pathways including cancer stem cells.

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Immunol. 2004 Mar;34(3):726-34 [14991602.001]
  • [Cites] Trends Genet. 2004 Jun;20(6):235-43 [15145576.001]
  • [Cites] Cancer Res. 2004 May 15;64(10):3525-32 [15150107.001]
  • [Cites] Cancer Res. 2004 Aug 1;64(15):5140-7 [15289317.001]
  • [Cites] Cell. 1987 May 22;49(4):465-75 [3032456.001]
  • [Cites] Cell Growth Differ. 1990 Apr;1(4):161-70 [1707299.001]
  • [Cites] Oncogene. 1991 Dec;6(12):2277-84 [1685017.001]
  • [Cites] Curr Biol. 1994 Jan 1;4(1):1-7 [7922305.001]
  • [Cites] Oncogene. 1995 Apr 6;10(7):1269-74 [7731676.001]
  • [Cites] Anal Biochem. 1995 Mar 20;226(1):91-9 [7785785.001]
  • [Cites] Am J Pathol. 1997 Jan;150(1):1-13 [9006316.001]
  • [Cites] Oncogene. 1997 Feb 20;14(7):865-71 [9047394.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Sep 2;94(18):9648-53 [9275177.001]
  • [Cites] Carcinogenesis. 1998 Sep;19(9):1573-81 [9771927.001]
  • [Cites] Oncogene. 1998 Nov 5;17(18):2305-12 [9811461.001]
  • [Cites] J Pathol. 1999 Jul;188(3):237-44 [10419589.001]
  • [Cites] Breast Cancer Res. 2004;6(6):R605-15 [15535842.001]
  • [Cites] Nat Cell Biol. 2005 Feb;7(2):165-71 [15619621.001]
  • [Cites] Cancer Res. 2005 Sep 15;65(18):8166-73 [16166291.001]
  • [Cites] Cell Cycle. 2005 Dec;4(12):1808-16 [16294019.001]
  • [Cites] Development. 2006 Jan;133(2):363-9 [16368933.001]
  • [Cites] Mod Pathol. 2006 Feb;19(2):264-71 [16341146.001]
  • [Cites] Cancer Res. 2006 May 15;66(10):5104-10 [16707433.001]
  • [Cites] Cell Death Differ. 2006 Jun;13(6):1003-16 [16543940.001]
  • [Cites] Oncogene. 2006 Jun 8;25(24):3463-70 [16449974.001]
  • [Cites] Oncogene. 2006 Sep 25;25(43):5906-11 [16998505.001]
  • [Cites] Cancer Cell. 2006 Nov;10(5):437-49 [17097565.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jan 9;104(2):618-23 [17202265.001]
  • [Cites] Cell Res. 2007 Jan;17(1):42-9 [17211451.001]
  • [Cites] Blood. 2007 Feb 15;109(4):1736-42 [17032926.001]
  • [Cites] Nature. 2007 Feb 8;445(7128):661-5 [17251932.001]
  • [Cites] Nature. 2007 Feb 8;445(7128):656-60 [17251933.001]
  • [Cites] Cancer Cell. 2007 Feb;11(2):103-5 [17292821.001]
  • [Cites] J Biol Chem. 2007 Feb 23;282(8):5842-52 [17179143.001]
  • [Cites] Genes Dev. 2007 Mar 1;21(5):562-77 [17344417.001]
  • [Cites] Hum Mutat. 2007 Jun;28(6):622-9 [17311302.001]
  • [Cites] Am J Pathol. 2007 Jun;170(6):2030-41 [17525270.001]
  • [Cites] Trends Cell Biol. 2007 Jun;17(6):286-91 [17481900.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jul 17;104(29):12111-6 [17626182.001]
  • [Cites] PLoS Biol. 2007 Aug;5(8):e201 [17676974.001]
  • [Cites] Stem Cell Rev. 2007 Jun;3(2):169-75 [17873349.001]
  • [Cites] Science. 2007 Nov 16;318(5853):1108-13 [17932254.001]
  • [Cites] Science. 2008 Mar 7;319(5868):1352-5 [18323444.001]
  • [Cites] Nat Genet. 2008 May;40(5):499-507 [18443585.001]
  • [Cites] Nat Cell Biol. 2008 Jun;10(6):676-87 [18454141.001]
  • [Cites] Cancer Res. 2008 Jun 15;68(12):4674-82 [18559513.001]
  • [Cites] Cell. 2008 Jul 11;134(1):62-73 [18614011.001]
  • [Cites] Breast Cancer Res. 2008;10(3):R43 [18471300.001]
  • [Cites] Neurobiol Aging. 2009 Mar;30(3):483-97 [17850928.001]
  • [Cites] Nature. 2009 Jul 23;460(7254):529-33 [19626115.001]
  • [Cites] Genome Biol. 2007;8(5):R76 [17493263.001]
  • [Cites] Oncogene. 2000 Feb 21;19(8):968-88 [10713680.001]
  • [Cites] Oncogene. 2000 Feb 21;19(8):1052-8 [10713689.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3444-9 [10716706.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 1996 Jan;1(1):5-19 [10887477.001]
  • [Cites] Nature. 2000 Nov 16;408(6810):307-10 [11099028.001]
  • [Cites] Am J Pathol. 2000 Dec;157(6):2151-9 [11106587.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Feb;10(2):83-7 [11219776.001]
  • [Cites] Oncogene. 2001 Aug 2;20(34):4621-8 [11498785.001]
  • [Cites] Nat Genet. 2002 May;31(1):55-9 [11967536.001]
  • [Cites] FASEB J. 2002 Jun;16(8):881-3 [11967232.001]
  • [Cites] Cancer Cell. 2002 Apr;1(3):289-98 [12086865.001]
  • [Cites] Mutat Res. 2003 Jan 28;522(1-2):69-83 [12517413.001]
  • [Cites] Hum Mutat. 2003 Mar;21(3):292-300 [12619115.001]
  • [Cites] Cancer Res. 2003 Oct 1;63(19):6140-3 [14559792.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15853-8 [14668450.001]
  • (PMID = 20110418.001).
  • [ISSN] 1525-2191
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / R01 ES015739; United States / NCI NIH HHS / CA / R01-CA105452; United States / NCI NIH HHS / CA / R01 CA095164; United States / NCI NIH HHS / CA / R01 CA105452; United States / NCI NIH HHS / CA / R01-CA095164; United States / NIEHS NIH HHS / ES / R01-ES015739
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Estrogen; 0 / Receptors, Notch; 0 / Receptors, Progesterone; 0 / Tumor Suppressor Protein p53; 68238-35-7 / Keratins; EC 2.7.10.1 / Erbb2 protein, mouse; EC 2.7.10.1 / Receptor, ErbB-2
  • [Other-IDs] NLM/ PMC2832161
  •  go-up   go-down


76. Winkler R: [Viral-induced tumours and pre-malignant cutaneous diseases of the perianal region]. Zentralbl Chir; 2005 Feb;130(1):60-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Viral-induced tumours and pre-malignant cutaneous diseases of the perianal region].
  • [Transliterated title] Virusinduzierte Tumoren und Präkanzerosen der Analregion.
  • HPV-induced tumours and pre-malignant cutaneous diseases of the anal region are rare, without the exception of condylomata acuminata.
  • Paget) the danger of mis-interpretation and thereby mis-therapy is great, so that they are not seldom diagnosed in the stage of malignant degeneration.
  • [MeSH-major] Anus Neoplasms / diagnosis. Papillomavirus Infections / diagnosis. Precancerous Conditions / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Bowen's Disease / diagnosis. Bowen's Disease / surgery. Carcinoma, Basal Cell / diagnosis. Carcinoma, Basal Cell / surgery. Condylomata Acuminata / diagnosis. Condylomata Acuminata / surgery. Humans. Paget Disease, Extramammary / diagnosis. Paget Disease, Extramammary / surgery. Reoperation. Surgical Flaps

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15717242.001).
  • [ISSN] 0044-409X
  • [Journal-full-title] Zentralblatt für Chirurgie
  • [ISO-abbreviation] Zentralbl Chir
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


77. van Oosten EJ, Kuijpers DI, Thissen MR: Different pain sensations in photodynamic therapy of nodular basal cell carcinoma Results from a prospective trial and a review of the literature. Photodiagnosis Photodyn Ther; 2006 Mar;3(1):61-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Different pain sensations in photodynamic therapy of nodular basal cell carcinoma Results from a prospective trial and a review of the literature.
  • BACKGROUND: Pain is a major side effect of topical photodynamic therapy (PDT), a relatively new and non-invasive treatment for particular types of basal cell carcinoma (BCC).
  • Furthermore, we studied if gender, tumour size and localization as well as different light sources with comparable wavelengths had an influence on the pain.
  • Gender as well as tumour localization and size did not alter the pain scores.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 25049028.001).
  • [ISSN] 1572-1000
  • [Journal-full-title] Photodiagnosis and photodynamic therapy
  • [ISO-abbreviation] Photodiagnosis Photodyn Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


78. Kamat G, Yelikar B, Shettar S, Karigoudar MH: Pigmented trichoblastoma with sebaceous hyperplasia. Indian J Dermatol Venereol Leprol; 2009 Sep-Oct;75(5):506-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Trichoblastoma is a rare benign trichogenic tumour with epithelial and mesenchymal components recapitulating the germinal hair bulb and associated mesenchyme.
  • Microscopy of tumour revealed nodular tumour spanning the entire dermis with collection of mesenchymal cells resembling follicular papilla.
  • There is a need for differentiation of this tumor which is benign, from other pigmented tumors having basaloid arrangement of cells such as basal cell carcinoma.
  • [MeSH-major] Neoplasms, Glandular and Epithelial / diagnosis. Sebaceous Gland Neoplasms / diagnosis
  • [MeSH-minor] Humans. Hyperplasia. Male. Middle Aged. Skin Neoplasms / complications. Skin Neoplasms / diagnosis. Skin Neoplasms / pathology. Skin Pigmentation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19736433.001).
  • [ISSN] 0973-3922
  • [Journal-full-title] Indian journal of dermatology, venereology and leprology
  • [ISO-abbreviation] Indian J Dermatol Venereol Leprol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


79. Yoon J, Jung SY, Ahn B, Heo K, Jin S, Iyoda T, Yoshida H, Ree M: Order-order and order-disorder transitions in thin films of an amphiphilic liquid crystalline diblock copolymer. J Phys Chem B; 2008 Jul 24;112(29):8486-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Order-order and order-disorder transitions in thin films of an amphiphilic liquid crystalline diblock copolymer.
  • In this study, we quantitatively investigated the temperature-dependent phase transition behaviors of thin films of an interesting amphiphilic diblock copolymer, poly(ethylene oxide)-b-poly(11-[4-(4-butylphenylazo)phenoxy]undecyl methacrylate) (p(EO)-b-p(MAAZ)) and the resulting morphological structures by using synchrotron grazing incidence X-ray scattering (GIXS) and differential scanning calorimetry.
  • The quantitative GIXS analysis showed that the diblock copolymer in the homogeneous, isotropic melt state undergoes phase-separation near 190 degrees C and then forms a body-centered cubic (BCC) structure of spherical p(EO) domains in the p(MAAZ) matrix, at which point the p(EO) domains and the p(MAAZ) matrix are both in amorphous, liquid states.
  • The BCC structure of spherical p(EO) domains is converted to a hexagonal cylinder structure near 120 degrees C, which is induced by the transformation of the isotropic phase of the p(MAAZ) matrix to the smectic A phase, which is composed of a laterally ordered structure of p(MAAZ) blocks with fully extended side groups.
  • The resulting hexagonal cylinder structure is very stable below 120 degrees C.
  • This microscopic hexagonal cylinder structure is retained as the smectic A phase of the p(MAAZ) matrix undergoes further transitions to smectic C near 104 degrees C and to a smectic X phase near 76 degrees C, while the amorphous, liquid phase of the p(EO) cylinders undergoes crystallization near -15 degrees C.
  • These complicated temperature-dependent disorder-order and order-order phase transitions in the films were found to take place reversibly during the heating run.
  • A face-centered orthorhombic structure of p(EO) domains was also found during the heating run and is an intermediate structure in the hexagonal cylinder structure to BCC structure transformation.
  • We use these structural analysis results to propose molecular structure models at various temperatures for thin films of the diblock polymer.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18588338.001).
  • [ISSN] 1520-6106
  • [Journal-full-title] The journal of physical chemistry. B
  • [ISO-abbreviation] J Phys Chem B
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


80. Mukherjee S, Bhattacharya RK, Roy M: Targeting protein kinase C (PKC) and telomerase by phenethyl isothiocyanate (PEITC) sensitizes PC-3 cells towards chemotherapeutic drug-induced apoptosis. J Environ Pathol Toxicol Oncol; 2009;28(4):269-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The present study investigates the effects of natural isothiocyanate phenethyl isothiocyanate (PEITC) in modulating the activities of PKC and telomerase in the androgen-independent human prostate adenocarcinoma (PC-3) cell line.
  • Basal level of PKC delta, a proapoptotic form, was very poor and its modulation was not significant.
  • Studies were conducted to measure the degree of apoptotic cell death induced either by PEITC alone or in combination with adriamycin or etoposide.
  • PEITC exhibited remarkable efficacy in sensitizing PC-3 cells to undergo cell death by adriamycin and etoposide, which might prove to be of considerable value in synergistic therapy of cancer.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Apoptosis / drug effects. Isothiocyanates / pharmacology. Prostatic Neoplasms / enzymology. Protein Kinase C / antagonists & inhibitors. Telomerase / antagonists & inhibitors
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / pharmacology. Biomarkers, Tumor / metabolism. Caspases / metabolism. Cell Line, Tumor. Cytochromes c / metabolism. Down-Regulation / drug effects. Doxorubicin / pharmacology. Drug Resistance, Neoplasm. Etoposide / pharmacology. Humans. Male

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20102325.001).
  • [ISSN] 2162-6537
  • [Journal-full-title] Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer
  • [ISO-abbreviation] J. Environ. Pathol. Toxicol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / Isothiocyanates; 6PLQ3CP4P3 / Etoposide; 6U7TFK75KV / phenethyl isothiocyanate; 80168379AG / Doxorubicin; 9007-43-6 / Cytochromes c; EC 2.7.11.13 / Protein Kinase C; EC 2.7.7.49 / Telomerase; EC 3.4.22.- / Caspases
  •  go-up   go-down


81. Rink T, Truong PN, Schroth HJ, Diener J, Zimny M, Grünwald F: Calculation and validation of a plasma calcitonin limit for early detection of medullary thyroid carcinoma in nodular thyroid disease. Thyroid; 2009 Apr;19(4):327-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Calculation and validation of a plasma calcitonin limit for early detection of medullary thyroid carcinoma in nodular thyroid disease.
  • Elevated plasma calcitonin concentrations (pCT-Cs) are generally a specific and sensitive indicator for C-cell hyperplasia or MTC.
  • Hence, in endemic goiter regions, there is a need for information regarding the pCT-C values that are indicative of C-cell hyperplasia or MTC.
  • The aim of this study, therefore, was to determine an upper pCT-C to distinguish patients with and without MTC in a collective with nodular thyroid disease, and to give an estimation of the prevalence of MTC in an endemic goiter area.
  • METHODS: Basal pCT-C was measured in 21,928 patients with thyroid nodules living in central Germany, an area with endemic goiter due to previous iodine deficiency.
  • A nominal normal range for basal pCT-C was calculated with data from 21,900 subjects without known MTC.
  • RESULTS: For basal pCT-C, calculation of the three-sigma borders after logarithmic transformation revealed upper limits of the nominal normal range of 14.6 ng/L in females and 32.8 ng/L in males, respectively.
  • However, three male patients with small MTCs had basal pCT-Cs between 15 and 33 ng/L.
  • None of the patients with MTC had a basal pCT-C below 15 ng/L or an increase in pCT-C after pentagastrin stimulation that was less than 80 ng/L.
  • In the basal pCT-C range between 15 and 50 ng/L (n = 192; eight with MTC), the positive predictive value for the detection of MTC was 4% in our group.
  • Applying an upper limit for basal pCT-C of 15 ng/L in both sexes, 329 of the total of 21,928 patients exceeded this range.
  • CONCLUSIONS: An upper limit of 15 ng/L instead of 10 ng/L for basal pCT-C is able to detect all MTC and reduce false-positive cases.
  • The prevalence of MTC in nodular thyroid disease in our group was approximately 1.8 per thousand.
  • [MeSH-major] Calcitonin / blood. Carcinoma, Medullary / diagnosis. Thyroid Neoplasms / diagnosis. Thyroid Nodule / blood

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. Calcitonin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19355822.001).
  • [ISSN] 1557-9077
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 9007-12-9 / Calcitonin
  •  go-up   go-down


82. Yin H, Smith M, Glass J: Stable expression of C/EBPalpha in prostate cancer cells down-regulates metallothionein and increases zinc-induced toxicity. Prostate; 2005 Feb 15;62(3):209-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The transcription factor C/EBPalpha regulates terminal differentiation of various cell types.
  • C/EBPalpha is expressed in prostate epithelium but its role in prostate development and malignant transformation is unknown.
  • METHODS: The prostate cancer cell lines DU145, LNCaP, and PC3 with stable overexpression of C/EBPalpha were established with a retroviral expression system.
  • RESULTS: Under basal conditions and in response to zinc, forced overexpression of C/EBPalpha decreased expression of MT isoforms 1A, B, F, and H, IIA and III.
  • [MeSH-major] CCAAT-Enhancer-Binding Protein-alpha / biosynthesis. Metallothionein / biosynthesis. Prostatic Neoplasms / metabolism. Zinc / pharmacology
  • [MeSH-minor] Amino Acid Sequence. Base Sequence. Blotting, Western. Cell Line, Tumor. Cell Proliferation. DNA, Neoplasm / chemistry. DNA, Neoplasm / genetics. Humans. Male. Molecular Sequence Data. Oligonucleotide Array Sequence Analysis. Promoter Regions, Genetic. Up-Regulation

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. ZINC, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2004 Wiley-Liss, Inc.
  • (PMID = 15389791.001).
  • [ISSN] 0270-4137
  • [Journal-full-title] The Prostate
  • [ISO-abbreviation] Prostate
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CCAAT-Enhancer-Binding Protein-alpha; 0 / DNA, Neoplasm; 9038-94-2 / Metallothionein; J41CSQ7QDS / Zinc
  •  go-up   go-down


83. Astolfi A, Landuzzi L, Nicoletti G, De Giovanni C, Croci S, Palladini A, Ferrini S, Iezzi M, Musiani P, Cavallo F, Forni G, Nanni P, Lollini PL: Gene expression analysis of immune-mediated arrest of tumorigenesis in a transgenic mouse model of HER-2/neu-positive basal-like mammary carcinoma. Am J Pathol; 2005 Apr;166(4):1205-16
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression analysis of immune-mediated arrest of tumorigenesis in a transgenic mouse model of HER-2/neu-positive basal-like mammary carcinoma.
  • To identify the molecular events responsible for effective tumor prevention and to define the tumor gene expression signature, we used microarrays to analyze the expression profile of mammary tissue of untreated transgenic mice and of vaccine-treated, tumor-free mice at different time points.
  • Mammary tissue from vaccinated mice displayed a gene expression profile different from that of untreated, tumor-bearing mice but similar to that of normal/hyperplastic mammary gland.
  • Comparison of treated and untreated mice at 15 weeks of age revealed up-regulation of genes encoding antibodies, chemokines, gamma-interferon-induced genes and inflammatory molecules, and down-regulation of early genes induced by tumor development.
  • The gene expression signature of HER-2/neu-transformed tumor cells showed modulation of genes promoting proliferation, angiogenesis, migration, invasion, and metastasis and inhibiting apoptosis and immune response.
  • Moreover murine and human HER-2/neu-positive tumors share the signature of basal-like breast cancers.
  • This gene expression analysis reveals the immune events associated with prevention of tumor development and shows that HER-2/neu transgenic mice represent a good model of a poor-prognosis group of human breast tumors.
  • [MeSH-major] Cancer Vaccines / therapeutic use. Gene Expression Regulation, Neoplastic / drug effects. Mammary Neoplasms, Experimental / genetics. Mammary Neoplasms, Experimental / prevention & control. Receptor, ErbB-2 / metabolism
  • [MeSH-minor] Animals. Disease Models, Animal. Gene Expression / drug effects. Gene Expression Profiling. Humans. Male. Mice. Mice, Transgenic

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Immunol Immunother. 1998 Dec;47(4):183-90 [9875670.001]
  • [Cites] Nat Rev Cancer. 2003 Nov;3(11):832-44 [14668814.001]
  • [Cites] Cancer Immunol Immunother. 1999 Feb;47(6):337-42 [10203064.001]
  • [Cites] Int J Cancer. 1999 Oct 29;83(3):393-400 [10495433.001]
  • [Cites] Lab Invest. 1999 Oct;79(10):1261-9 [10532589.001]
  • [Cites] Int J Cancer. 2000 Jul 15;87(2):186-94 [10861472.001]
  • [Cites] J Cell Sci. 2000 Aug;113 ( Pt 16):2813-9 [10910765.001]
  • [Cites] Cancer Res. 2000 Jul 15;60(14):3782-9 [10919651.001]
  • [Cites] Nature. 2000 Aug 17;406(6797):747-52 [10963602.001]
  • [Cites] Lancet. 2000 Dec 9;356(9246):1981-2 [11130529.001]
  • [Cites] Microsc Res Tech. 2001 Jan 15;52(2):190-203 [11169867.001]
  • [Cites] Gene Ther. 2001 Jan;8(1):75-9 [11402305.001]
  • [Cites] J Immunol. 2001 Sep 15;167(6):3367-74 [11544327.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74 [11553815.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11462-7 [11562467.001]
  • [Cites] J Exp Med. 2001 Nov 5;194(9):1195-205 [11696586.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Dec 4;98(25):14452-7 [11734645.001]
  • [Cites] Nature. 2002 Jan 31;415(6871):530-6 [11823860.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 May 14;99(10):6567-72 [12011421.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 May 14;99(10):6967-72 [12011455.001]
  • [Cites] Am J Pathol. 2002 Oct;161(4):1171-85 [12368191.001]
  • [Cites] J Immunol. 2003 Jan 1;170(1):270-8 [12496409.001]
  • [Cites] Cancer Res. 2003 Jan 1;63(1):132-9 [12517789.001]
  • [Cites] Trends Immunol. 2003 Feb;24(2):62-6 [12547501.001]
  • [Cites] Nucleic Acids Res. 2003 Feb 15;31(4):e15 [12582260.001]
  • [Cites] Biotechniques. 2003 Feb;34(2):374-8 [12613259.001]
  • [Cites] Vaccine. 2003 Mar 28;21(13-14):1317-26 [12615426.001]
  • [Cites] J Immunol. 2003 Mar 15;170(6):3233-42 [12626582.001]
  • [Cites] Genome Biol. 2003;4(4):R27 [12702208.001]
  • [Cites] Oncogene. 2003 May 1;22(17):2680-8 [12730682.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8418-23 [12829800.001]
  • [Cites] J Clin Invest. 2004 Mar;113(5):709-17 [14991069.001]
  • [Cites] Cancer Res. 2004 Jun 1;64(11):4001-9 [15173014.001]
  • [Cites] J Immunol. 2004 Aug 15;173(4):2288-96 [15294941.001]
  • [Cites] Oncogene. 1994 Dec;9(12):3417-26 [7970700.001]
  • [Cites] Nat Med. 1995 Jul;1(7):644-8 [7585144.001]
  • [Cites] Oncogene. 1995 Dec 7;11(11):2233-41 [8570173.001]
  • [Cites] Genomics. 1996 Aug 1;35(3):523-32 [8812487.001]
  • [Cites] J Exp Med. 1998 Aug 3;188(3):589-96 [9687535.001]
  • [Cites] Int J Cancer. 1998 Sep 11;77(6):937-41 [9714068.001]
  • [Cites] Cancer Res. 1998 Dec 1;58(23):5466-72 [9850080.001]
  • [Cites] Cancer Res. 2003 Aug 15;63(16):4920-6 [12941816.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 2;100(18):10393-8 [12917485.001]
  • [Cites] Nat Rev Immunol. 2003 Aug;3(8):630-41 [12974478.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Mar 16;96(6):2907-12 [10077610.001]
  • (PMID = 15793299.001).
  • [ISSN] 0002-9440
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cancer Vaccines; EC 2.7.10.1 / Receptor, ErbB-2
  • [Other-IDs] NLM/ PMC1602398
  •  go-up   go-down


84. González F, García A: [Periocular basal cell carcinoma]. Arch Soc Esp Oftalmol; 2005 May;80(5):275-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Periocular basal cell carcinoma].
  • [Transliterated title] Carcinoma basocelular periocular.
  • PURPOSE: Brief review of basal cell carcinomas (BCCs) of the periocular area.
  • [MeSH-major] Carcinoma, Basal Cell. Eyelid Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15918094.001).
  • [ISSN] 0365-6691
  • [Journal-full-title] Archivos de la Sociedad Española de Oftalmología
  • [ISO-abbreviation] Arch Soc Esp Oftalmol
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 49
  •  go-up   go-down


85. Khramtsov AI, Khramtsova GF, Tretiakova M, Huo D, Olopade OI, Goss KH: Wnt/beta-catenin pathway activation is enriched in basal-like breast cancers and predicts poor outcome. Am J Pathol; 2010 Jun;176(6):2911-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Wnt/beta-catenin pathway activation is enriched in basal-like breast cancers and predicts poor outcome.
  • In this study, invasive and in situ breast cancer tissue microarrays containing luminal A, luminal B, human epidermal growth factor receptor 2 (HER2)(+)/ER(-) and basal-like breast cancers were analyzed for beta-catenin subcellular localization.
  • We demonstrate that nuclear and cytosolic accumulation of beta-catenin, a read-out of Wnt pathway activation, was enriched in basal-like breast cancers.
  • In contrast, membrane-associated beta-catenin was observed in all breast cancer subtypes, and its expression decreased with tumor progression.
  • Moreover, nuclear and cytosolic localization of beta-catenin was associated with other markers of the basal-like phenotype, including nuclear hormone receptor and HER2 negativity, cytokeratin 5/6 and vimentin expression, and stem cell enrichment.
  • In addition, beta-catenin accumulation was more often observed in basal-like in situ carcinomas than other in situ subtypes, suggesting that activation of this pathway might be an early event in basal-like tumor development.
  • Collectively, these data indicate that Wnt/beta-catenin activation is an important feature of basal-like breast cancers and is predictive of worse overall survival, suggesting that it may be an attractive pharmacological target for this aggressive breast cancer subtype.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Clin Pract Oncol. 2008 Mar;5(3):149-59 [18212769.001]
  • [Cites] Cancer Res. 2008 Feb 15;68(4):989-97 [18281472.001]
  • [Cites] Breast Cancer Res. 2008;10(3):R53 [18559090.001]
  • [Cites] Histol Histopathol. 2009 Mar;24(3):385-98 [19130408.001]
  • [Cites] PLoS One. 2009;4(3):e4968 [19319191.001]
  • [Cites] Cancer Res. 2009 May 15;69(10):4116-24 [19435916.001]
  • [Cites] Histopathology. 2000 Apr;36(4):313-25 [10759945.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4262-6 [10759547.001]
  • [Cites] Nature. 2000 Aug 17;406(6797):747-52 [10963602.001]
  • [Cites] Carcinogenesis. 2000 Nov;21(11):1935-40 [11062151.001]
  • [Cites] Eur J Surg Oncol. 2001 Feb;27(1):31-6 [11237489.001]
  • [Cites] J Pathol. 2001 Apr;193(4):433-41 [11276001.001]
  • [Cites] Nat Cell Biol. 2001 Sep;3(9):793-801 [11533658.001]
  • [Cites] J Pathol. 2002 Feb;196(2):145-53 [11793365.001]
  • [Cites] Am J Pathol. 2002 Sep;161(3):1087-97 [12213737.001]
  • [Cites] Br J Cancer. 2002 Nov 18;87(11):1281-6 [12439718.001]
  • [Cites] Cancer Res. 2003 May 15;63(10):2658-64 [12750294.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2003 Apr;8(2):145-58 [14635791.001]
  • [Cites] Cancer Cell. 2004 Jan;5(1):91-102 [14749129.001]
  • [Cites] Cancer. 2004 May 15;100(10):2084-92 [15139049.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Aug 24;101(34):12682-7 [15314234.001]
  • [Cites] Cell. 1987 Aug 14;50(4):649-57 [3111720.001]
  • [Cites] Cell. 1988 Nov 18;55(4):619-25 [3180222.001]
  • [Cites] Cancer Res. 1990 Nov 1;50(21):7057-61 [2208173.001]
  • [Cites] J Clin Pathol. 1993 Feb;46(2):189-90 [8459046.001]
  • [Cites] Biometrics. 1994 Dec;50(4):933-44 [7787006.001]
  • [Cites] Virchows Arch. 1997 Sep;431(3):167-72 [9334837.001]
  • [Cites] Am J Pathol. 1998 Jan;152(1):75-82 [9422525.001]
  • [Cites] Nat Med. 1998 Jul;4(7):844-7 [9662379.001]
  • [Cites] J Pathol. 1998 Jul;185(3):262-6 [9771479.001]
  • [Cites] J Cancer Res Clin Oncol. 1999;125(5):297-304 [10359135.001]
  • [Cites] Br J Cancer. 1999 Jun;80(7):1046-51 [10362114.001]
  • [Cites] Breast Cancer Res Treat. 2005 Apr;90(3):249-56 [15830138.001]
  • [Cites] J Cell Sci. 2005 Aug 15;118(Pt 16):3585-94 [16105882.001]
  • [Cites] Mod Pathol. 2006 May;19(5):617-21 [16528377.001]
  • [Cites] Cancer Res. 2006 May 15;66(10):5487-94 [16707478.001]
  • [Cites] BMC Genomics. 2006;7:96 [16643655.001]
  • [Cites] JAMA. 2006 Jun 7;295(21):2492-502 [16757721.001]
  • [Cites] Mod Pathol. 2006 Nov;19(11):1506-11 [16941011.001]
  • [Cites] Cell. 2006 Nov 3;127(3):469-80 [17081971.001]
  • [Cites] J Clin Oncol. 2007 Jan 1;25(1):118-45 [17159189.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jan 9;104(2):618-23 [17202265.001]
  • [Cites] J Cell Sci. 2007 Feb 1;120(Pt 3):468-77 [17227796.001]
  • [Cites] J Pathol. 2007 Mar;211(4):389-98 [17212342.001]
  • [Cites] Clin Cancer Res. 2007 Apr 15;13(8):2329-34 [17438091.001]
  • [Cites] J Mol Histol. 2007 May;38(2):113-21 [17318343.001]
  • [Cites] Cancer. 2007 May 1;109(9):1721-8 [17387718.001]
  • [Cites] Cells Tissues Organs. 2007;185(1-3):191-203 [17587825.001]
  • [Cites] Clin Cancer Res. 2008 Jul 1;14(13):4038-44 [18593979.001]
  • (PMID = 20395444.001).
  • [ISSN] 1525-2191
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA125183; United States / NCI NIH HHS / CA / R03 CA132143; United States / NCI NIH HHS / CA / R03 CA132143-01A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Wnt Proteins; 0 / beta Catenin; EC 2.7.10.1 / Receptor, ErbB-2
  • [Other-IDs] NLM/ PMC2877852
  •  go-up   go-down


86. Kuroda N, Hirano K, Ohara M, Hirouchi T, Mizuno K, Kubo A, Enzan H: Adenoid basal carcinoma arising in the cervical polyp: an immunohistochemical study of stromal cells. Med Mol Morphol; 2007 Jun;40(2):112-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenoid basal carcinoma arising in the cervical polyp: an immunohistochemical study of stromal cells.
  • Adenoid basal carcinomas of the uterine cervix are uncommon neoplasms and generally run a favorable clinical course.
  • Although it is well known that these tumors do not evoke the stromal reaction, we immunohistochemically examined a stromal reaction in a case of adenoid basal carcinoma.
  • Histological examination revealed the finding of adenoid basal carcinoma.
  • Immunohistochemically, a smaller number of CD34-positive and CD31-negative stromal cells, namely fibroblasts, in the stroma of tumor center than in normal cervical stroma were observed.
  • On the other hand, alpha-smooth muscle actin-positive and h-caldesmon-negative stromal cells, namely myofibroblasts, were completely absent in the stroma of tumor center.
  • Finally, our preliminary report suggests that the decrease of CD34-positive fibroblasts in adenoid basal carcinoma may show an early stromal reaction to tumor invasion.
  • Gynecologists and pathologists should bear in mind that adenoid basal carcinoma may arise in a cervical polyp.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma, Adenoid Cystic / pathology. Neoplasms, Basal Cell / pathology. Polyps / pathology. Stromal Cells / metabolism. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Gynecol Pathol. 2002 Oct;21(4):327-46 [12352182.001]
  • [Cites] Am J Surg Pathol. 1999 Oct;23(10):1308-9 [10524536.001]
  • [Cites] Int J Gynecol Pathol. 1997 Oct;16(4):301-6 [9421067.001]
  • [Cites] Am J Surg Pathol. 1999 Apr;23(4):448-58 [10199475.001]
  • [Cites] Am J Surg Pathol. 1998 Aug;22(8):965-75 [9706976.001]
  • [Cites] Int J Gynecol Pathol. 1997 Oct;16(4):299-300 [9421066.001]
  • [Cites] Virchows Arch. 2002 Dec;441(6):564-8 [12461613.001]
  • [Cites] Med Mol Morphol. 2006 Dec;39(4):209-13 [17187184.001]
  • [Cites] Histopathology. 2002 Sep;41(3):185-207 [12207781.001]
  • [Cites] Adv Anat Pathol. 2002 Sep;9(5):290-300 [12195218.001]
  • [Cites] Int J Gynecol Pathol. 1997 Oct;16(4):307-12 [9421068.001]
  • [Cites] Med Mol Morphol. 2006 Sep;39(3):161-3 [16998627.001]
  • [Cites] Med Electron Microsc. 2000;33(4):241-5 [11810481.001]
  • (PMID = 17572848.001).
  • [ISSN] 1860-1480
  • [Journal-full-title] Medical molecular morphology
  • [ISO-abbreviation] Med Mol Morphol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Biomarkers, Tumor
  •  go-up   go-down


87. Simeonov R, Simeonova G: Comparative morphometric analysis of recurrent and nonrecurrent canine basal cell carcinomas: a preliminary report. Vet Clin Pathol; 2010 Mar;39(1):96-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative morphometric analysis of recurrent and nonrecurrent canine basal cell carcinomas: a preliminary report.
  • BACKGROUND: Most reports of canine basal cell carcinomas (BCCs) focus on morphologic appearance rather than biologic behavior.
  • Quantitative nuclear morphometry may be useful in predicting tumor recurrence.
  • The dogs were monitored by their owners over a period of 60 weeks to detect local recurrence of the tumor; recurrent tumors were confirmed histologically.
  • For each initial tumor specimen, nuclei of at least 100 neoplastic cells were measured by 2 independent observers, and mean nuclear area (MNA), mean nuclear perimeter (MNP), and mean nuclear diameter (MND) were calculated.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Vet Clin Pathol. 2010 Jun;39(2):133; author reply 133-4 [20624263.001]
  • (PMID = 19645743.001).
  • [ISSN] 1939-165X
  • [Journal-full-title] Veterinary clinical pathology
  • [ISO-abbreviation] Vet Clin Pathol
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


88. Thompson MS, Andersson-Engels S, Svanberg S, Johansson T, Palsson S, Bendsoe N, Derjabo A, Kapostins J, Stenram U, Spigulis J, Svanberg K: Photodynamic therapy of nodular basal cell carcinoma with multifiber contact light delivery. J Environ Pathol Toxicol Oncol; 2006;25(1-2):411-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy of nodular basal cell carcinoma with multifiber contact light delivery.
  • In the present work the treatment light was delivered using a system in which three or six clear-cut fibers were placed in direct contact with the tumor area.
  • Twelve nodular basal cell carcinomas were treated employing delta-aminolevulinic acid and 635 nm laser irradiation.
  • [MeSH-major] Carcinoma, Basal Cell / drug therapy. Lasers. Photochemotherapy / methods. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16566732.001).
  • [ISSN] 0731-8898
  • [Journal-full-title] Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer
  • [ISO-abbreviation] J. Environ. Pathol. Toxicol. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / Protoporphyrins; 553-12-8 / protoporphyrin IX; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


89. Mannor GE, Chern PL, Barnette D: Eyelid and periorbital skin basal cell carcinoma: oculoplastic management and surgery. Int Ophthalmol Clin; 2009;49(4):1-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Eyelid and periorbital skin basal cell carcinoma: oculoplastic management and surgery.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Cryosurgery / methods. Eyelid Neoplasms / surgery. Facial Neoplasms / surgery. Mohs Surgery / methods. Skin Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20348854.001).
  • [ISSN] 1536-9617
  • [Journal-full-title] International ophthalmology clinics
  • [ISO-abbreviation] Int Ophthalmol Clin
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 82
  •  go-up   go-down


90. Fritsch C, Ruzicka T: Fluorescence diagnosis and photodynamic therapy in dermatology from experimental state to clinic standard methods. J Environ Pathol Toxicol Oncol; 2006;25(1-2):425-39
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The role of photodynamic therapy (PDT) in the treatment of in situ neoplasias and tumors of the skin is steadily increasing.
  • Epithelial skin tumors such as basal cell carcinomas also respond very well, however, a debulking procedure of the exophytic tumor tissue is an absolute prerequisite to a successful cure.
  • [MeSH-major] Fluorescence. Photochemotherapy. Skin Neoplasms / diagnosis. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16566733.001).
  • [ISSN] 0731-8898
  • [Journal-full-title] Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer
  • [ISO-abbreviation] J. Environ. Pathol. Toxicol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / methyl 5-aminolevulinate; 88755TAZ87 / Aminolevulinic Acid
  • [Number-of-references] 18
  •  go-up   go-down


91. Buscarini M, Quek ML, Gilliam-Hegarich S, Kasahara N, Bochner B: Adenoviral receptor expression of normal bladder and transitional cell carcinoma of the bladder. Urol Int; 2007;78(2):160-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenoviral receptor expression of normal bladder and transitional cell carcinoma of the bladder.
  • OBJECTIVE: The insertion of absent or underexpressed genes into cancer cells to alter their malignant phenotype is an important potential application of available gene therapy technology.
  • Adenoviral infection of cells is mediated through a complex pathway, initiated following viral-cell attachment.
  • Adenoviral-cell attachment occurs following interactions with a 46-kDa transmembrane protein with high affinity for both the Coxsackie and adenovirus, designated the CAR (Coxsackie and adenoviral receptor).
  • Additional important cell-viral interactions that occur involve the alpha(v)-based integrins, specifically alpha(v)beta3 and alpha(v)beta5.
  • MATERIAL AND METHODS: Frozen tissue samples of normal bladder and invasive transitional cell cancers of the bladder were evaluated.
  • Tissue blocks containing muscle-invasive transitional cell carcinoma (TCC) were obtained following radical cystectomy, which were performed at our institution.
  • Thirty-two invasive transitional cell bladder tumors were evaluated, each with a matched sample of histologically normal-appearing bladder used as a control.
  • Four additional samples of normal bladder were obtained from patients with no evidence of disease of the bladder and served as further controls.
  • Bladder transitional cell carcinoma: CAR immunoreactivity against TCC cells was uniformly decreased compared to normal transitional cells.
  • Transitional cell cancers demonstrated a similar pattern of expression of alpha(v)beta5, in which all tumor cells exhibited minimal or no staining.
  • CONCLUSIONS: The success of all viral-mediated gene therapy strategies relies on the ability of the vector to efficiently deliver its genetic material to a target cell population.
  • Deeper layers of the epithelium also express CAR, including the basal layer cells.
  • Bladder tumor tissue may be less susceptible to an adenoviral-mediated gene therapy approach in which a significant percentage of tumor cells require transduction.
  • Adenoviral uptake by tumor or peritumoral cells with subsequent gene transfer could be predicted by the level of CAR and alpha(v)-based integrin expression.
  • [MeSH-major] Carcinoma, Transitional Cell / metabolism. Integrin alphaVbeta3 / biosynthesis. Integrins / biosynthesis. Receptors, Virus / biosynthesis. Receptors, Vitronectin / biosynthesis. Urinary Bladder / metabolism. Urinary Bladder Neoplasms / metabolism

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2007 S. Karger AG, Basel
  • (PMID = 17293658.001).
  • [ISSN] 0042-1138
  • [Journal-full-title] Urologia internationalis
  • [ISO-abbreviation] Urol. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / CLMP protein, human; 0 / CLMP protein, mouse; 0 / Coxsackie and Adenovirus Receptor-Like Membrane Protein; 0 / Integrin alphaVbeta3; 0 / Integrins; 0 / Receptors, Virus; 0 / Receptors, Vitronectin; 0 / integrin alphaVbeta5
  •  go-up   go-down


92. Perrin GQ, Fishbein L, Thomson SA, Thomas SL, Stephens K, Garbern JY, DeVries GH, Yachnis AT, Wallace MR, Muir D: Plexiform-like neurofibromas develop in the mouse by intraneural xenograft of an NF1 tumor-derived Schwann cell line. J Neurosci Res; 2007 May 1;85(6):1347-57
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plexiform-like neurofibromas develop in the mouse by intraneural xenograft of an NF1 tumor-derived Schwann cell line.
  • Plexiform neurofibromas are peripheral nerve sheath tumors that arise frequently in neurofibromatosis type 1 (NF1) and have a risk of malignant progression.
  • Past efforts to establish xenograft models for neurofibroma involved the implantation of tumor fragments or heterogeneous primary cultures, which rarely achieved significant tumor growth.
  • We report a practical and reproducible animal model of plexiform-like neurofibroma by xenograft of an immortal human NF1 tumor-derived Schwann cell line into the peripheral nerve of scid mice.
  • The S100 and p75 positive sNF94.3 cell line was shown to possess a normal karyotype and have apparent full-length neurofibromin by Western blot.
  • Localized intraneural injection of the cell line sNF94.3 produced consistent and slow growing tumors that infiltrated and disrupted the host nerve.
  • The xenograft tumors resembled plexiform neurofibromas with a low rate of proliferation, abundant extracellular matrix (hypocellularity), basal laminae, high vascularity, and mast cell infiltration.
  • [MeSH-major] Cell Line, Tumor. Lung Neoplasms / pathology. Neurofibromatosis 1 / pathology. Schwann Cells / cytology
  • [MeSH-minor] Adult. Animals. Blotting, Western. Female. Humans. Mice. Mice, SCID. Neoplasm Transplantation / methods. Nerve Tissue Proteins / metabolism. Neurofibromin 1 / genetics. Transplantation, Heterologous / methods. ras Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17335073.001).
  • [ISSN] 0360-4012
  • [Journal-full-title] Journal of neuroscience research
  • [ISO-abbreviation] J. Neurosci. Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / T32-CA09126-27
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Nerve Tissue Proteins; 0 / Neurofibromin 1; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


93. Rüttinger C, Bergmann M, Fink L, Pesch S, Seitz K, Trautmann A, Steger K, Konrad L, Brehm R: Expression of connexin 43 in normal canine testes and canine testicular tumors. Histochem Cell Biol; 2008 Sep;130(3):537-48
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cx43 is known to play a role in the differentiation and proliferation of these cell types.
  • The dog has been proposed as a model for studies of the male reproductive system, because of the frequent occurrence of testicular neoplasms.
  • Cx43 protein was mainly present in the basal compartment.
  • [MeSH-major] Connexin 43 / metabolism. Testicular Neoplasms / metabolism. Testis / metabolism

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Endocrinol. 1990 Nov;127(2):235-42 [2123496.001]
  • [Cites] Cardiovasc Res. 2004 May 1;62(2):228-32 [15094343.001]
  • [Cites] Biol Reprod. 1999 May;60(5):1263-70 [10208994.001]
  • [Cites] Cell Biol Int Rep. 1978 Jul;2(4):381-7 [743745.001]
  • [Cites] Mol Hum Reprod. 1998 Oct;4(10):939-45 [9809674.001]
  • [Cites] J Androl. 1995 Sep-Oct;16(5):400-9 [8575979.001]
  • [Cites] Lab Invest. 2003 Mar;83(3):449-56 [12649345.001]
  • [Cites] Proc Biol Sci. 1994 Feb 22;255(1343):125-32 [8165225.001]
  • [Cites] Curr Biol. 2000 Sep 21;10(18):1083-91 [10996788.001]
  • [Cites] Anat Embryol (Berl). 2006 Jun;211(3):223-36 [16429274.001]
  • [Cites] Vet Pathol. 2005 Sep;42(5):633-41 [16145209.001]
  • [Cites] Microsc Res Tech. 1992 Jan 1;20(1):3-33 [1611148.001]
  • [Cites] C R Acad Sci III. 1999 Feb-Mar;322(2-3):151-9 [10196667.001]
  • [Cites] Anat Rec. 2001 Sep 1;264(1):13-24 [11505367.001]
  • [Cites] Neoplasia. 2006 Jun;8(6):499-509 [16820096.001]
  • [Cites] Carcinogenesis. 1991 Sep;12(9):1701-6 [1893531.001]
  • [Cites] Exp Lung Res. 2001 Apr-May;27(3):231-43 [11293326.001]
  • [Cites] Eur J Cell Biol. 1993 Apr;60(2):250-5 [7687215.001]
  • [Cites] Biochim Biophys Acta. 2005 Jun 10;1711(2):154-63 [15955300.001]
  • [Cites] Cell. 1996 Feb 9;84(3):381-8 [8608591.001]
  • [Cites] Eur J Cell Biol. 1979 Aug;19(3):269-75 [385322.001]
  • [Cites] J Pathol. 2002 Aug;197(5):647-53 [12210085.001]
  • [Cites] Cancer Res. 1999 Aug 15;59(16):4104-10 [10463615.001]
  • [Cites] J Cell Physiol. 2006 Oct;209(1):153-61 [16823880.001]
  • [Cites] Circ Res. 1993 Aug;73(2):344-50 [8392450.001]
  • [Cites] Biochim Biophys Acta. 2005 Dec 20;1719(1-2):125-45 [16359943.001]
  • [Cites] Biol Reprod. 2007 May;76(5):804-12 [17229929.001]
  • [Cites] Int Rev Cytol. 1993;147:25-96 [8225836.001]
  • [Cites] Biol Reprod. 2001 Sep;65(3):829-38 [11514348.001]
  • [Cites] J Cell Sci. 1992 Sep;103 ( Pt 1):81-96 [1331136.001]
  • [Cites] J Cell Biol. 1991 Dec;115(5):1357-74 [1659577.001]
  • [Cites] Am J Physiol. 1994 Aug;267(2 Pt 1):C570-80 [7521131.001]
  • [Cites] Histochem Cell Biol. 1999 Sep;112(3):215-20 [10502068.001]
  • [Cites] Vet Pathol. 1993 May;30(3):287-95 [8392765.001]
  • [Cites] Biochim Biophys Acta. 1979 Feb 4;560(1):1-65 [216404.001]
  • [Cites] Gene Expr Patterns. 2007 Jan;7(1-2):66-71 [16829210.001]
  • [Cites] Neuron. 1991 Mar;6(3):305-20 [1848077.001]
  • [Cites] Biol Reprod. 1984 Feb;30(1):239-48 [6696964.001]
  • [Cites] Am J Pathol. 2007 Jul;171(1):19-31 [17591950.001]
  • [Cites] Int J Cancer. 1992 Jun 19;51(4):522-9 [1318266.001]
  • [Cites] Biol Chem. 2005 Apr;386(4):325-32 [15899694.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2001 Aug;281(2):G533-43 [11447034.001]
  • [Cites] J Neuropathol Exp Neurol. 1997 Jul;56(7):835-9 [9210880.001]
  • [Cites] J Pathol. 1998 Jan;184(1):37-43 [9582525.001]
  • [Cites] Acta Vet Scand. 1987;28(3-4):445-6 [3454555.001]
  • [Cites] BMC Dev Biol. 2007 Apr 04;7:26 [17408477.001]
  • [Cites] Am J Physiol. 1995 Feb;268(2 Pt 2):H729-39 [7864199.001]
  • [Cites] J Cell Biol. 1977 Aug;74(2):629-45 [889612.001]
  • [Cites] Reproduction. 2001 Feb;121(2):287-96 [11226053.001]
  • [Cites] Int J Cancer. 1994 Jan 2;56(1):87-94 [8262683.001]
  • [Cites] J Histochem Cytochem. 2000 Jun;48(6):793-805 [10820153.001]
  • [Cites] Glia. 2001 Feb;33(2):107-17 [11180508.001]
  • [Cites] Mol Carcinog. 2003 Dec;38(4):179-87 [14639657.001]
  • [Cites] Vet J. 2006 Jul;172(1):178-80 [16772144.001]
  • [Cites] J Pathol. 2004 Feb;202(2):241-6 [14743507.001]
  • [Cites] J Reprod Fertil. 2000 Nov;120(2):443-52 [11058461.001]
  • [Cites] J Cell Sci. 1994 Jan;107 ( Pt 1):83-95 [8175925.001]
  • [Cites] Mol Cell Biol. 1991 Jan;11(1):363-9 [1846023.001]
  • [Cites] Carcinogenesis. 1990 Jul;11(7):1051-8 [2197009.001]
  • [Cites] Equine Vet J. 2007 Mar;39(2):122-7 [17378440.001]
  • [Cites] Prostate. 1999 Jan 1;38(1):55-9 [9973110.001]
  • (PMID = 18542985.001).
  • [ISSN] 0948-6143
  • [Journal-full-title] Histochemistry and cell biology
  • [ISO-abbreviation] Histochem. Cell Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Connexin 43; 0 / RNA, Messenger; 0 / Vimentin
  •  go-up   go-down


94. Smith VH, Soon C, Dharma B, Eltigani EA, Bedlow AJ, Carr RC: Basal cell carcinomas arising in travel vaccination scars. Clin Exp Dermatol; 2008 Jul;33(4):515-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinomas arising in travel vaccination scars.
  • [MeSH-major] Carcinoma, Basal Cell / etiology. Skin Neoplasms / etiology. Travel. Vaccination / adverse effects

  • MedlinePlus Health Information. consumer health - Immunization.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Traveler's Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18477001.001).
  • [ISSN] 1365-2230
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / BCG Vaccine; 0 / Hepatitis A Vaccines
  •  go-up   go-down


95. Schmit TL, Zhong W, Nihal M, Ahmad N: Polo-like kinase 1 (Plk1) in non-melanoma skin cancers. Cell Cycle; 2009 Sep 1;8(17):2697-702
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We recently demonstrated that Plk1 is overexpressed in human melanoma and gene-knockdown as well as chemical-inhibition of Plk1 resulted in a significant decrease in melanoma cell viability and growth without affecting the growth of the normal human epidermal melanocytes (NHEMs).
  • Further, the observed anti-proliferative response of Plk1 was found to be accompanied with a significant G(2)/M cell cycle arrest, mitotic catastrophe and induction of apoptosis in melanoma cells.
  • In this study, we determined the expression profile of Plk1 in non-melanoma skin cancers viz. basal cell carcinoma (BCC) and squamous cell carcinoma (SCC).